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Multidrug resistance (MDR) - the phenomena where cancer cells become resistant to 
previously effective drugs - is a common obstacle in successful treatment of cancer. There 
are several causative factors of MDR. The active extrusion of drugs mediated by a family of 
membrane transporters, the p-glycoproteins, is one of the major factors resulting in treatment 
failure. If these drug transporters could be inhibited it would mean that lower doses of 
chemotherapeutic drugs could be used, making treatment more bearable and effective. 
Among many promising inhibitors is a large family of plant metabolites known as flavonoids. 
They have the advantage of huge diversity and a basic scaffold containing several hydroxyl 
groups suitable for derivatization and adding extensions. 
The mechanism of the p-gps is also of considerable interest. How can a single protein 
transport such a diversity of substrates? The structure of p-gps consist of a tandem of 
transmembrane domain (TMD) and a nucleotide binding domain (NBD), to yield a protein 
constructed as [TMD-NBD][TMD-NBD]. There is a great interest in how the NBDs cooperate 
to hydrolyse ATP and effect the translocation of drugs. 
In this study, we explore the use of a photoactivatable ATP analogue, 2',3',4'-0-(2.4,6, 
trinitrophenyl)8-azido-adenosine triphosphate (TNP-8N3-ATP) as a probe of the A TP site. 
Specific derivatization of one or both ATP sites would allow elucidation of active site residues, 
possibly yield insights into site-site cooperativity and coupling, and provide a valuable means 
of measuring drug binding to the ATP site through competitive inhibition of photolabeling. 
There is evidence that the TNP moiety increases the affinity for the ATP site of p-gps 1000­
fold over ATP. This could make TNP-8N3-ATP a valuable probe of these sites. 
The first p-gps investigated were the yeast proteins PdrSp and Yor1 p. PdrSp is implicated in 
pleiotropic drug resistance, while Yor1 p confers oligomycin resistance to yeasts in which it is 
over expressed. It is of interest to note that PdrSp maintains a membrane topology of [NBD­
TMD][NBD-TMD], the opposite of human and mouse p-gp, while Yor1 p (a member of the drug 
resistance conferring MRP family) has a similar membrane topology to that of human and 
mouse p-gp - [TMD-NBD][TND][NBD]. We found that the yeast pumps, PdrSp and Yor1 p, are 
well photolabeled at acidic pH with pKa(PdrSp) =7.3. PdrSp and Yor1p bind TNP-8N3-ATP 
with a fairty modest affinity(Kd =16 - 40 j.1M), and efficiency of labeling is approximately 80 
% for PdrSp. Photolabeling is dependent on Mg2+ and is inhibited up to 90 % by ATP ­
Ki(ATP) =0.44 mM and 0.322 mM for PdrSp and Yor1p respectively. 
Photolabeling of the NBDs was also studied by using soluble recombinantly expressed mouse 










Ser1276and LNBD2 from Lys1025 - . Both TNP-8Na-ATP and BNa-ATP photoprobes were used. 
Both sNBD2 and LNBD2 behaved very similarly. Photolabeling of both proteins was 
characterised by tight nucleotide binding (Kd(TNPBNa-ATP) = O.B - 2.6 JiM and Kd(BNa-ATP) 
= 37 J.1M), with efficient derivatization, close to mol/mol, at acidic pH (pKa =6.B and 7.B for 
sNBD2 and LNBD2 respectively). Labeling of both proteins with both probes at acidic pH was 
completely inhibited by ATP, yielding a K.i(ATP) =0.5 - 2.7 mM. Interestingly, we find that 
both sNBD2 and LNBD2 are labeled extremely well even in the absence of Mg2+. Since the 
specificity is excellent, as judged from the complete inhibition of photolabeling by various 
nucleotides, it suggests that both isolated domains are largely folded correctly. This was 
somewhat unexpected since sNBD2 appears to lack essential (3-strands in two (3-sheets 
flanking the ATP binding site according to the crystal structure of the histidine transporter 
nucleotide binding domain, HisP. Yet, there may be important differences in site architecture 
of the isolated domains and the whole protein, especially in relation to the Mg2+ site. An 
exciting possibility is that the differences reflect the lack of the trans membrane domain in the 
isolated NBD2. It could mean that the three fairly large extra membranous loops of the 
transmembrane domain are required for proper constitution of the ATP site. 
Considerable effort was expended in trying to identify the amino acids(s) derivatised by 
photolabeling with TNP-8Na-ATP, but unfortunately it was unsuccessful. The main problems 
were: the hydrophobic nature of the NBDs which necessitated manipulation in 4-8 M urea; the 
need to use thermolysin as a proteolytic enzyme, both because of its stability in 4 M urea and 
because most other proteases catalytically hydrolyse the TNP moiety from the TNP-peptide 
adduct; the fact that, in general, many TNP-peptide were produced and the yield and range 
were variable, and the limited availability of p-gp protein. 
Thirty one f1avonoids from the classes of f1avonols, chalcones and chrysins were investigated 
for binding to the ATP site of mouse NBDs. Many contained prenylated extensions that had' 
previously been shown to bind tightly to the isolated NBDs. However, our work showed that 
such extensions prevented binding to the ATP site. The only direction for elaboration was in 
ring B, seen in the tight binding of kaempheride and even the greatly extended 
dehydrosilybin. The 3-0H group was shown to be essential for binding to the A TP site, as 
none of the chrysins. which lack this group, were able to bind. An exception to this 3-OH rule 
and blockage by prenylated extensions to ring A, was broussochalcone A, which has an open 
ring C. Its ability to bind to the ATP site is obviously related in some way to this increase 
flexibility between the A and B rings. Identification of these structural requirements for binding 
to the ATP site is important for the future design of more powerful flavonoid reversers of 
multidrug resistance. Perhaps as important is the finding that hydrophobic f1avonoids that 
previously have been shown to bind to the isolated NBDs and to reverse drug pumping do not 











A new photoprobe of ATP sites, namely (4-azido-2-nitrophenyl)AMP, where the phenyl ring is 
linked to the phosphonyl group, was synthesised. This ATP analogue may be useful for 
labeling amino aCid residues adjacent to the y-phosphate of A TP. The probe was shown to 
be photoactive and to bind to LNBD2 with an affinity similar to A TP. Addition of the TNP­
moiety onto the ribose increase the binding affinity approximately 100-f6Id, making it's binding 
similar to TNP-BN3-ATP. However, irradiation of ANP-TNP-AMP did not appear to yield a 
covalent nucleotide-protein adduct as judged from the lack of subsequent inhibition of 
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CHAPTER 1: LITERATURE OVERVIEW 
Introduction 
Emerging drug resistance to previously effective treatr('lent is a common theme in many 
diseases today (Neu, 1992). The malarial parasite, Plasmodium falciparum, first reported to 
be resistant to the anti-malarial drug Chloroquine in the 1960's (Newbold, 1990). is one of 
many organisms that developed means of escaping the damaging effects of drugs. At· 
present, drug resistance to anticancer therapy is the primary reason for treatment failure in 
cancer. (Chan et al., 1991; Ling. 1992) 
Successful treatment of tumors during chemotherapy -involves several steps. These include 
delivery of anticancer drugs to the tumor, transport into the tumor cells (passive or active), 
possible metabolism to an active form and interaction with the target molecules. Interference 
in any of these steps could contribute to drug resistance in tumors. Decreased drug uptake 
may result from changes in the physiochemical properties of the cellular membrane; 
increased drug efflux can be mediated by energy dependent drug efflux pumps; there could 
be reduced metabolic activation of the drug or increased deactivation of the drug; increased 
expression of target sites; structural changes in the target site due to point mutations; or 
increased repair mechanisms for damaged target sites (Hayes and Wolf, 1990; Bradshaw and 
Arceci, 1998). Drug resistance may be the result of a combination of the above mentioned 
mechanisms. 
Tumor cells can be either intrinsically resistant, being unresponsive to treatment from the 
outset, or acquire resistance after repeated exposure to anticancer drugs (Genach et al., 
1987; Hayes and WOlf, 1990). Classical Multi Drug Resistance (MDR) is the phenomenon 
whereby cancer cells become resistant to a wide variety of structurally unrelated compounds 
with different subcellular targets, after prolonged exposure to a single compound. The protein 
responsible for MDR was identified as a 150 -170 kDa membrane protein, called the P­
glycoprotein (p-gp) (Kartner et al., 1983; Comwell et al., 1986). 
ATP binding cassette superfamily 
The first human p-gp was cloned and purified and it was demonstrated that transfection of 
full-length cDNA for the human MDR1 into wild type cells rendered the cells resistant to a 
variety of chemotherapeutics (Hamada and Tsuruo, 1988; Pastan et al., 1988). The 
sequencing of the human p-gp revealed homologies with many other transport proteins and 
this was the " birth of a new major superfamily of proteins, called the ATP Binding Cassette 
Family (ABC type transporters). Over the years the family expanded to include proteins of 
various origins, ranging from man to micro-organisms, binding and transporting a large 
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ABC proteins had been cloned and characterized, while presently some 1 500 ABC genes 
have been sequenced (Cole et al., 1998., A. Goffeau, personnel communication). 
At the time of writing this thesis, 30 human ABC full length sequences are known (Reviewed 
by Klein et al., 1999). These ABC proteins can be grouped into 8 subfamilies, most of which 
are involved in the translocation of various substrates. The White subfamily transporters are 
involved with the transport of eye pigment precursors into pigment cells, while the members of 
the ANZA subfamily (ANZAI and ANSAII) are multi component arsenite transport systems. 
The 4 ALD subfamily transporters (ALDP, PMP70,·ALCPR and PMP69) are all localized to 
the peroxisomal membrane and mutations in these proteins lead to peroxisomal disorders. 
The functions of the members of the ABC1 subfamily - the largest of the human ABC proteins 
- are currently being elucidated and there is evidence supporting the involvement of these 
proteins in the engulfment of apoptotic cells by macrophages. The function of ABC50, the 
only member of the GCN20 subfamily, is unknown. Not fulfilling a transport function, the 
OABP (or RNAse L inhibitor) subfamily acts as regulatory proteins whose co-expression 
inhibits activation of RNase L. The proteins implicated in multi drug resistance are part of the 
subfamilies MDR1ITAP and MRP/CFTR and are discussed in more detail below. 
The sequencing of several microorganisms' genomes revealed that the ABC family is very 
well represented and appears to be involved in the transport of a wide variety of substrates. 
Thermogata maritima, a thermophilic bacterium belonging to. the order Thermotogales, 
possesses a large number of carbohydrates and amino acid transporters. Of these, 84 % are 
members of the ABC super family - with 9 sugar ABC transporters, 11 oligopeptide ABC 
transporters and several miscellaneous transporters: one ribose transporter, two maltose 
transporters, one glycerol transporter, two amino acid transporters, a phosphate transporter 
and a spermidine transporter (Nelson et al., 1999). The genome of Mycobacterium 
tuberculosis. responsible for the chronic infectious disease tuberculosis, revealed 10 ABC 
transporters, The roles of these transporters again proved to be diverse and were postulated 
to be involved in electron transport (cydC and cydD). sugar uptake (sugC). molybdate uptake 
(modC). phosphate transport and uptake (phoT and pstB). osmoprotection (proV) and. of 
course, drug resistance (drrA giving rise to daunorubicin resistance) (Cole et al., 1998). 
The yeast genome yielded 29 putative ABC proteins. Of these, 19 are predicted to be 
localised in the plasma membrane. 2 are localised either in the. endoplasmic reticulum or 
plasma membrane. 5 are predicted to be soluble and 3 are localised in the mitochondria 
(Decottignies et al., 1997). Of the 29 proteins, biochemical or physiological information is 
available for only 10 proteins (STE6, Pdr5p, SNQ2, Yor1p. YCF1, GCN20, YEF3, PXA1. 
YKL88, and ATM1). Six families could be distinguished according to amino acid sequence 
homologies and these could be further divided into 10 subclusters. The majority of these 
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single peptide [rMD-NBD-TMD-NBD] (ctuster I) or [NBD-TMD-NBD-TMD] (ctuster II) and 
another 6 as "halfe proteins", [rMD-NBD][rMD-NBD] or [NBD-TMD][NBD-TMD (ctuster II). 
The five proteins allocated to ctuster IV are unique in displaying two NBDs but no 
transmembrane domains and are postulated to interact with tRNAs, while the smallest yeast 
ABC protein is the YFL028 (ctuster VI) with only one NBD - resembling a soluble ATP-binding 
subunit. 
In the future, by comparing sequences of ABC proteins found in microorganisms, the human 
equivalents could be identified and knowledge of these related proteins utilized in functional 
studies - shedding light on mechanisms of human disease. Analysis of human genes 
expressed in yeast cells can also be very powerful in elUCidating the function of unknown 
human ABC transporters. 
The MORITAP subfamily 
Well known members of this family are the mammalian p-glycoproteins: the human MDR1, 2 
and 3, the rat and murine Mdr1a, Mdr1b (also called Mdr3 and Mdr1) and Mdr2 and the 
hamster Pgp1, 2 and 3 (Borst, 1997). Of these the human MDR1, the rat and murine Mdr1 a 
and Mdr1 b and the hamster Pgp1 and Pgp2 are responsible for the MDR phenotype 
observed in the cells in which they are over expressed. There is also evidence that these 
proteins act as broad specificity translocases for short chain phospholipids in vivo (Bosch et 
a/., 1997). The human MDR2 and 3, the rat and murine Mdr2 and the hamster Pgp3 are 
phosphatidylcholine translocators responsible for phosphatidylcholine transport into bile 
(Ruetz and Gros, 1994, Bo~t, 1997, Dekkers et a/., 1998, Smith et a/., 1998,). 
P-gp typically consists of two homologous-membrane associated halves. Each half is made 
up of a transmembrane domain (TMD) - postulated by hydropathy amino acid analysis to 
span the membrane 6 times - and a nucteotide binding domain (NBD) on the cytoplasmiC 
face of the membrane (yoshima et a/., 1989, Liu et a/., 1998, van Veen et a/., 1998). The 
mammalian protein is arranged in a [rMD-NBD-TMD-NBD] configuration and is expressed as 
a single polypeptide (Fig 1.1). 
TMD1 












Figure 1.1. Mammalian p-gp is expressed as a single polypeptide and is arranged in 
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Other members of this subfamily, TAP1 and TAP2, exist as half transporters - [TMD-NBD]. 
By forming a heterodimer the TAP1ITAP2 complex acts as a peptide transporter carrying 
peptides across the endoplasmic reticulum membrane, making the peptides available for 
immunorecognition by the major histocompatibility complex. Although different membrane 
topologies for p-gp have been suggested, present data favour the "six-plus-six" model 
(Revievved Higgins et a/., 1997, Kast et a/., 1996, Loo and Clarke, 1995). 
The NBDs have 3 sequence signatures characteristic of ABC transporters and other ATP 
binding proteins: the consensus Walker A [G(X)4GKSIT] and Walker B [RlK(X)&8L(Hyd)4D] 
motifs and a short linker peptide -LSGG(XhRHydXHydA- between the Walker A and Walker 
B motifs (where Hyd indicates a hydrophobic amino acid) (Walker et a/., 1982, Ames et a/., 
1992). The conserved lysine residue in the walker A motif (K) proved to be essential for drug 
transport and ATPase activity in all ABC transporters characterized to date; the yeast Pdr5p 
being the ex~ption to this rule 'as it lacks this lysine residue in NBD1(Cole et al. 1998). 
Intronlexon analysis of the MDR1 gene suggests that p-gp arose by a gene fusion event of 
two related but independently evolved proteins, rather than by gene duplication as previously 
suggested (Chen et a/., 1986, Gros et al., 1986, Chen et a/., 1990). Again a subject of 
debate, the oligomeric state of p-gp appears to be a monomer (Loo and Clarke, 1996). This 
is supported by a recent low resolution structure (2.5 nm) of hamster p-gp where the crystal 
structure exhibits a single protein consisting out of two mirror images, each made up from 6 
TMD units (Rosenberg et al., 1997). 
The MRP/CFTR subfamily 
An additional protein, the Multidrug-Resistance-Associated Protein (MRP1), was also found to 
confer a multi drug resistance phenotype in vitro (Berger et al., 1997, Deeley and Cole, 1997. 
Norris et al., 1996; Grant et al., 1994; Kruh et al., 1994; Cole et al., 1992). This new member 
of the ABC family has a molecular weight of 190 kDa and shared a 15 % amino acid identity 
with p-gp. MRP is able to transport glutathione (GSH) conjugates of drugs, explaining how 
MRP1 can provide resistance to small hydrophiliC oxyanions like arsenite and antimonite 
(Borst et al., 1997). Arsenite can form trivalent complexes with GSH and there is proof that 
this is the form in which arsenite is extruded from cells by MRP1. The human canacular 
Multispecific Organic Anion Transporter (cMOAT) (also called MRP2) functions as an anionic 
conjugate transporter and absence of this protein results in the Dubin-Hohnson syndrome --a 
condition characterized by conjugated hyperbilirubinemia and impaired secretion of anionic 
conjugates from hepatocytes into bile. 
Not long after the identification of the first MRP, several other structurally similar transport 
proteins were identified which now constitute the MRP branch of the ABC superfamily. Other 
proteins belonging to the MPR branch are the sulfonylurea receptor and K+ channel regulator 
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1997). ATP sensitive potassium channels, K(ATP), are made up from heteromultimers - 4 
pore forming, inwardly rectifying I< channel subunits, Kir6.x, complexed with 4 regulatory 
sulfonylurea receptor (SUR) subunits (Reviewed by Babenko et a/., 1998). Typically, 
SUR1/Kir6.2 complexes are found in neuronal and pancreatic beta-cells, SUR2AlKir6.2 in the 
heart and SUR2B/Kir6.1 in vascular smooth muscle (Dorschner et a/., 1999). Inwardly 
rectifying K+ channels are affected by nudeotide levels and therefore couple membrane 
conductance to metabolism by regulating electrical activity of cells through controlling 
membrane potential or modulation of action potential (Schwanstecher et a/., 1998). In ~-cells 
of the pancreas, opening of Kir6.2 sets a resting potential while dOsing depolarizes the 
plasma membrane, causing Ca2+ influx through a voltage sensitive L-type Ca2+ channel and 
insulin release. Mutations in channel subunits that prevent dosure, cause Familial 
Hyperinsulinism. Hypoglycemic sulfonylureas like glipizide and tolbutamide, dose the ATP­
sensitive potaSSium channels of ~-cells(Ashfield et a/., 1999). 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a cr channel in lung 
epithelial. Defects in this protein are responsible for Cystic Fibrosis - one of the most 
common lethal genetic diseases among Caucasians today (Riordan et a/.,1989). CFTR is a 
cr channel and also possibly regulates other channels in lung epithelial. Being structurally 
similar to p-gp, CFTR also contains the duplicated [rMD-NBD-TMD-NBD1 motif, but differs by 
the presence of a large cytoplasmic "R-domain" found between the two halves of the protein. 
Phosphorylation of this R-domain by protein kinase A is essential for channel function. 
Although the 2 NBDs of CFTR function cooperatively in catalysis the NBDs are not 
structurally and functionally as similar as seen with p-gp (Senior and Gadsby, 1997, Cotten 
and Welsh., 1998, Gadsby et a/., 1998, Ramjeesingh et a/., 1999, Szabo et a/., 1999). This is 
one of the major differences between these 2 groups -the NBDs of p-gps are very similar and 
performs the same function while the NBDs of MRP proteins are markedly less similar and 
are postulated to act in a functionally distinct manner. Hydrolysis of ATP at the N-terminal 
NBD is the rate-limiting step for opening a phosphorylated CFTR channel, while hydrolysis at 
the C-terminal NBD triggers channel closing. Channel regulation is, however, not yet 
completely understood and is complicated by phosphorylation of multiple sites in the R­
domain and by ATP hydrolysis at the NBD's. 
MRPs differ structurally from p-gps by the presence of a third N-terminal transmembrane 
spanning region, where the protein crosses the membrane 5 times with the N-terminus 
extracellular, joined to the rest of the protein by a intracellular linker region (Kast and Gros, 
1998). Intron/exon analysiS of MRP coding genes suggests a fusion event bet;ween a gene 
encoding the additional N-terminal membrane-spanning region and the gene encoding a 
common 4-domain ancestor, resulting in a [rMD-TMD-NBD-TMD-NBD] polypeptide 
configuration (Grant et a/. 1997, Tusnady et a/. 1997). The function of this additional 
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behaves like wild-type MRP1 in both transport function and regulation of membrane targeting 
(Bakos et a/. 1998). There are no three dimensional structures available on this branch of 
the ABC family. 
MDRIT AP and MRP/CFTR subfamilies of micro organisms 
The ABC transporters of microorganisms linked to drug resistance, have also been divided 
into two groups according to their mammalian family members (van Veen and Konings, 1998, 
Klein et a/.• 1999). The MDR group consists of, among others, the Pdr5p and Snq2p proteins 
from Saccharomyces cerevisiae, responsible for pleiotropic drug resistance in yeasts (Balzi et 
a/., 1994; Decottignies et a/., 1995) the Cdr1p protein expressed by Candida albicans, 
conferring antifungal resistance (Prasad et a/., 1995) and the pfMDR1 protein from 
Plasmodium falciparum, implicated in drug resistance in malarial parasites (Foote et a/., 1989; 
Wilson et a/., 1989). The mechanism of pfMDR1 mediated drug resistance is uncertain 
however, as previous evidence of resistance to quinoline-containing antimalarial drugs by 
active extrusion in yeast 9verexpressing pfMDR1, proved not to be reproducible (Ruetz et a/., 
1996b; Ruetz et a/. 1999). Examples of the MRP group are the Ycf1p and Yor1p proteins from 
Saccharomyces cerevisiae, conferring cadmium and pleiotropiC drug resistance respectively 
and 1tPgpA from Leishmania tarento/ae, giving rise to heavy metal resistance (callaghan et 
a/., 1991,Szczypkaeta/., 1994; Cui eta/., 1996, Decottignieseta/., 1998.). 
Similar to their mammalian relatives, the p-gJycoproteins of microorganisms are also 
expressed in a "six-plus-six" membrane topology with variations on the [TMD-NBD-TMD­
NBD] theme. Yeast proteins PdrSp and Snq2p are typically expressed as a single 
polypeptide with a membrane topology of [NBD-TMD-NBD-TMD] - the reverse of the 
mammalian protein topology - while pfMDR1 retains the topology seen for p-gp. Other ABC 
proteins of microorganisms, such as LmrA of Lactococcus lactis and ADP1p of S.Cerevisiae, 
are expressed as half p-gps with a single TMD domain and NBD in a [TMD-NBD] 
configuration. There is evidence that these two halves associate in the membrane to fonn a 
single active transporter - [TMD-NBD][TMD-NBD] (Berkower and Michaelis, 1991, Berkower 
et a/., 1996. Gao et a/.• 1996). As another variation on the theme, the DrrAB transporter of 
Streptomyces expresses its TMDs as a single polypeptide which associates with a second 
NBD containing polypeptide to fonn an active transporter - [TMD-TMD][NBD-NBD]. 
Functional Similarities of p-gp and MRP 
Not surprisingly, proteins of the ABC family demonstrate functional similarities and can 
successfully swop the roles under challenge. With conservative replacements, such as the 
mouse Mdr2 protein with its human homolog MDR3, the introduced protein completely 
restores the excretion of phospholipids into the bile (Smith et a/., 1998). Both mouse mdr3 
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et al., 1992. Volkman et al., 1995). Human MRP1 also partially restores mating in yeast 
lacking Ste6p and completely regenerates resistance to cadmium completely in cadmium­
sensitive. Ycf1p lacking, yeast (Tommasins et al., 1996. Ruetz et al., 1996a). Surprisingly, 
when the bacterial antibiotic-resistance protein, LmrA, was expressed in human lung 
fibroblast cells. it proved to be completely functionally interchangeable with human MDR1 ­
showing similar phannacological characteristics and affinities for vinblastine and Mg-ATP (van 
Veen and Konings, 1998). EVen MRP, that shows low levels of structural homology to Ste6p, 
restores mating in sterile Ste6 mutants (Ruetz et al.• 1996a). When MDR1 residues 0330, 
V331 and L332 of membrane spanning domain 6 were introduced into human MDR2 (a 
phosphatidylcholine transporter), it was sufficient to allow MDR2 to transport several MDR1 
substrates, again indicating close functional relationships between proteins of the ABC family 
(Zhou et al., 1999). 
Nucleotide Binding Domains of p-gp 
P-gp shows a characteristic drug-stimulated. vanadate-inhibited, ATPase activity with a Km for 
MgATP of 1 mM and a Vmax of 0.3 - 2 ).lfl1OI per min per mg of protein. The 2 nucleotide 
binding domains of p-gp share over 80 % sequence identity and almost all of the sequence of 
NBD1 can be exchanged with the corresponding NBD2 fragments with no significant loss of 
function (AI-Shawi et al" 1994, Beaudet et al., 1998). Vanadate trapping of ATP (Fig 1.2) ­
where vanadate trapping requires hydrolysis of the nucleotide - in one NBD completely 
inhibits ATP hydrolysis in the other site showing that the amino- and carboxy- tenninal 
nucleotide-binding domains (NBD1 and NBD2) cannot function independently as catalytic 
sites (Urbatsch et al., 1995). 
! 
Pi 
k+1 k+2 k+3 k+4 
MgA TP + p-gp ~ p-gp·MgATP ~ p-gp·MgADP·Pi ~ p-gp·MgADP ---l p-gp + MgADP
~1 ~2 k~ '!k; 
P-gp·MgADP·Vi 
Figure 1.2. The mechanism for vanadate trapping of ATP, adapted from Senior et al.. 1995 
Vanadate trapping of Mg - or Co-8N3-ATP - followed by photo-attachment of the nucleotides 
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that hydrolysis is possible at both nucleotide binding domains (Urbatsch et al., 1995). 
Vanadate trapping of ATP is completely abolished in mouse Mdr3 mutants showing no 
ATPase activity (point mutations in the Walker A - K429R, K1072R - or Walker B motifs ­
D551 N, D1196N - in each of the two NBOs). Mutations in one NBD site prevents a single 
turnover and trapping in the nonmutated site, again showing that the NBDs cannot function 
independently as catalytic sites (Urbatsch et al., 1998). NBD1 and NBD2 can both bind and 
hydrolyze ATP, but apparently ATP is not hydrolyzed Simultaneously by both sites. 
Reconstituted p-gp incubated with ATP or 8Ns-ATP and subjected to photochemical peptide 
bond cleavage with orthovanadate and ultraviolet light yielded cleavage products 
representative of either of the ATP sites, suggesting that ATP hydrolysis is limited to one 
binding site at a time (Hrycyna et al., 1998). Mutations in one NBD (lysine to methionine and 
cysteine to alanine in the Walker A motif), completely inhibit ATP hydrolysis even when the 
nonmutated NBD contains a bound nucleotide (Takada et al., 1998). 
N-ethylmaleimide (NEM) inactivation of ATPase activity is another powerful tool to dissect 
events taking place at either NBD. NEM reacts with cysteine residues (CyS431 and Cys1074 in 
the human sequences or Cys430 and Cys 1072 in the mouse sequence) within the Walker A 
motif and inactivates ATPase activity (Loo and Clarke, 1995a). The cysteine itself in each 
NBD is not essential as p-gp devoid of cysteine residues retains it's ability to confer 
resistance similar to wildtype, indicating that the ethyl succinimide moiety of NEM is probably 
positioned close to the catalytic site of p-gp (Loo and Clarke, 1995a., Liu and Sharom, 1996). 
In the latter study, where a single cysteine was re-introduced into a cysteine-less p-gp mutant, 
it was shown that covalent modification of a single cysteine residue by NEM within either of 
the nucleotide binding domains was adequate for complete inhibition of ATPase activity (Loo 
and Clarke, 1995b). Similar results were obtained when p-gp was allowed to react with 7­
chlor0-4-nitrobenzo-2-oxa-1,3-diazole (NBD-CI) that modifies the same cysteine residues as 
NEM, CyS431 and Cys1074 in the human and hamster sequence or CyS430 and Cys 1072 in the 
mouse sequence (Senior et al., 1998). The nucleotide binding domains are labeled 'in a non­
selective fashion, and reaction of one site with NBD-CI prevents reaction with the other site 
and completely inhibitions ATPase activity (Senior et al., 1998). This supports the vanadate­
induced ATP trapping experiments showing that NBD1 and NBD2 interact strongly and that 
catalytic cooperativity between NBD1 and NBD2 is mandatory for ATPase activity. 
Analysis of the drug and nucleotide binding sites has relied heavily on the use of radiolabeled 
photoactive substrates, reversers and nucleotides (Kotzybe-Hilbert et ai, 1995, Greenberger, 
1998). The majority of these analogs contain either tritiated or iodinated phenyl-substituted 
arylazide groups. Aromatic azides are some of the most widely used photoaffinity probes, but 
this common use is more related to the chemical stability in the dark and ease of synthesiS 
than it's general suitability for the task. On ultraviolet irradiation of a phenyl azide, the azide is 
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b) undergo intersystem crossing to a triplet azide, which can also loose a nitrogen to form a 
triplet nitrene. The different intermediates lead to different reactions in photoaffinity labelling 
experiments. In the case of the singlet nitrene an ideal, seemingly non-ciiscrimative, reaction 
with any amino acid residue or medium constituents is expected. Triplet azides react with 
nucleophiles such as cysteinyl and histidinyl residues, while triplet nitrenes lead to less 
predictable radical chemistry. The latter two species are not ideal labelling reagents as they 
react slowly and preferably with nucleophiles. Inherently, photoactive ligands also present 
certain limitations. The addition of a photoactive moiety changes the structure of the ligand, 
possibly perturbing receptor-ligand interaction. The reactive domain of the ligand may be 
some distance away from the actual site of interaction and the reactive intermediate could 
have a long half-life, allowing it to diffuse from the binding site at the time of irradiation giving 
rise to non-specific labeling (Greenberger, 1998). 
P-gp has been shown be derivatised by the photoactive nucleotide derivatives B-azido-ATP, 
2-azido-ATP and 2',3'-O-(2,4,6-trinitrophenyl)8-azido-ATP (TNP-8N3-ATP) (Comwell et al., 
1986, al-Shawi et a/., 1994, Sankaran et al., 1997b, Decottignies et al., 1998). The 
recombinant mouse C-terminal nucleotide binding domain and N-terminal nucleotide binding 
domain, overexpressed in Escherichia coli, bound the TNP derivatives of ADP and A TP ­
TNP-ADP and TNP-ATP - and MANT ATP (2'(3')-N-methylanthraniloyl-ATP) with high affinity 
(Baubichon-Cortay et a/., 1994, Dayan et a/., 1997). Vanadate-assisted trapping of Mg-8­
azido-ADP in the catalytiC site of P-9p, followed by photoactivation, led to the identification of 
Tyr398 and Tyr1041 as the labeled amino acids (Sankaran et a/., 1997b). 
Drug Binding Sites 
The P-9p's ability to bind a wide range of structurally diverse compounds suggests the 
existence of either many different binding sites or a non-specific promiscuous site. Several 
mutagenesiS and photolabeling studies placed the drug binding sites of P-9P in the membrane 
spanning regions (TM) of the protein. In a site-directed mutagenesiS study, the 
transmembrane segment 6 (TM6) of human P-9P proved to play an important role in drug­
protein interaction and coupling of drug binding to ATPase activity (Loo and Clarke., 1994a). 
Further studies showed that TM6 and TM12, possibly situated close to each other in the 
tertiary structure, form part of a drug binding pocket (Zhang et a/., 1995, Loo and Clarke, 
1997a). Mutations located within TM4-6 reduced the inhibitory effect of various steroids, 
suggesting poor binding of these steroids to a disrupted binding site (Quang and Gruol, 
1999). Other transmembrane helixes may also be involved: mutations to His61 in TM1 of 
human P-9P to influences substrate specificity while mutations in TM3 (GIy185Val) result in a 
decrease in drug transport (not due to a decrease in drug binding, but in bound drug released 
from the protein) and mutations in TM11 led to decreased drug binding to P-9P (Safa et a/., 
1990, Kajiji et a/., 1993, Taguchi et a/., 1997). When hamster p-gp was photolabeled with a 
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of TM11 and the end of TM12 (Demeule et al., 1998). The binding sites of prazosin and 
forskolin were also placed at TM6 and TM12 according to photolabeling studies with azide 
derivatives (Greenberger et a/., 1991, Greenberger et a/., 1993, Zhang et al., 1995). 
25Photolabeling of hamster p-gp with C 'Jiodomycin showed the binding site to be formed by 
the last segment of TM4, the beginning of TM5 (Demmer, et a/., 1997). In summary, using 
both mutagenesis and photo labeling studies, drug binding sites had been allocated to TM 
4,5,6,11 and 12, while mutations in TM1 and 3 was also demonstrated to be involved in drug 
binding and translocation. 
Evidence of multiple drug binding sites is mounting. The p-gp substrate, vinblastine and the 
p-gp reverser, verapamil (discussed below), compete for the same or overlapping sites, while 
nicardipine binds on a distinct but interacting site (Pascaud et a/., 1998). Azidopine, a 
photoactive compound, labels p-gp in two distinct locations - one within the amino half of the 
protein and one in the carboxy half of the protein (Bruggemann et a/., 1992). Using 
25C 'Jiodoarylazidoprazosin, a photoactive analog of prazosin, two nonidentical drug-interaction 
sites were located on p-gp, again one on each halve of the protein (Dey et al., 1997). 
Verapamil and progesterone derivatives are also shown to bind in a noncompetitive fashion, 
pointing to distinct binding sites for these compounds on p-gp (Oriowski et al., 1996). Two 
photo reactive analogs of taxol, 3' and 7'-p-benzoyldihydrocinnamoyl (BzDC) , specifically 
photolabeled murine mdr1b at two distinct sites - 3'-BzDC identifying a region that includes 
half of transmembrane domain 12, terminating just after the Walker A motif of NBD2 and 7'­
BzDC identifying a region including all of TM7 and half of TMB fY'Ju et a/., 1998). An 
overlapping site for steroids and anthracyclines within the first half of the protein and a 
taxzane site within the second half of the protein has also been proposed (Quang et a/., 
1999). 
It is clear that the interaction of drugs with the TM domains and drug binding sites of p-gp are 
complex. In a feasible proposal explaining the non-specificity of the drug binding sitels, 
Shapiro and Ling argued that substrates and reversers bind to the drug binding sitels of p-gp 
from of the lipid bilayer (Shapiro and Ling., 1998b). An idea previOUsly proposed by Ravivet 
a/. (1990) using 5-[125IJiodonaphthalene-1-azide ([125IJINA) and confirmed by Homolya et a/. 
(1993); that demonstrated that the hydrophilic free acid from of an acetoxymethyl ester was 
not exported by MDR1. The high local substrate concentration in the restricted bilayer 
volume could lead to the binding to low affinity, low specificity site/so Shapiro and Ling also 
propose the presence of at least two sites, each interacting with the other in a positive c0­
operative manner. Following Hoechst 33342 and/or Rhodamine 123 movement after ATP 
addition by monitOring the initial rate of decrease in fluorescence as the compounds are 
transported into the inside-out vesicle interior, several conclusions were drawn (Shapiro and 
Ling, 1997b). The fluorescent dyes, Hoechst 33342, and Rhodamine 123 both bind to 
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inhibited Hoechst transport while stimulating Rhodamine 123 transport. On the other hand, 
Daunorubicin and other anthraoyclines had the opposite effect - they stimulated Hoecht 
33342 transport, while inhibiting transport of Rhodamine 123. Other p-gp modulators like 
vinblastine, actinomycin D, and etoposide inhibited both Hoechst 33342 and Rhodamine 123 
transport, indicating that these drugs ate binding to both sites. 
In an extensive overview of current photolabeling data by Greenberger (1998) and Safa 
(1998) photolabeling studies points to the presence of four overlapping but distinct modulator 
binding sites - one for vinblastine, verapamil, cyclosporin A and phenothiazines, a second for 
dihydropyridine calcium channel blockers, a third site for megestrol acetate and the calcium 
channel blockers bepridil and prenylamine; and a fourth for [1251]arylazidoprazosin 
([1251]AAP). Using equilibrium and kinetic radioligand binding assays Martin et a/. (2000) 
identified the presence of at least 4 distinct binding sites on p-gp - 3 of which are drug binding 
sites. The current literature supports the presence of more than one drug binding site, but the 
complex allosteric interactions between these various sites and the modulator binding sites 
discussed further in the next section, remain to be elucidated. 
Modulator Binding Sites 
Several compounds, called p-gp modulators, also interact with p-gp, having various effects on 
ATPase activity, drug binding and extrusion. Reversers are a group of hydrophobic, 
structurally diverse p-gp modulators responsible for decreased drug extrusion and the 
reversal of multi drug resistance. The mechanism of inhibition of drug extrusion can be 
diverse. Some may act as substrates of p-gp and competitively inhibit efflux of the cytotoxic 
agents from the cell. Others may bind at the substrate site, but not be transported. Binding at 
a second substrate binding site or to a separate allosteric inhibitory sites - either in the 
membrane domain or in the NBD - can also lead to p-gp inhibition. Compounds that inhibit 
A TP binding and hydrolysis have also received attention as potential p-gp reversers. 
Examples of classical reversers are the calcium channel blockers verapamil and SR33557, 
antiarrhythmic agents such as quinidine, the immunosuppressant cyclosporin A, vinca 
alkaloid analogs and the anticancer drug. tamoxifen (Tsuro et a/., 1981. Slater et a/., 1986, 
Zamora et a/.• 1988. Solary et a/.• 1991, Callaghan et a/., 1995, Jaffrezou et a/., 1995 and 
Nayfield et a/.• 1995). Different reversers bind to p-gp at different sites and the resulting effect 
is often complex with respect to ATPase activity as well as the modulation of drug binding and 
transport. Martin et a/. (2000) demonstrated the existence of 4 binding sites on p-gp - 3 drug 
binding sites and 1 regulatory site. The 4 binding sites were shown to display complex 
allosteric interactions. where binding at one site switches the other sites between high and 
low affinity conformations. Not all modulators tested seemed to interact with p-gp at the 
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Studies using various reversers further demonstrate regulatory complexity. Reversers 
verapamil and progesterone both increase basal ATPase activity, reversing drug resistance 
by competing with the transported substrate vinblastine (Garrigos et al., 1997, Callaghan et 
al., 1997). Verapamil inhibits vinblastine binding in a competitive manner, but since these two 
compounds have different effects on both basal p-gp activity and on MgATP concentration 
dependence of p-gp ATPase activity, it suggests that they bind p-gp either on different and 
overlapping sites or on distant but interacting sites. Typically, vinblastine has little or no 
stimulatory effect on ATPase activity, whileverapamil activates. Also, lower concentrations of 
MgATP are needed for half maximal ATPase activity in the presence of verapamil than in the 
presence of vinblastine. Progesterone inhibits vinblastine binding in a non-competitive 
manner, suggesting a separate site for this reverser (Garrigos et al., 1997). A photoreactive 
dihydropyridine, (2,6-dimethyl-4-(2-(tritluoromethyl)-phenyl)-1,4-dihydropyridine-3,5­
dicarboxylic acid {2-[3-(4-benzoyiphenyl)propionyiaminO]ethyl} ester ethyl ester) labels 
multiple reverser binding sites - as was demonstrated by the noncompetitive nature of 
inhibition by various compounds - distinct from the vinblastine binding site on p-gp in 
membranes of multidrug-resistant CCRF-ADR5000 cells (Boer et al., 1996). 
Depending on steroid hydrophobicity and the phosphorylated state of p-gp, steroids can act 
as either substrates or reversers (Barnes et al., 1996). There is evidence of multiple steroid 
binding sites on p-gp as shown by the mutually non-exclusive inhibition of ATPase activity by 
four progesterone derivatives (Orlowski et al. 1996). This apparent lack of specificity could, 
alternatively, reflect the ability of the steroids to accumulate within the p-glycoprotein 
containing membranes - where greater accumulation of a specific steroid will be reflected in 
higher concentrations of steroid available for interaction with p-gp (Quang and Gruol, 1999). 
Photoaffinity labeling of human p-gp with tritiated progesterone, FH]progesterone, placed the 
progesterone binding site in the membranous domain of p-gp, since photolabeling of the p-gp 
is overcome by a 200 fold molar excess of vinblastine (Qian and Beck, 1990). The more 
recent results contradict the earlier, placing the progesterone binding site separate from the 
vinblastine binding site (Garrigos et al. 1997). In a study where tryptophan fluorescence was 
used to report modulator binding to a mouse recombinant NBD1 (corresponding to segment 
371-705, where Trp696 fluorescence is monitored) the steroid RU 486 and AS-progesterone 
bound to a site distinct form the nucleotide binding site on the NBD (Dayan et al. 1997). 
MonitOring the effect that various peptides, drugs and reversers (including progestero~, 
verapamil and vinblastine) had on ATPase activity, the existence of a common drug and 
modulator binding site is also argued (Borgnia et al., 1996). 
Of particular importance to this study, another class of reversers called flavonoids, was shown 
to bind at the nucleotide binding domains of p-gp. Again using tryptophan fluorescence, the 
binding site of various flavonoids was placed next to the ATP binding site and overlapping 
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nucleotide binding domain (H6-NBD2) of mouse p-gp (Conseil et al., 1998). Binding of a 
flavone to recombinantly expressed C-terminal NBD2 of Itnndr1 of Leishmania tropics was 
directly correlated with flavone inhibition of daunomycin efflux and parasite growth inhibition in 
the presence of flavone - the first study to demonstrate the relationship between reverser , 
binding to NBD and reversal of drug resistance of p-gp (Perez-Victoria et al., 1999), 
Recently, several contradictory findings were reported on the naturally occurring flavonoids 
quercetin, kaempferol and genistein (Ferte et al., 1999). For example, quercetin was 
demonstrated to activate p-gp, resulting in an increase in doxorubicin resistance, while other 
groups demonstrated that quercetin inhibited'p-gp mediated transport of rhodamine 123 and 
Hoechst 33342 (Critchfield et al., 1994, Scambia et al., 1994, Shapiro arid Ung, 1997a). 
Since flavonoids are found in abundance in plants, fruit and vegetables, it should be 
considered as a contributing factor during chemotherapy treatment (Perez-Victoria et a/., 
1999). 
Drug design and structure activity relationships 
First generation reversers, mainly verapamil, cydosporin A and structurally related analogues 
had mediocre benefits in dinical trails - the benefit of mdr reversal overshadowed by the 
added toxicity of the reverser (Dhainaut et al., 1996). A common theme in many MDR 
reversers are that these structurally diverse compounds are generally hydrophobic or 
amphipathic, mostly protonated, contain a CYClic tertiary amine and several aromatic ring 
syStems (Zamora et al., 1988, Gottesman and Pastan, 1993, Pajeva and Wiese, 1998, Berger 
et al., 1999). Rational drug design is aimed at providing a new generation of reversers with a 
higher affinity for p-gp with more potent inhibitory effects at lower concentrations of drug with 
fewer side effects or added toxicity. In drawing conclusions about the efficiency of reversers 
of multidrug resistance, both immediate effects of the reverser on the p-gp - like drug 
extrusion inhibition - and the long tenn effects on the cell system in vivo - like cell toxicity 
must be considered (Ferte et al., 1999). In order to give a short overview of recent 
developments in this field, especially novel flavonoid derivatives, 3 representative studies are 
briefly discussed below. 
In one study, 28 flavonoid derivatives (from parent compound diosmentin, Fig 1.3) containing 
a N-benzylpiperazinechain (Fig 1.4) were evaluated for MDR-modulating activity (Ferte et a/., 
1999). 
Figure 1.3. The chemical 
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The rationale behind these new derivatives was to increase it's lipophilic properties (by mono 
or diacetylation of the phenol groups at various positions) and to introduce a basic nitrogen 
(by adding a N-benzyl group). Previous studies looking at structure-activity relationships of p­
gp interacting drugs and their effects on ATPase activity showed that p-gp affinity for drugs 
was highly correlated with the surface area of the drug while ATPase stimulation was 
dependent on the partition coefficient of the drug into the plasma membrane (Litman et a/., 
1997). In the Ferte et al. study a variety of factors influenced reverser characteristics, but 
lipophilic compounds containing several ring systems and a tertiary amine are good 
candidates for MDR modulation. Importantly, the nature of substituents on the flavonoid 
phenols and on the benzyl ring were critical in determining the potency of the molecule. 
Replacement of the flavone ring by flavanone (the double bond at position 2,3 on ring C is 
reduced, see Fig 1.7 for labeling) did not alter the MDR-modulating efficiency of the molecule, 
but did prove to be less toxic in vivo. Substitution of flavone hydroxyl groups showed a direct 
correlation between the position of substitution and mdr-modulation activity, while there was a 
more complex relationship between the benzyl substitution pattem and modulation potency of 
p-gp. Quaternization of the basic nitrogen proved to be detrimental to activity and suggests a 
critical requirement of reversers to display a basic nitrogen. This probably reflects the 
charged compound's inability to cross the lipid membrane, rather than it's inability to interact 
with the drug binding site. It appears that lipophilicity is not the sole determinant of the 
degree of MDR-modulating activity of a reverser, but can be regarded as a favourable 
parameter within a homologous series. The most active compounds were either a flavone or 
a flavanone moiety with a 2,3,4-trimethoxybenzylpiperazine chain (Fig 1.4) and were more 
potent than the classical reverser, verapamil. 
OMe 
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4) R1 - 2,3.4-(MeO) 




Figure 1.4. The chemical structures of diosmetin derivatives identified to be potent MDR reversers 
Using verapamil as the parent compound (Fig 1.5), 59 a-aryl-a.-thioether-alkyl, -alkanenitrile, 
and --alkanecarboxylic acid methyl ester tetrahydroisoquinoline and isoindoline derivatives 
were synthesised in the quest to find tight binding, low toxicity p-gp reversers (Berger et a/., 
1999). Several of these compounds restored sensitivity to vincristine in mice and proved not 
to be cytotoxic at doses needed for mdr reversal. 
MeO 
MeO 
Figure 1.5. The chemical structure ofVerapamii 
This effect was believed to be the result of direct interaction with p-gp. Compound 15h (Fig 
1.6), the most potent of this series of reversers, was demonstrated to bind directly to p-gp 
25through its' prevention of p-gp photolabeling with C 11iodoarylazidoprazosin - a reporter of 
the vinblastine binding site. Compound 15h is not extruded by p-gp like verapamil and 
cyclosporin A, which would argue for either tighter binding to the same site as vinblastine or 
binding to a second distinct site. It appears from their work that electron donating alkoxy 
substituents on the aromatic rings provided greater inhibition than halogens in the same 
position. Altering the steric bulk of R5 and R6 grollPS affected binding to p-gp strongly. 
Changes to linker chain length, n, and larger substituents at R1-R4 were well tolerated. Thus, 
although the p-gps bind a wide variety of structurally unrelated substrates and reversers, they 
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the effective compounds were shown to be nontoxic, reverse drug resistance in vivo, and to 
directly interact with the p-gp. 
R1 - OMe 
R2 - OMe 
R3 - OMe 
~-Ome 
Rs - p-tolyl 
Rt; - CN 
n-5 
m - 2 
Figure 1.6. The chemical structure of compound 15h 
Tight binding halogenated chalcones are i;llso promising candidates for MDR reversers (Bois 
et aI., 1998). Variations on naturally occurring chalcones, flavones, and isoflavones (Fig 1.7) 
showed that flavones generally have a higher affinity for recombinantly expressed mouse C­
terminal NBD than isoflavones. A hydroxy group at position 5 (or position 2 in chalcones) on 
ring A proved to be essential for tight binding to the NBD, while substitutions at position 7 (or 
position 4 in chalcone) were well tolerated. Reducing the double bond at position 2,3 on ring 
C in flavones had a detrimental effect on binding to the NBD. 
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Site-Site interaction 
Not only do the two nucleotide binding domains of p-gp interact strongly with each other, but 
interaction between the transmembrane domains and the nucleotide binding domains is 
mandatory for drug binding and translocation. When the NH2- and COOH- terminal halves of 
human p-gp were expressed separately in HEK 293 cells, each half molecule exhibited basal 
ATPase activity, but no drug stimulated ATPase activity was detected (Loo et aI., 1994). 
When the half molecules were expressed together, full drug-stimulated ATPase activity was 
restored showing coupling of ATPase activity with drug binding. Stoichiometric coupling of 
drug transport with A TP hydrolysis is shown in several studies with coupling ratios from 0.35 ­
1 molecules of drug transported per molecule of ATP hydrolyzed (Eytan et al., 1996, 
Ambudkar et al., 1997, Shapiro et al., 1998). On the other hand, keeping in mind the high 
basal ATPase activity displayed by p-gp, ATP hydrolysis cannot be viewed as rigidly 
associated with drug transport. 
By following the change in fluorescence of 2-(4-maleimidoanilino)naphthalene-6-sulfonic acid 
(MIANS) labeled p-gp - labeling the same cysteine as NEM and NBD-CI - quenching by ATP 
and drugs were shown to be different, pointing to different conformational changes upon 
either nucleotide or drug binding (Liu and Sharom, 1996). These results were confirmed by a 
number of subsequent studies. Conformational changes in p-gp upon nucleotide binding was 
shown by changes in the proteolysis profile of trypsin-treated p-gp (Wang et al., 1997). 
Binding of vinblastine or verapamil alone produced a unique conformational change. The 
conformation adopted by p-gp was different depending on the presence of either both 
nucleotide and drug or nucleotide or drug alone, indicating different conformations associated 
with different stages of transport (Mechetner et al. 1997, Wang et al., 1998). Tryptophan 
quenching experiments showed distinct conformational changes in p-gp upon ATP binding 
and ATP hydrolysis and another tv.Io conformational changes were detected upon the addition 
of anthracycline derivatives in the presence and absence of MgATP (Sonveaux et aI, 1999). 
Utilizing vanadate trapping of MgADP to report on conformational changes in the nucleotide 
binding domain upon nucleotide or drug binding, several insights were gained into the 
interaction between nucleotide binding sites and drug binding sites. Vanadate trapping 
prevented labeling of p-gp by photoreactive substrate analogs, indicating that ATP hydrolysis 
results in conformational change with a reduced affinity for substrates - a change that could 
reflect drug being released from a low affinity site after transport across the cell membrane 
(Ramachandra et al., 1998). The rate of vanadate dependent nucleotide trapping was directly 
related to drug concentration, indicating the direct relationship between ATPase activity and 
drug binding (Szabo et al., 1998). In human p-gp, where drug extrusion and ATPase activity 
appear to be more tightly coupled than hamster p-gp, vanadate trapping of MgADP is 
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in the absence of drugs (Rao, 1998). This suggests a different catalytic cycle for basal 
ATPase activity and drug stimulated ATPase activity. 
In a p-gp containing mutations in NBD1 Walker B motif residues [ERGA - DKGT] (522-525) 
and T578C, the affinity for ATP was similar to wild type - as reflected by the Km(ATP) 
measured at increasing concentrations of MgATP under conditions of optimal drug stimulation 
- while drug-stimulated ATPase activity (Vmax) was severely affected. Both the mutants 
showed complete loss of verapamil-induced ATPase activity while retaining a degree of 
valinomycin-induced ATPase activity. Binding of these drugs to p-gp was not affected as 
shown by photolabeling studies with [1251]iodoarylazidoprazosin, suggesting that these 
residues are involved in a signal pathway between the drug and ATP binding sites (Beaudet 
et al., 1998). Introducing cysteine residues into TM6 and TM12, which are directly connected 
to NBD1 and NBD2, and monitoring the effect of substrate and ATP binding on crosslinking 
between these two helices, it was shown that TM6 and TM12 u dergo different 
conformational changes upon drug binding or during ATP hydrolysis. CroSS-linking was 
inhibited by cyclosporin A, verapamil, vinblastine and colchicine, showing that movement 
between TM6 and TM 12 is also essential for drug-stimulated ATPase activity (Loa and 
Clarke, 1997a). Structural flexibility of the linker region, connecting the first [TMD-NBD] of the 
protein with the second rrMD-NBD], also appears to be a prerequisite for ATP hydrolysis and 
drug transport. A 17 amino acid insertion of a predicted flexible structure between amino 
acids 681 and 682 yielded a functional p-gp capable of conferring drug resistance. In 
contrast, a 34 amino acid deletion from the middle of the linker region eliminated ATP 
hydrolysis and drug transport activities, indicating the importance of this peptide in 
communication between drug binding and ATP hydrolysis (Hrycyna et al., 1998a). 
The role of phosphorylation of p-gp remains to be elucidated.. P-gp is phosphorylated at 
several sites in the linker region of the protein. Mutating serines 661, 667, 675 and 683 in 
human MDR1 proved that phosphorylation by protein kinase C does not effect the rate of drug 
transport and does not playa role in the establishment of the multi drug resistance phenotype 
(Germann et aI., 1996, Goodfellow at al., 1996). Phosphorylation of the linker region does, 
however, modulate the interaction of certain drugs with MDR1 and had been shown to playa 
role in the ability of p-gp to modulate volume activated chloride channels (Barnes et al., 1996, 
Szabo et aI., 1997, Bond et al., 1998). 
CatalytiC Mechanisms 
Several catalytic mechanisms have been suggested by various authors, all of them trying to 
reconcile drug binding to more than one site coupled to ATP hydrolysis at the two interacting 
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The model proposed by Senior, Fig 1.8, shows alternating ATP hydrolysis, where if one site 
enters a transition state conformation, the other cannot do so (Senior and Gadsby, 1997). 
Drug transport is coupled to ATP hydrolysis through the relaxation of the high energy catalytic 
site conformation generated by ATP hydrolysis. This is different from other transport 
ATPases, since p-gp does not utilize a covalent E-P catalytic intermediate, suggesting that 
ATP hydrolYSiS itself generates a high chemical potential conformation. The relaxation of this 
intermediate is most likely coupled to drug transport - from a high affinity, inside-facing drug 










Figure 1.8. Catalytic mechanism of p-gp as proposed by Senior et al., 1997. 
In Fig 1.8, the circles, squares and hexagon represent the different conformations of the two 
NBDs, while the rectangles represent the two TMDs. In this scenario (top left), ATP is bound 
to the C-terminal (NBD2), but not to the N-terminal (NBD1), with the drug bound to the inside­
facing, high affinity drug binding site. Binding of ATP at NBD1 allows ATP hydrolYSiS at 
NBD2, resulting in a conformational change that prevents hydrolysis of ATP bound NBD1. 
This high chemical potential conformation (p-gp.Mg-ADP.Pi) couples drug extrusion with 
conformation relaxation in the next step when Pi is released and the drug binding site 
changed into an outside facing, low affinity site. When ADP is released, the protein is ready 
for another cycle, this time using ATP hydrolysis at the NBD1 to drive the formation of the 
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Considering the possibility of two drug binding sites together with two sequential ATP binding 
sites, with a coupling ratio of one substrate molecule transported per ATP hydrolyzed, 
Shapiro postulated six step catalytic cycle (Fig 1.9) (Shapiro and Ling, 1998b). In the Shapiro 
model, only one ATP binding site is occupied at a time - the binding of ATP to one of the two 
sites prevents binding of a second A TP to the other site. Hydrolysis of the bound ATP is 
coupled to the transport of one of the two drugs bound to the two drug binding sites. ADP.Pj 
release allows occupation of the altemating ATP binding site by ATP. Both drug binding sites 
need to be occupied in this model, in agreement with the experimental evidence that the 
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A third model proposed by Stein (Fig 1.10) incorporates the "vacuum cleaner model", where 
drugs are mopped up from the lipid bilayer and extruded (Stein, 1997). It is in agreement with 
alternating ATP binding sites and a conformational change from a high affinity drug binding 
site to a low affinity drug binding site, responsible for drug movement upon ATP hydrolysis. It 
also takes into account the three dimensional structure of the protein - proposing that drugs 
are preferentially scavenged from the membrane, transported into the aqueous cavity of p-gp 
from which it is expelled upon binding of the second ATP to the alternating site (Rosenberg et 
al., 1997). This model also includes two interacting drug binding sites, where the binding of 
the second drug from within the lipid bilayer (together with the second ATP binding to the 
alternating ATP binding site) plays a role in the conformational change needed to expel the 
first drug from within the aqueous cavity. 
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Figure 1.10. Catalytic mechanism of p-gp as proposed by Stein, 1997. 
Three dimensional structures of ATP Binding Cassette Proteins 
A three dimensional reconstruction of p-gp purified from Chinese hamster ovary CHrS30 cells 

has been made using single particle images and Fourier projection maps of two-<jimensional 

crystalline arrays (Rosenberg et al., 1997). When viewed from above (Fig 1.11), the 

extracellular face of the membrane, the projection map of the protein shows a protein ring 

surrounding a large central aqueous pore of 5 nm in diameter - the protein ring made up from 
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./Transmembrane 
/' domain (TMD) 
Figure 1.11. A three dimensional reconstitution of p-gp, adapted from Higgins et a/., 1997, based 
on 3 dimensional studies done by Rosenberg et a/., 1997. 
The protein ring is divided into two halves - the two transmembrane domains (TMD) - each 
made up from the three extracellular loops connecting pairs of membrane spanning helixes. 
The two membrane spanning domains can be orientated with respect to each other in two 
ways (Fig 1.12). The first possibility being true twofold symmetry, where helixes 1 and 6 of 
the first TMD neighbors helixes 12 and 7 of the second TMD respectively. The second 
possibility is mirror symmetry where helix 1 and 6 of the first TMD neighbors helix 7 and 12 of 
the second TMD respectively. Cross-linking studies showed that helix 6 and 12 are in close 




Figure 1.12. Two possible orientations of the membrane spanning regions of p-gp, adapted 
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Viewed from the side, the cone shaped pore spans the membrane and is closed at the 
cytoplasmic face of the membrane, presumably by the NBDs and the cytoplasmic loops 
connecting the membrane spanning helixes. The central pore is open to the lipid phase 
within the plane of the membrane, potentially providing access between the central pore and 
the lipid phase. It is here that the substrates are postulated to bind to the drug binding sites of 
p-gp from within the lipid bilayer, to be transported into the aqueous pore and extruded. The 
two nucleotide binding domains at the cytoplasmic face of the membrane are snuggled 
against the TMDs in the membrane, appearing to be more closely associated with its 
corresponding TMD than with each other. The two NBDs are also asymmetrically organized. 
Since structural determination was done in the absence of both ATP and substrates, it is 
possible that direct interaction between the two NBDs only occur in the presence of the above 
mentioned ligands. Indirect coupling between the two NBDs can also be mediated through 
transmembrane domain interaction. 
The crystal structure of a NBD of the peri plasmic histidine permease of Salmonella 
typhimurium became available in late 1998 (Hung et al., 1998). This protein is expressed as 
four separate subunits that assemble in the membrane as a functional unit. It typically 
consists of two transmembrane domains, HisQ and HisM, with two nucleotide binding 
domains, HisP, to form a membrane bound complex HisQMP2. This membrane bound 
complex also interacts with a ligand presenting subunit, HisJ, that induces ATP hydrolysis 
upon binding to the membrane bound complex at the peri plasmic surface of the protein. The 
HisP protein was crystallized as a dimer. As seen in Fig 1.13, the HisP subunit is L shaped, 
with the dimer interface consisting of a p-sheet of 6 strands (p3 and PS-p 12). ATP binds near 
the bottom of this p-sheet in the figure shown. The middle section of each subunit is a 
mixture of a-helixes and p-sheets (P1, P2, P4-P7, a1 and a2), while the free end consists 
mainly of a-helices (a3-a9). 
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The amino acids interacting with ATP and possibly with Mg2+ are indicated in Fig 1.14. As 
expected, ATP interacts directly with the Walker A sequence motif, also called the phosphate 
binding loop, residues Gly39 to Lys45, linking [33 to a1. This phosphate binding loop wraps 
around the phosphates of ATP, allowing hydrogen bonding between the [3-phosphate and the 
main chain nitrogens of Ser41 to Lys45 and the y-phosphate and Ser41. Tyr16 is also involved in 
stabilizing ATP binding, this being the tyrosine previously placed at the ATP binding site 
through 8N3-ATP photolabeling (Senior et al., 1996). A bit further away, ASp178 (on the end of 
[39) also interacts with the y-phosphate of ATP through a water molecule. This water 
molecule most likely takes the place of Mg2+ that was absent from the crystal. Asp 178 is highly 
conserved in all ABC transporters and is predicted to be the residue that interacts with the 
divalent cation during ATP hydrolysis. Glu179 and GIn 100 also form hydrogen bonds with a 
second water molecule interacting with the y-phosphate - this water molecule could play a 
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Interaction betvveen the NBD and TMD takes place at the top face of the dimer, opposite from 
the ATP binding site. Mutations in these interacting domains uncouples HisP from regulatory 
control by HisQ and HisM or disrupts the tertiary structure of the top part of the NBD, 
perturbing communication between the ATP binding site and the rest of the protein (Petronelli 
et a/., 1991). ATP hydrolysis is induced by the presentation of ligand by HisJ at the 
peri plasmic surface of the protein, resulting in cross-membrane signaling between the 
liganded peri plasmic receptor and the cytoplasmic ATP-binding sites. This could occur in two 
ways. Firstly, confonnational changes at HisQ and HisM can result in conformational 
changes in the top part of HisP that contain residues that is important for ATP hydrolysis 
(Gln1OO, Asp178 and Glu179) and can lead directly to hydrolysis of ATP at the bottom part of 
HisP. Alternatively. ATP hydrolysis can also be the direct result of a change in orientation 
between the bottom ATP binding domain of HisP and the top interacting part of HisP induced 
by direct movement between the six-stranded IJ-sheet shared by the two regions. 
In summary, the three dimensional data seem well supported by previously found 
experimental data. The ATP binding domains interact strongly, as seen with the dimer 
structure in HisP. ATP hydrolysis is directly coupled to ligand/substrate binding and is 
accompanied by a conformational change in the protein. Substrates appear to have access 
to the protein from within the lipid bilayer from where they can be transported into the 
aqueous pore. 
In this study 
Proteins of particular interest to this study are the yeast proteins PdrSp and Yor1p as well as 
the recombinant NBDs of the mouse p-gp, mdr1 (Decottignies et a/.• 1994, Decottignies at a/., 
1998, Boubichon-Cortay et a/., 1994). The yeast p-gp protein PdrSp is typically expressed as 
a single polypeptide with a membrane topology of [NBD-TMD-NBD-TMDl - the reverse of the 
mammalian protein topology - while the yeast MRP protein Yor1p's membrane topology is 
similar to the mammalian p-gp. Being under the control of the PDR1 and PDR3 transcription 
factor genes, PdrSp gives rise to pleiotropiC drug resistance in the cells in which it is 
overexpressed. PdrSp ATPase activity is optimal over a broad pH range, extending from 5.5 
to 8.0. Typically. a plasma membrane bound Pdr5p exhibits a Krn(ATP) =0.5 mM and a 
Vmax = 2.51JI1101 of Pit mini mg of protein and can also hydrolyze CTP, GTP, UTP and ADP 
but not AMP. The purified enzyme yields a Krn(ATP) = 0.25 mM and a Vmax =0.251J.mo/ Pil 
mini mg of protein. PdrSp ATPase activity was inhibited by known MDR substrates and 
reversers such as vanadate, oligomycin and actinomycin D and the UTPase activity 
stimulated on the addition of verapamil. The Yor1p yeast MRP protein is responsible for 
oligomycin and reveromycin A resistance on overexpression (Katzmann et a/., 1995). 
The recombinant NBD2 of mouse mdr1 p-gp (sNBD2 and LNBD2) were initially designed to 
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These recombinant NBDs, expressed as either a fusion proteins to GST or a histidine tagged 
protein, bound ATP in the mM concentration range, as well as the ATP derivatives, TNP-ATP 
and TNP-AOP, in the micromolar range. Little or no ATPase activity was measured for these 
recombinant NBOs. In the absence of membrane located substrate or modulator binding 
sites, it was established that not only does NB02 bind nucleotide, but also steroids and 
f1avonoids at sites close to and partially over1apping the ATP binding site (Conseil et a/., 
1998). 
Aims of this research programme 
The overall theme of the project was to apply TNP-8Ns-ATP as a photoaffinity probe of the 
ATP binding sites of p-gps. There was evidence that TNP-ATP bound much more tightly than 
ATP to the ATP binding site of p-gp (Baubichon-Cortay et a/., 1994, Senior et a/., 1995). 
Specific photolabeling is a good measure of the integrity of the ATP binding site. active site 
amino acids can be identified and inhibitors of nucleotide binding can be identified and 
characterised. 
1) To test whether TNP-8Ns-ATP could be used as a photoaffinity probe of yeast protein 
Pdr5p. P-gps are expressed in small amounts in mammalian cell plasma membrane and it is 
difficult to obtain amounts of protein suitable for identifying active site residues and for kinetic 
studies. The laboratory of Prof. A Goffeau, University of Louvain-Ia-Neuve, Belgium was 
able to overexpress several yeast pumps, including Pdr5p, Snq2pand Yor1p. by selective 
elimination of transcription factors and unwanted pumps. Large amounts of protein can be 
prepared from yeast culture in this way. 
2) To characterise the nucleotide binding properties of Yor1p by photolabeling with TNP-8Ns­
ATP. While Pdr5p and Snq2p had been well characterised at the start of the programme. 
Yor1 p was in the process of being investigated by A Decottignies in Prof. Goffeau's 
laboratory. Preliminary work: suggested that the pump had very low or zero ATPase activity. 
This study set out to ascertain whether Yor1p could bind nucleotides 
3) To characterise the nucleotide binding site of soluble recombinant NBD2 of mouse p-gp 
and identify amino acid residues ligating ATP. Many bacterial ABC transporters are of 
modular construction and the laboratory of Dr A Oi Pietro was engaged in producing the 
nucleotide binding domain (NBOs) of mouse p-gp. The aim of this study was to understand 
the nucleotide binding properties of individual domains and also to investigate whether drugs I 
reversers binding sites existed on the NBDs. We undertook to establish whether TNP-8N3­
ATP could be used as a probe of mouse NB02. 
4) To investigate the interaction of flavonoids with the ATP binding site of mouse NBD2 using 
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NBD2 with TNP-8Na-ATP and 8Na-ATP suggested that they could be used to monitor binding 
of drugs I reversers I flavonoids to the ATP binding site. Using tryptophan fluorescence, Dr. 
A. Di Pietro's laboratory had established that several flavonoids bind to the recombinant 
mouse NBD with high affinity. The question was whether these flavonoids bind to the ATP 
binding site or to a separate binding site as was proposed (Conseil et al., 1998). 
5) Synthesis of new derivatives of TNP-8Nr ATP and 8Nr ATP, designed to photolabel the 
phosphate binding region of the ATp site in addition to the adenine region. Bifunctional 
crosslinkers offer the possibility of derivatization providing measurement of the distance 
between residues and preventing domain movements. We looked into placing an aryl azido 
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Materials 
All the buffers used, the tri-n-octylamine and tri-butylamine salt of pyrophosphoric acid, 5,5'­
dithiobis{2-nitrobenzoic acid) (DTNB), ethyleneglycol-bis-(p-aminoethyl ether) N.N.N' ,N' ,­
tetraacetic acid (EGTA), trypsin, dialysis tubing, Triton X-100 and phospho(enol)pyruvate 
were from Sigma. Dioxan, ether, DC plastikfolien PEl Cellulose F and molecular sieve 4A 
were from Merck. Dimethyl formamide, tri-n-butylamine, sodium dodecyl sulphate (SDS), 
acetonitrile, urea, MgCb, CH3COOCH4 and potassium phosphate was from BOH Laboratory 
Supplies. The diphenylphosphochloridate and imidazole were from Aldrich and the methanol 
from Baxter Healthcare Corporation. The pyridine and glycerol were from Analar, the TEAD 
and 2,4,6-trinitrobenzenesulphonic acid (TNBS) from Fluka. The AG1-X4 resin was from Bio­
RAD, the DE52 resin from Whatman, the PD-10 sephadex columns from Pharmacia Biotech, 
the Sep-Pak C18 cartridges from Waters and the Ni2+His-Bind metal chelation resin from 
Novagen. The NADH, pyruvate kinase, lactate dehydrogenase and thermolysin were from 
Boehringer Mannheim. Glycerol and trichloroacetic acid were from Merck and the QuickSave 
Scintillant from Zinsser Analytic. Peptide sequence analYSis was performed using a gas 
phase sequenator similar to commercial machines. The amino acids were converted to the 
phenylthiohydantoin derivatives (PTH) and analysed by HPLC using standard procedures. 
MALDITOF analyses were performed on a Voyager Perseptive Biosystems DE-PRO with (X.­
hydroxy cynammic acid as matrix. The transmembrane predictions were done by TMPred at 
ExPASy Tools: http://www.ch.embnet.org/softwareITMPREDform.html. and the sequence 
alignments with DNAMAN ver 4.13, Lynnon BioSort, USA. 
Chemical Syntheses 
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4-Azido-2-nitrophenol (ANP) was synthesised from 4-amino-2-nitrophenol according to the 
method of Lauquin (Lauquin et al., 1980). ANP-AMP was synthesised according to the 
general method of Michelson for the synthesis of nucleotide anhydrides (Michelson, 1964). 
AMP, 100 JlfllOI, (free acid) was suspended in 700 Jd methanol; 100 J.lmol tri-n-oclylamine was 
added and the nucleotide dissolved at 60°C in a water bath. Methanol was removed under 
reduced pressure. The residue was redissolved in 150 J.l1 DMF and solvent removed under 
reduced pressure (1-2 h) to remove traces of moisture. The tri-n-octylammonium saH of AMP 
was dissolved in 700 j.d dioxan, and if insoluble, a further 300 J.l1 DMF was added. These 
steps were all carried out under a nitrogen atmosphere and in the dark. The solution was 
vortexed vigorously. . 
To make the P'-nucleoside-5'-p2 -diphenyl pyrophosphate, 30 J.l1 of diphenylphosphochloridate 
and 45 J.l1 tri-n-butylamine was added and the solution kept at room temperature for 1 h. 
Solvent was removed under reduced pressure ovemight. The P' -nucleoside-5' _p2-diphenyl 
pyrophosphate was redissolved in 100 J.l1 dioxan and 200 J.lmol ANP, dissolved in 200 J.l1 
pyridine, was added to the solution and left at room temperature for 3 h. Solvents were 
removed under reduced pressure and the ANP-AMP precipitated by the addition of 2 ml 
ether, washed three times with 1 ml ether and dried under reduced pressure. The 
precipitated material was dissolved in 1 ml water and passed through a C18 Sep-Pak 
cartridge to remove contaminating AMP. The nucleotide was eluted with 60 % acetonitrile. 
ANP-AMP was purified on a strong anion exchange column, AG1X4, and eluted with 
discontinuous increasing concentrations of HO. Typically, 100 J.lmol ANP-AMP eluted in 50 
ml60 mM HCI from a 5.5 ml bed volume of AG1X4 column. The final yield of ANP-AMP was 
- 20 %, but yields did vary betvteen yntheses. The purity was checked by analytical HPLC, 
which showed essentially a single peak, eluting at 17 % (v/v) acetonitrile off a C18 colunm. 
The reaction was followed throughout by means of TLC (PEI-Cellulose F sheets from MERC, 
using 1 m LiCI as running buffer). The formation of AMP-ANP could be clearly observed as a 
new major spot, migrating just below AMP that increased over time concurrent with AMP 
decline. 
Synthesis of 4-azid0-2-nitrophenyl-2', 3'-0-(2, 4, 6-trinitrophenyl) adenosine monophosphate 
(ANP-TNP-AMP). 
Addition of the TNP moiety was carried out using the method described by Seebregts 
(Seebregts et al. o 1989). 5,5'-dithiobis(2-nitrobenzioc acid) (DTNB), 25 J.lmol, and 17 J.lmol of 
2,4,6-trinitrobenzenesulfonic acid (TNBS) was dissolved in 1 ml 0.8 M Na~WNaHC03 
mixture. This was added to 1 JlfllOI ANP-AMP dissolved in 1 ml water and stirred in the dark 
at room temperature for 16 h. The reaction mix was passed through a Sep-Pak cartridge, the 
cartridge washed with 2.5 ml15 % (v/v) acetonitrile, and the nucleotide eluted with 1 ml 60 % 
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evaporated by a nitrogen stream. Preparative purifications of nucleotide were carried out on 
a Waters reverse phase radially compressed PAD-C18 cartridge where solvent A was 10 % 
(v/v) acetonitrile, 10 mM KPi, pH 6.0 and solvent B was 50 % (v/v) acetonitrile, 10 mM KPi, 
pH 6.0. A Spectra-Physics 8700XR pump delivered the solvent. A Bromma 2151 variable 
wavelength monitor monitored effluent at a wavelength of 210 nm. Analytical HPLC was 
carried out on a Vydac reverse phase C18 or C4 column with a Beckman System Gold 
solvent module 126 and diode array detector module 168, with standard solvent A as 10 mM 
KPi, pH 6.0 and solvent B as 60 % (v/v) acetonitrile, 10 mM KPi, pH 6.0. ANP-TNP-AMP 
eluted at -30 % B. The final yield of ANP-TNP-AMP was from 11% to 20%, and the purity as 









Synthesis of 4-azido-2-nitrophenyl-BN:radenosine mono phosphate (ANP-BN:rAMP) and 4­
azido-2-nitrophenyl-2',3'-O-(2,4,6-trinitrophenyl)-B-azido-adenosine mono phosphate (ANP­
TNP-BN:rAMP) 
For making the BN3-derivatives of ANP-AMP and ANP-TNP-AMP, the same experimental 
procedures were followed as described above for the azido-Iess nucleotides. 8N3-nucleotides 
were available in the laboratory and were originally synthesised accprding to the method of 
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ANP-TNP-8N3-AMP 
Synthesis of1y-32PjBN:rATP and 1y-32PjTNP-BN:rATP 
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High specific activity [y-32p]8N3-ATP was synthesised essentially according to the exchange 
method of Glynn and Chappell (1964). TRIS.HCI, 2SO III 200 mM,112 mM MgCI2, pH 8.0 
stock solution was added to a thick walled glass bottle with 51 III 100 mM NaOH, 2 "" SOO mM 
cysteine, 15 "" 15 mM 8N3-ATP, 5 "" 100 mM phosphoglyceric acid, 8 "" 0.1 mglml 
glyceraldehyde 3-phosphate dehydrogenase, 6 III 0.01 mgIml phosphoglycerate kinase and 2 
mCi ~2Pi]. The mixture was kept at room temperature for 1 h in the dark with occasional 
mixing. Adequate exchange of FPi] to [y-32p]8N3-ATP was checked after 1 h by thin layer 
chromatography (TLC) - a minimum amount of the reaction mix was spotted on PEI-Cellulose 
F paper and developed in 1 M UCI. The reaction mix was applied to a 2cm x O.Scm OE52 
.	vveak anion exchange column with 1/8" 10 outlet tubing (1 ml dead volume). All fractions were 
collected in thick-walled glass bottles. The reaction bottle was washed out with 0.5 ml HP 
that was also applied to the column. The column was washed with 5 ml H20 and acidified 
with 5 ml 1 mM HC!. The ~2pij and 8N3-AOP were eluted with 7 ml 10 mM HCI and a further 
1 ml of 30 mM HCI (outlet tubing dead volume). The [y_32P]8N~ATP was eluted with 7 ml 30 
mM HCI and collected in a freeze-drying flask. The fraction was neutralised with 120 III 0.8 M 
Na2CO~NaHC~ to - pH 7.0 and freeze-dried ovemight. 
For the addition of the TNP moiety, the [y-32p]8~-ATP was dissolved in a minimum amount of 
H20 and 83 "" of 5,5'-dithiobis(2-nitrobenzioc acid) (TNBS) and 2,4,6-trinitrobenzenesulfonic 
acid (OTNB) stock solution added (6 mg TNBS and 12 rng OTNB dissolved in 500 III 0.8 M 
N~CO~aHC~). The reaction was left at room temperature for 4 h in the dark, stirring 
continuously. Conversion to [y-32p]TNP-8N~ATP was monitored as before on TLC. The 
reaction mix was diluted with 5 ml H20 to reduce the salt concentration and applied to a 4 em 
x 0.5 em (10) OE52 vveak anion exchange column with 3/8"10 outlet tubing (2.5 ml dead 
volume). The column was wash d with 5 ml HP, 10 ml 0.2 mM ammonium formate (AF) pH 
8.2. 15 ml 0.5 mM AF pH 8.2 and 4 ml1 mM AF pH 8.2. These fractions were discarded. 
The [y-32p]TNP-8N3-ATP was eluted in 21 ml1 mM AF pH 8.2. The eluate was applied to a 
C18 SeJrPak cartridge and washed with 2 ml10 mM KPi. pH 7.0 and an additional 0.8 ml H~ 
to remove the salt. The [y-32p]TNP-8N~ATP was eluted with 2 ml 60 % CH3CN and the 
CH3CN evaporated under a stream of nitrogen. The purity was checked by analytical HPLC 
(over 95 %) and the activity of the 8N~roup confirmed by monitoring the disappearance of 
the 280 nm absorbance peak, characteristic of the azido adenine moiety, on a diode array 
spectrophotometer after irradiation of [y-32prrNP-8N~ATP for 60 s. Diode array scans were 
performed on a Hewlett Packard Diode Array spectrophotometer (8450A). The final 2 ml 
sample was aliquoted and stored at -20°C. The synthesiS are generally performed with 2-3 
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Proteins 
The two recombinant carboxyl-terminal nucleotide binding domains from mouse p-gp (sNBD2 
and LNBD2) used in this study were expressed in Ecoli as described by Boubichon-Cortay et 
al. (1994) and Conseil et al. (1998) in the laboratory of Dr. Attilio Di Pietro. In this study two 
polypeptides of different lengths were investigated - sNBD2 from Thr1044 to Thr1224 and a 
longer polypeptide. LNBD2. from Lys1025 to Ser1276. The proteins were either expressed as 
recombinant fusion proteins attached to the N-terminal end of glutathione S-transferase 
(GST) or as hexahistidine-tagged recombinant proteins (Fig 2.1). 
For the GST fusion proteins, the cDNA encoding the relevant protein was produced and 
amplified by reverse transcription peR from mouse adrenal cell mRNA, inserted into a pGEX­
KT vector and used to transform JM105 Ecoli cells. Induced cells containing expressed 
fusion proteins were lysed using a SLM-Aminco French pressure cell press. Lysed cells were 
centrifuged at 30 000 x g for 30 min and the supernatant mixed with glutathione-Sepharose 
2B gel equilibrated with PBS buffer containing 1 % Triton X-100 at 4 °e. The GST-NBD2 
fusion protein was eluted with 10 mM reduced glutathione in 50 mM Tris-Hel, pH 8.0, and 
stored in liquid nitrogen in the presence of 15 % glycerol. The recombinant proteins were 
cleaved from the GST fusion protein using freshly prepared thrombin with a thrombin to fusion 
protein ration of 1 :200, leaving two amino acids, G and S before the start of the relevant 
mouse sequence. Released sNBD2 or LNBD2 was purified as an unretained fraction from a 
Fractogel EMD-DMAE-650(M) column equilibrated with 50 mM Tris-Hel, 10 % glycerol, pH 
7.5 and 1 mM dithiothreitol. 





For the hexahistidine-tagged proteins (Ha-tagged in this case) the cDNA encoding domain 
was amplified by peR from the recombinant plasmid encoding the GST -NBD2. restriction 
digested, ligated into the corresponding sites of linearized pQE-30 vector and used to 
transform JM109 ECO/i cells. Again. induced cells expressing the recombinant protein were 
lysed by French press treatment and recombinant HS-NBD2 purified from the soluble fraction 
by using nickel-nitrilotriacetic acid affinity column. The protein of interest was eluted from the 
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NaCI. 20 % glycerol and 0.01 % HECAMEG at pH 6.8. The full amino acid sequence of 
sNBD2 and LNB02 is shown in supplement 1 and 2 at the end of this chapter. 
The yeast proteins PdrSp. Yor1p and SNQ2 were overexpressed in yeast and plasma 
membrane fractions were prepared as described by Decottignies et a/. (1998) in the 
laboratory of Prof. Andre Goffeau. Overexpression of the yeast proteins was accomplished 
by performing multiple deletions sequentially in the US50-18C POR1-3 strain by repeated use 
of the hisG-URA3-hisG casette followed by selection of the ura3 auxotrophic marker with 5­
f1uoroorotic acid. The gene promoters and ORF ends were cloned into a pSK vector and the 
linearized fragments of the plasmids used to transform the yeast strain. Plasma membranes 
were isolated from the pellet sedimented at 15 000 x g for 40 min. This step was preceded by 
selective precipitation of the mitochondria at pH 5.2. Plasma membrane proteins (5mglml) 
were solubilized with 0.2· % (w/v) n-dodecyl-I3-D-maltoside and 8 mM Tris-HCI. pH 7.5 and the 
solubilized proteins separated on a 33.3 ml linear sucrose gradient. The full amino acid 
sequence of PdrSp and Yor1p is shown in supplement 3 and 4 at the end of this chapter. 
Photolabeling and SOS-PAGE 
The standard irradiation medium for LNB02 and sNB02 was 25 mM buffer. 20% (w/v) 
glycerol. 0.01% (w/v) Triton X-100. 1 mM MgCI2 and a) 5 mM EGTA at < pH 7.0. 0.5 mM 
EGTA at >pH 7.0 or b) 10 mM EOTA in a volume of.75 ~I. The standard photolabeling 
conditions came about as a result of initial experiments shown in chapter 4. where the 
influence of salt, Triton X-100, buffer, pH and glycerol on photolabeling. were investigated. 
The standard irradiation medium for the yeast proteins PdrSp and Yor1p was similar except 
that Triton X-100 was omitted. The irradiation time was chosen as 1 min, since irradiation for 
longer times did not increase the amount of photolabeling observed. The buffer and pH. as 
well as conditions deviating from the standard, are specified in the legends to the figures. 
Samples were irradiated using a 100 Watt Xenon lamp (Hi-Teck) with quartz cuvettes of fresh 
toluene positioned at either side of the central quartz cuvette to protect the protein form U.v 
damage (cut off at 290 nm). Irradiated samples were transferred to Eppendorf tubes on ice 
and 8 ..u 20% (w/v) SOS. containing bromophenol blue, was added. LNB02lsNB02 samples 
were separated in 15% (w/v) polyacrylamide gels prepared according to Laemmli (Laemmli et 
a/., 1970) and run for 3 h at 4 °C at 35 mA. Yeast proteins were separated in a similar 
manner in 7.5 % (w/v) polyacrylamide gels. Gels were dried and the radioactivity quantified 
using an Instant Imager (Packard Instrument Company). Graphs were drawn using Sigma 
Plot 3.0 (Jandel Scientific Software) and nonlinear regression were used for fittings. 
The data obtained from concentration dependent photolabeling of proteins with [y-32p]TNP­
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Y =(Ymax . S)/(Kd + S) 
Where Y = relative counts, Ymax - relative maximum counts, [SJ = nudeotide probe 
concentration and Kd =concentration of probe at which half maximal labelling is obtained. 
Data obtained from ATP (or inhibitor) inhibition of either [y-32p]TNP-BN3-ATP or [y-32PJBN:;­
ATP photolabeling was fitted to the binding algorithm 
Y ={100·Ko.5(Am/(Ko.5(ATP) + [ATP]} + F 
where Y = percentage photolabeling, F = offset, Kd = concentration of ATP at half maximal 
inhibition. 
The "true" dissociation constant for ATP (or inhibitor) binding was obtained from the equation 
Ki (ATP) =Kd(ATP) /{1 + ([rNP-BN:;-ATP]/Kd[TNP-8N3-ATPJ)} 
where TNP-BN3-ATP could also be BNs-ATP, depending on the identity of the radiolabel. 
This equation was deduced from the standard binding equation 
Y = [L]/Ko + [I.] 
which can be rewritten for competitive inhibition as 
1 - Y =1 - ([L]/Ko.5 + [L]) =Ko.sI(Ko.5 + [L]) 
where Ko.5 =Ko{1 + ([L]/Ki)} and Ko = Ki(ATP), Ko.5 = Kd(ATP} and Ki = Kd(radiolabel) 
The pKa values for pH dependent photolabeling of various proteins with [y-32p]TNP-8N3-ATP 
or [y-32p]BN3-ATP were obtained from the equation 
Y ={(A·1(fI(&.X)/(10PI(&.X + 1)} + F 
where Y =percentage photolabeling, x =pH and F =offset 
This equation was deduced from the standard binding equation 
pH =pKa + log Y/(Ymax-1) 
Preparative LNBD2 photolabeling, dialysis and processing of peptides by HPLC 
Samples were irradiated for 5 min to compensate for inner-filter effects, in 2.5 ml standard 
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MgCb). transferred to dialysis bags (Sigma 0-9277, size cut off 12 000 Da) and dialyzed for 6 
h against 2 I! 25 mM NH4HC03, pH 7.4, with buffer changes every 2 h. The protein 
precipitated during dialysis and the contents of the dialysis bag was transferred to a centrifuge 
tube and pelleted at 3000 rpm for 15 min. The protein was washed twice by re-pelleting in 2.5 
ml 100 mM NH4HC03, pH 7.5. The final pellet was dissolved in 600 ,.d 8 M urea with the help 
of a Potter Elevehjem homogenizer. The urea concentration was lowered to 6 or 4 M 
(thermolysin) and 4 M (trypsin, V8 protease, and clostripain) with 300 ul 100 mM NH4HC03 
and the pH adjusted to pH 7 - 8. Digestion with thermolysin was always carried out in the 
presence of 5 mM MgCI. Digestion was performed at various times, protease concentrations 
and temperatures as indicated in the legend to the figure. The digest was separated by 
HPLC (Beckman System Gold 319, Diode Array Detector Module 168) using a C4 reverse 
phase column (4.5 mm X 250 mm, Vydac) Solvent A: 10 mM KPi, pH 6.0; Solvent B: 10 mM 
KPi, pH 6.0, 60% (v/v) acetonitrile. Selected peaks were further purified on a C18 reverse 
phase column (4.5 mm X 250 mm, Vydac) - Solvent A: 10 mM CH3COONH4 pH 6.4; Solvent 
B: 10 mM CH3COON~, 60 % (v/v) acetonitrile. 
Preparative LNBD2 photolabeling, Ni2 + column purification and processing of peptides 
by HPLC 
Samples were irradiated for 5 min in 2.5 ml standard medium (25 mM MES, pH 6.0, 20% 
(w/v) glycerol, 0.01% (w/v) Triton X-100 and 1 mM MgCI2). Irradiated samples were pooled 
and placed on ice. Solid urea was added to a final concentration of 8 M. The sample was 
applied to a nickel column (0.5 em X 1em, equilibrated in 5 mM imidazole, 0.5 M NaCI and 20 
mM Tris.HCI, pH 7.9), washed with 4 ml of wash buffer (8 M urea, 0.5 M NaCI and 20 mM 
Tris.HCI, pH 7.9) and eluted in 900 ul elution buffer (8 M urea, 1 M imidazole, 0.5 M NaCI and 
20 mM Tris.HCI pH 7.9). The eluate was diluted two fold and digested with 20 % thermolysin 
(w/wassuming 100% protein yield) for 2.5 h at 30 °C in the presence of 5 mM MgCI. The 
digest was analyzed on a C4 reverse phase column, as above. 
Preparative PdrSp photolabeling, size exclusion column purificatron and processing of 
peptides by HPlC 
Samples were irradiated for 5 min in 2.5 ml medium (25 mM MES, pH 6.0, 20% (w/v) glycerol 
and 11 mM MgCI2). Irradiated samples were kept on ice. Samples were applied to a PD10 
size exclusion column (Sephadex G-25 M) and the protein eluted in 3.5 ml 25 mM N~HC03, 
pH 7.6. The eluate pH was adjusted to pH 7.5, CaCI2added to a final concentration of 5 mM 
and digested with 4 % (w/w) thermolysin at 37 °C for 2 h. TNP-peptides were separated on a 
C18 Sep-Pak cartridge and eluted with 60 % CH3CN, 10 mM KPi, pH 5.5. The CH3CN was 
evaporated under a stream on nitrogen and the digest was analyzed on a C18 reverse phase 
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Quantification of photolabeling by filtration 
Various concentrations of sNBD2 (0.25, 0.5, 1 and 111M) and PDR5 (0.2, 0.4, O.B and 1.37 
11M) were irradiated for 5 min in 1 ml 25 mM MES, pH 6.0,20% (w/v) glycerol, 0.01% (w/v) 
Triton X-100 and 1 mM MgCI2 (for sNBD2) and in 1.23 ml 25 mM MES, pH 6.0, 20% (w/v) 
glycerol and 1 mM MgCI2 (for Pdr5p). The [y-32p]TNP-BN3-ATP concentration was 30 11M for 
sNBD2 and 50 11M for PDR5. The protein was precipitated by the addition of 1 ml 10% (w/v) 
trichloro acetic acid (TCA) and cotlected on a GFIF 2.5 em Whatman filter with a mild vacuum. 
The filters were washed twice with 5 ml of 5% (w/v) TCA and assayed for radioactivity on a 











CHAPTER 2: METHODS 
Supplement 
Amino acid sequence of sNBD2 
1044 trpnipv 1qg1s1evkk 2qt1a1v2ss 2cgkstvvq1 
1081 1erfydpmag svf1dgkeik q1nvqw1rah 
19ivsqepi1 fdcsiaenia ygdnsravsh 
1141 eeivraakea nihqfidslp dkyntrvgdk gtq1sggqkq 
riaiaEa1vr qphillldea 
1201 tsa1dtesek vvqea1dkar egrt 
Amino acid sequence of LNBD2 
1276 kpt11e 
gnvkfngvqf nyptrpnipv 1qg1s1evkk 2qt1a1v2ss gcgkstvvq1 
1081 1erfydpmag svf1dgkeik q1nvqw1rah 19ivsqepi1 
fdcsiaenia ygdnsravsh 
1141 eeivraakea nihqfids1p dkyntrvgdk gtq1sggqkq 
riaiaEa1vr qphillldea 
1201 tsa1dtesek vvqea1dkar egrtciviah r1stiqnad1 
ivviengkvk ehgthqq11a 
1261 qkgiyfsmvq agakrs 
Amino acid sequence of PdrSp 
1 mpeak1nnnv ndvtsyssas sstenaad1h nyngfdehte ariqk1art1 
aqsmqnstq 
61 sapnksdaqs ifssgvegvn pifsdpeapg ydpk1dpnse nfssaawvkn 
mah1saadpd 
121 fykpys1gca wknlsasgas advayqstvv nipykilksg 1rkfqrsket 
ntfqilkpmd 
181 gc1npge11v v1grpgsgct t11ksissnt hgfd1gadtk isysgysgdd 
ikkhfrgevv 
241 ynaeadvh1p h1tvfet1vt var1ktpqnr ikgvdresya nh1aevamat 
yg1shtrntk 
301 vgndivrg:!s qgerkrvsia evsicgskfq cwdnatrg1d sata1efira 
1ktqadisnt 
361 satvaiyqcs qdayd1fnkv cv1ddgyqiy ygpadkakky fedmgyvcps 
rqttadflts 
421 vtspsert1n kdm1kkgihi pqtpkemndy wvkspnyke1 mkevdqr11n 
ddeasreaik 
481 eahiakqskr arpsspytvs ymmqvky1li rnmwrlrnni gftlfmi1gn 
csma1i1gsm 
541 ffkimkkgdt stfyfrgsam ffai1fnafs slleifs1ye arpitekhrt 
ys1yhpsada 
601 fasv1seips kliiavcfni ifyf1vdfrr nggvfffyll inivavfsms 
h1frcvgs1t 
661 kt1seamvpa sm111a1smy tgfaiQkkki 1rwskwiwyi nQ1ay1fes1 
linefhgikf 
721 pcaeyvprgp ayanisstes vctvvgavpg qdyv1gddfi rgtyqyyhkd 
kwrgfgigma 
781 yvvffffvy1 flceynegak qkgeilvfpr sivkrmkkrg v1teknandp 
envgersd1s 
841 sdrkm1qess eeesdtygei glskseaifh wrn1cyevqi kaetrri1nn 
vdgwvkpgt1 
901 talmg:asg:ag: kttlldc1ae rvtmgvitgd ilvngiprdk sfprsigycq 
qqd1hlktat 
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1021 gveltakpkl Ivfldeptsg Idsqtawsic qlmkklanhg qailctihqp 
sailmqefdr 
1081 llfmqrggkt vyfgdlgegc ktmidyfesh gahkcpadan paewmlevvg 
aapgshanqd 
1141 yyevwrnsee yravqseldw merelpkkgs itaaedkhef sqsiiyqtkl 
vsirlfqqyw 
1201 rspdylwskf iltifnglfi gftffkagts 1991qngmla vfmftvifn:e 
.!.J:..ggylpsfv 
1261 qqrdlyeare rpsrtfswis fifagifvev pwnilagtia yfiyyypigf 
ysnasaagql 
1321 hergalfwlf scafyvyvgs mallvisfnq vaesaanlas Ilftmslsfc 
gvmtt:esamp 
1381 rfwifmyrvs :eltyfigall avgvanvdvk cadyelleft ppsgmtcgqy 
mepylqlakt 
1441 gyltdenatd tcsfcqistt ndylanvnsf yserwrnygi ficyiafnyi 
agvffywlar 
1501 vpkkngklsk k 
II 
Amino acid sequence of Yor1p 
1 mtitvgdavs etelenksqn vvlspkasas sdistdvdkd tssswddksl 
Iptgeyivdr 
61 nkpqtylnsd diekvtesdi fpqkrlfsfl hskkipevpq tdderkiYPl 
fhtniisnmf 
121 fwwvlQilrv gykrtiqpnd Ifkmdprmsi etlyddfekn miyyfektrk 
kyrkrhpeat 
181 eeevmenaki pkhtvlrall ftfkkgyfms ivfailanct sgfnpmitkr 
liefveekai 
241 fhsmhvnkgi gyaigaclmm fvngltfnhf fhtsqltgvq aksiltkaam 
kkmfnasnya 
301 rhcfpngkvt sfvttdlari efalsfqpfl agfpailaic ivllivnlgp 
ialvgigiff 
361 ggffislfaf klilgfriaa niftdarvtm mrevlnnikm ikyytweday 
ekniqdirtk 
421 eiskvrkmql srnfliamam sl:esiaslvt flamykvnkg grqpgnifas 
lslfgvlslg 
481 mffl:eiaigt gidmiiglgr lqslleaped dpnqmiemkp spgfdpklal 
kmthcsfewe 
541 dyelndaiee akgeakdegk knkkkrkdtw gkpsastnka krldnmlkdr 
dgpedlekts 
601 frgfkdlnfd ikkgefimit gpiitikssl Inamagsmrk tdgkvevngd 
llmcgypwiq 
661 nasvrdniif gspfnkekyd evvrvcslka dldilpagdm teigergitl 
sggqkarinl 
721 arsvykkkdi ylf4dvlsav dsrvgkhimd ecltgmlank trilathqls 
lierasrviv 
781 19tdgqvdig tvdelkarnq tlinllqfss qnsekedeeq eavvagelgq 
lkyesevkel 
841 teikkkatem sqtansgkiv adghtsskee ravnsislki yreyikaavg 
kwgfial:ely 
901 ailvvgttfc slfssvwlsy wtenkfknrp psfvroglysf fvfaafifmn 
ggftilcamg 
961 imaskwlnlr avkrilhtpm syidttplgr ilnrftkdtd sldneltesl 
rlmtsqfani 
1021 vgvcvmcivy l:ewfaiai:ef llvifvliad hyqssgreik rleavqrsfv 
ynnlnevlgg 
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1141 afEisaasvg vlltvvlglE gllntilram tqtendmnsa erlvtyatel 
pleasyrkpe 
1201 mtppeswpsm geiifenvdf ayrpglpivl knlnlniksg ekigicgrtg 
agkstimsal 
1261 yrlneltagk ilidnvdisq 19lfdlrrkl aiipqdpvlf rgtirknldp 
fnertddelw 
1321 dalvrggaia kddlpevklq kpdengthgk mhkfhldqav eeegsnfslg 
erqllaltra 
1381 lvrqskilil deatssvdye tdgkiqtriv eefgdctilc iahrlktivn 
ydrilvlekg 
1441 evaefdtpwt lfsqedsifr smcsrsgive ndfenrs 
The Walker A and Walker B sequences are shown in bold and underlined. The predicted 











CHAPTER 3: CHARACTERISATION OF YEAST PROTEINS PDRSP AND YOR1P BY 
PHOTO LABELING WITH [y-32p]TNP-8N3-ATP. 
PdrSp 
Genome sequencing has shown that the yeast possesses 19 p-gps predicted to be located in 
the membrane (Decottignies et al., 1997). Of these, only Pdr5p, Yor1 p and Snq2p appear to 
be expressed in Significant amounts (Baubichon-Cortay et al., 1994). Deletion of any two of 
these genes, as well as some of the other p-gps, allows isolation of a preparation enriched in 
the desired protein . Mutation of the regulator genes PDR3 and PDR10 also results in 
enhanced expression (Decottignies et aI., 1994). The well-characterised yeast p-gp, Pdr5p, 
was investigated as a preliminary study leading into the characterisation of the newly 
discovered yeast protein, Yor1p. Pdr5p was previously shown to exhibit a robust ATPase 
activity and also interacted with several other nucleotides, while at the commencement of this 
study, no ATPase activity could be detected for Yor1 p. 
The protein composition of plasma membrane preparations containing the p-gps enriched 
either in Pdr5p, Snq2p or Yor1 p are shown in Fig 3.1. Conveniently, the 100-kDa yeast 
H+/I<'-ATPase pump, PMA1, migrates just below the p-gps - that are of molecular size in the 
region of 160 kDa - and can be used to obtain relative expression levels of the yeast pumps. 
In the negative control the genes of six p-gps, including Pdr5p, Snq2p and Yor1p, have been 
deleted (lane 1). Overexpression of Pdr5p yields an amount of protein nearly equivalent to 
the plasma membrane H+/K+-ATPase, usually the most plentiful membrane protein (lane 2). 
Expression of Snq2p appears to be less (lane 3). Yor1p is well expressed and has a higher 
apparent molecular weight (lane 4). Lane 5 shows a yeast strain expressing both Yor1p and 
Snq2p, while lane 6 shows the unmodified parental strain expressing all of the p-gps. 
Figure 3.1. Coomassie blue stained 
Lane 
1 2 3 4 5 6 polyacrylamide gel of membrane 
enriched fractions of various yeast 
proteins. Lane 1: negative control, lane 
p-gp -. 2: Pdrp5p, lane 3: Snq2p, lane 4: 
PMA1 -. 
Yor1 p, lane 5: Yor1 p (top) and Snq2 
(bottom), lane 6: positive control 
containing all the proteins. 
Initially, photolabeling of Pdr5p was carried out at pH 8.5 as Pdr5p and Yor1 p displayed a 
maximal ATPase activity at alkaline pH (Decottignies et al., 1995., Decottignies et al., 1998). 
Photolabeling was carried out in 25 mM EPPS and 20 % (v/v) glycerol with ATP binding site 
concentration (one for PMA1 and two for Pdr5p) estimated to be below 111M. The protein 










CHAPTER 3: Characterisation of yeast proteins Pdr5p and Yor1 p by photolabeling with [y-32PjTNP-8N3­
ATP. 
PMA1 and the relevant yeast protein (Fig 3.1). According to Coomassie blue stained 
polyacrylamide gels. PMA 1 and p-gp proteins constitutes about 80 % of the total protein 
fraction . Using the total amount of protein as determined by Bradford analysis (Bradford. 
1976). the relative protein concentration was calculated and the samples diluted to an 
estimated concentration of below 1 11M for the p-gps. 
The divalent cation requirements of Pdr5p photolabeling with [y_32p]TNP-8N3-ATP was 
ascertained in the presence of either 1 mM MgCI2 or 2 mM EDT A (Fig 3.2). This experiment 
was carried out in the presence of 20 % (v/v) glycerol. as glycerol functions as a scavenger of 


















0 20 40 60 80 100 
Figure 3.2. Concentration dependent 
photolabeling of Pdr5p (circles) and 
PMA1 (triangles), in the presence of 25 
mM EPPS, pH 8.5 and 20 % (v/v) 
glycerol, with increasing concentrations 
of [y-32p]TNP-8N:t-ATP in the presence 
of 1 mM MgCb (filled symbols) and 
absence (open symbols) of MgCb. The 
lower figure shows an autorad of the 
SOS-PAGE of this experiment. The 
band on the far right is the 
sarcoplasmic reticulum Ca2+ ATPase 
(110 kOa), included as a positive 










In the presence of 1 mM MgCb. [y_32p]TNP-8N3-ATP photolabeled both Pdr5p and PMA1 
successfully and displayed a binding constant for PDR5 (Kd) of 46 11M and PMA1 of 74 11M. 
In the absence of the divalent cation little labeling was observed. 
When this experiment was repeated in the absence of glycerol, similar results were obtained 
with Kd (Pdr5p) = 40.1 11M and Kd(PMA1) = 44.7 11M (Fig 3.3), shOwing that glycerol does not 












CHAPTER 3: Characterisation of yeast proteins PdrSp and Yor1p by photolabeling with [y-32p]TNP-BN3­
ATP. 
protein integrity. MgCI2 was again important for h_32p]TNP-8N3-ATP photolabeling of both 
proteins. 
120 
Figure 3.3. Concentration dependent 
photolabeling of PdrSp (circles) and100 
PMA1 (triangles) in 25 mM EPPS, pH
II) 
C B.5, in the absence of glycerol, with:::J 80 
0 
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To determine if [y_32p]TNP-8N3-ATP is binding to the nucleotide binding sites of Pdr5p (and 
PMA1) and to ascertain the degree of specificity of this interaction - the effect of increasing 
concentrations of ATP (in the presence and absence of 20 % (v/v) glycerol) on photolabeling 
with h_32PJTNP-8N:rATP, was tested (Fig 3.4). 
120 
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Figure 3.4. ATP inhibition of [y­
32pjTNP-BN3""ATP photolabeling of 
Pdr5p (top graph) and PMA1 (bottom 
graph) in 25 mM EPPS, pH B.5, with 20 
% (v/v) glycerol (circles, solid lines) or 
in the absence (triangles, dashed lines) 
of glycerol. The [y-32p]TNP-BN3""ATP 
concentration was 50 11M and the 





























0.01 0.1 10 
[ATP] (mM) 
For both PdrSp and PMA1 , increasing concentrations of ATP, in the presence of glycerol, 
shows significant inhibition of [y_32PJTNP-8N3-ATP photolabeling (circles, solid lines), with ­
80 % inhibition of photolabeling at 3 mM ATP. In this preliminary experiment, the Ki(ATP) is 
calculated to be - 0.2 mM for both PDRS and PMA 1, but more data is needed for an accurate 
value. ATP inhibition of photolabeling is less in the absence of glycerol (triangles, dashed 
lines) with only approximately SO % inhibition seen at 3 mM ATP. This suggests that there 
may be some non-specific labeling of the protein in the absence of glycerol, outside the ATP 
binding site. This is in agreement with studies on the Ca2+ ATPase of sarcoplasmic reticulum 
(Seebregts and Mcintosh, 1989). Consequently, glycerol was included in all future 
experiments. 
The pH dependence of PdrSp and PMA1 photolabeling with [y_32p]TNP-8N3-ATP is shown in 
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Figure 3.5. pH dependent 
photolabeling of PdrSp (circles, solid 
line) and PMA 1 (triangles, dashed line) 
with [y-32PjTNP-BN3-ATP. The [y­
32PlTNP-BN3-ATP concentration was 
50 JlM and irradiations done in 25 mM 
buffer, 20 % (v/v) glycerol and 1 mM 
MgCh MES was used for pH 6.0, 
HEPES for pH 7.0, EPPS for pH B.O 
and CHES for pH 9.0 and 10. The 
insert shows an autorad of a SDS­











CHAPTER 3: Characterisation of yeast proteins PdrSp and Yor1 p by photolabeling with [y-32p]TNP-8N3­
ATP. 
Photolabeling was significantly enhanced at lower pH for both Pdr5p (circles) and PMA1 
(triangles) with a pKa of 7.3 for Pdr5p and 7.5 for PMA1. Noticeably, the ratio of Pdr5p to 
PMA 1 photolabeling is also pH dependent, with approximately equal photolabeling of both 
proteins at alkaline pH (see Fig 3.2, bottom figure) while Pdr5p is labeled twice as much as 
PMA 1 at acid pH (see Fig 3.5 gel insert). 
The photolabeling performed at pH B.5 in the previous figures was clearly not under optimal 
conditions. Therefore the concentration dependent photolabeling of Pdr5p and PMA1 was 
repeated at pH 6.0 and is shown in Fig 3.6. 
120 j Figure 3.6. Concentration dependent 
photolabeling of PdrSp (circles, solid100 
/ 
lines) and PMA1 (triangles, dashed
2 . / / c lines) in 25 mM MES, pH 6.0, in the::J /o /U presence of 20 % (v/v) glycerol and 1 
Q) /
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[y_32p)TNP-8N3-ATP (IlM) 
Pdr5p is photolabeled by [y_32p]TNP-BN3-ATP with a Kd at pH 6.0 of 46.2 IlM. PMA1 is not 
saturated at 100 IlM [y-32p]TNP-BN3-ATP and the estimated Kd for PMA 1 for this experiment 
is 245 IlM. The average Kd of PMA1 for [y_32p]TNP-8N3-ATP at pH 6.0, taken over 6 
experiments with various protein preparations, is 146 IlM (data not shown). 
Different Pdr5p preparations were also tested for ATP site integrity. Pdr5p enriched 
membrane fractions kept frozen at - BO °C and purified, freeze dried Pdr5p (re-suspended in 
H20 prior to experiments) were both labeled with [y-32p]TNP-BN3-ATP and displayed affinities 
of Kd =61.4 IlM and Kd =16.2 IlM respectively at pH 6.0 (Fig 3.7). The Pdr5p mutant Sc31, 
with the amino acid mutation G1004A in the N terminal NBD displayed a Kd of 30 IlM, 
indicating that the ATP site was intact. The results suggest that the purified freeze dried 
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[y_32pjTNP-8N3-ATP (11M) 
Yor1p 
Figure 3.7. Concentration dependent 
photolabeling of various Pdr5p 
preparations in 25 mM MES, pH 6.0 
with [y-32 p]TNP-8N3-ATP in the 
presence of 20 % (v/v) glycerol and 11 
mM MgCI2. Cirdes - purified, freeze 
dried Pdr5p. Triangles - Pdr5p mutant, 
Sc31, freeze dried. Squares ­
membrane enriched Pdr5p, in solution 
stored at - 80°C. 
Having established optimal TNP-8Nr ATP photolabeling conditions for Pdr5p, Yor1p was also 
investigated. Initially, no ATPase activity could be detected for Yor1p and the integrity of the 
nucleotide binding domains came under suspicion. To determine if Yor1p had intact NBDs 
that was able to bind ATP, the interaction of Yor1p with TNP-8Nr ATP was investigated. 
Photolabeling of Yor1 p was carried out in standard medium - 25 mM MES, pH 6.0, 20% (w/v) 
glycerol - with a protein concentration of < 1 jlM. The divalent cation requirements of Yor1 p 
photolabeling IJVere tested (Fig 3.8). Two concentrations of MgCI2 (1 and 11 mM) were 
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[y_32pjTNP-8N3-ATP (~) 
Figure 3.8. Concentration dependent 
photolabeling of Yor1p in 25 mM 
MES, pH 6.0 and 20 % (v/v) glycerol 
with increasing concentrations of [y­
32 p]TNP-8NJ-ATP in the presence of 
MgCI2 (cirdes, 1 mM MgCb and 
triangles, 11 mM MgCI2) or in 2 mM 
EDTA (squares). The curve through 
the 11 mM MgCb data points was 
fitted to the average of the two 
experiments. The lower figure shows 
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+MgCI2 EDTA 
TNP-8N3-ATP (IJ-M) 
Yor1p is labeled with [y_32p]TNP-8N3-ATP in the presence of both 1 and 11mM MgCb 
(triangles and circles), with a Kd of 31.4 !lM - the average dissociation constant as calculated 
from two experiments. This yeast protein too is dependent on the presence of MgCI2 for little 
[y-32p]TNP-8N3-ATP labeling is seen in the presence of EDTA (squares). 
The effect of ATP on PMA1, Pdr5p and Yor1p [y-32P1TNP-8N3-ATP photolabeling. 
To determine if [y-32p]TNP-8N3-ATP is also interacting with the ATP binding site of these 
proteins with a degree of specificity at pH 6.0 - as was case at pH 8.5, in the presence of 
glycerol, for Pdr5p and PMA 1 - photolabeling of these proteins were done in the presence of 
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Figure 3.9. Effect of increasing 
concentrations of ATP on [y_32p]TNP_ 
8N3-ATP photolabeling of Yor1 p 
(squares), Pdr5p (circles) and PMA1 
(triangles) in 25 mM MES, pH 6.0. 1 
mM MgCI2 and 20 % (v/v) glycerol. 
The [y-32p ]TNP-8N3-ATP concentration 
was at the Kd for Pdr5p or Yor1 p 
respectively. The line is drawn as fitted 
for Pdr5p. 
The Ki(ATP) are 0.322 mM, 0.44 mM and 0.495 mM for Yor1p, Pdr5p and PMA1 respectively. 
The PMA 1 data is the average of two experiments. 
In summary, photolabeling of Pdr5p and Yor1p indicates a fair affinity for TNP-8N3-ATP (Kd 











CHAPTER 3: Characterisation of yeast proteins Pdr5p and Yor1 p by photolabeling with [y-32P1TNP-BN3­
ATP. 
Pdr5p. The specificity seems reasonable in the presence of glycerol as judged by the strong 
inhibition by ATP in the milli molar concentration range. 
Preparative photolabeling of Pdr5p with [y_32p]TNP-8N3-ATP 
In order to identify the amino acids derivatised by photolabeling of Pdr5p, a 210 Ilg sample of 
yeast membrane enriched with Pdr5p (but still containing PMA 1 and other minor proteins) 
was photolabeled with 50 IlM of TNP-BN3-ATP in 2.5 ml standard medium - 25 mM MES, pH 
6.0, 20% (w/v) glycerol - and 11 mM MgCI2. A negative control, where irradiation of TNP­
BN3-ATP was carried out prior to the addition of protein, was also performed to identify any 
tight binding photolysis products. The samples were applied to PD10 size exclusion columns 
and were eluted with 3.5 ml of 25 mM NH4HC03, followed by digestion with 4 % (w/w) 
thermolysin for 2 hat 37°C. The digests were applied to primed C1B Sep-pak cartridges and 
peptides eluted with 60 % (v/v) CH3CN. These samples were analysed on a C4 reverse 
phase column by HPLC. 
The HPLC profile of the negative control (Fig 3.10) shows most of the peptides eluting 
between 11 and 25 min (blue, 210 nm) with a very small amount of tight binding TNP 
photolysis products eluting at 15.5', 1B.6' and 26.6'(green, 40B nm). 
0.25 0.010 Figure 3.10. Negative 
control - HPLC profile of 210 
0.20 Ilg yeast membrane 
E 
c 











0.000 g 50 IlM of [y-32P1TNP-BN3"" 
ro ATP pre-irradiated for 5 min 
.0 
ro 0.10 .0 
'­'­
0 o in 25 mM MES, pH 6.0, 20% enen 
.0.0 
-0 .005 <t: (w/v) glycerol, 11 mM MgCb.<t: 0.05 
Purified sample was 
digested with 4 % (w/w)0.00 
thermolysin. The peptide 
profile is shown in blue, 210 
nm. The TNP profile is 
shown in green, 40B nm. 
Tight binding photolysis 
products can be seen at 
15.5',1B.6' and 26.6'. 
The HPLC profile of the sample irradiated in the presence of protein (Fig 3.11) displays a 















CHAPTER 3: Characterisation of yeast proteins Pdr5p and Yor1 p by photolabeling with [y-32p]TNP-8N3­
ATP. 
showing reproducible digestion of the protein. The 408 nm trace exhibits two large (16.5' ­


















0.010 Figure 3.11. HPLC 
profile of 210 I-Ig of yeast 
plasma membrane0.005 E 
c: enriched with Pdr5p andc:o 
0 
-q- PMA1 , irradiated for 5 
Q)
0.000 u min in the presence ofc: 
ro 
.0 [y_32p]TNP_
L.- 50 I-IM of 
a 
(/) 
.0 8N3-ATP in 25 mM MES, 
-0.005 <C 
pH 6.0, 20% (w/v) 
glycerol, 11 mM MgCI2, 
and digested with 4-0.010 
0 10 20 30 40 50 %(w/w) thermolysin . 
Time (min) 
When superimposing the two 408 nm traces of the two experiments (Fig 3.12), the later 
eluting large peak (18.5' - 19.5') overlaps with a peak of similar elution time in the negative 
control, suggesting that this peak is a photolysis product rather than a TNP-peptide. The 
remaining prominent peak (16.5' - 17.5) is consequently the main candidate for a TNP­
peptide. Unfortunately, this peak is co-eluted with a large amount of peptides, making further 
purification of this peak difficult. And, since the samples did not consist of pure Pdr5p, this 
TNP-peptide could also be from PMA 1. When this experiment was repeated in the presence 
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traces of digested 
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after irradiation of 
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-0.003 
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CHAPTER 3: Characterisation of yeast proteins PdrSp and Yor1 p by photolabeling with [y-32p]TNP-8N3­
ATP. 
Using 1.05 mg pure, freeze dried Pdr5p (containing no PMA1) photolabeling, digestion and 
purification were repeated as before (data not shown). Again, two large peaks and several 
smaller TNP-peaks were present at 408 nm. The later eluting peak coincided with a peak 
present in the negative control, in agreement with previous experiments. Efforts to purify the 
major peak away from contaminating peptides were unsuccessful. 
Although photolabeling of Pdr5p appears to be specific according to successful inhibition of [y-
32p]TNP-8N:;ATP photolabeling with ATP, a single major peak could not be identified on 
HPLC after photolabeling and digestion. This could be due to several reasons. Firstly, there 
is evidence of the presence of tight binding photolysis products that complicate the 408 nm 
profile. If both of the NBDs of PdrSp are photolabeled, more than one photolabeled peptide is 
expected. Thennolysin cleaves at hydrophobiC amino acids, and lack of specificity could lead 











CHAPTER 4: CHARACTERISATION OF SNBD2 BY PHOTOLABELING WITH [y-32p]8N3­
ATP AND [y-32p]TNP-8N3-ATP. 
In order to gain a better understanding of the nucleotide binding properties of individual 
domains of the p-gp, we investigated the recombinant carboxyl-terminal nucleotide binding 
domain from mouse p-gp. Two recombinant carboxyl-terminal nucleotide binding domains 
from mouse p-gp (sNBD2 and LNBD2) were used in this study. The shorter mouse NBD 
discussed in this chapter, sNBD2, constitutes Thr1044 to Thr1224. To determine if TNP-8N3-ATP 
would be a good photoprobe for monitoring interaction at the ATP binding site of sNBD2 and 
to establish if this recombinant sNBD had an intact ATP binding site, interaction of sNBD2 
with BN3-ATP and TNP-8N3-ATP was investigated. Optimal conditions for the photolabeling 
of sNBD2, with [y_32p]BN3-ATP and [y_32p]TNP-BN3-ATP was determined by examining 
various parameters, such as pH dependence, divalent cation requirements, influence of 
different buffers, salt concentrations and the presence of glycerol or sucrose in the irradiation 
medium. 
The pH dependence of sNBD2 photolabeling with [y_32p]BN3-ATP and [y_32p]TNP-BN3-ATP 
was assayed in 25 mM buffer, pH 6.0, 20 % (v/v) glycerol and 1 mM MgCI2 (Fig 4.1). 
Figure 4.1. pH dependent 
photolabeling of sNBD2 with [y-32p]BN3_ 
ATP (triangles, dashed line) and [y-
32p]TNP-BN3-ATP (cirdes, solid line) in 
25 mM buffer, 20 % (v/v) glycerol and 1 
mM MgCb. The sNBD2 concentration 
was 0.5 flM and 0.1 flM respectively. 
The [y-32p]TNP-BN3""ATP concentration 
was 50 flM and [y-32p]BN3-ATP 25 flM. 
MES was used as buffer for pH 6.0, 
HEPES for pH 7.0, EPPS for pH B.O 
and CHES for pH 9.0 and 10.0 The 
lower figure shows autorads of the 
SDS-PAGE of these experiments. 
6 7 B 9 10 6 7 B 9 10 
The pH dependent photolabeling of sNBD2 was maximal at acidic pH for both probes, with 
pKa for [y_32p]BN3-ATP = 6.B and [y-32p]TNP-8N3-ATP = 7.5 (the values being the average of 










CHAPTER 4: Characterisation of sNBD2 by photolabeling with [y-32p]8N3-ATP and [y-32p]TNP-8N3-ATP. 
Optimal photolabeling conditions were further investigated for [y-32prrNP-8N3-ATP by 
ascertaining the effect of potassium phosphate buffer, pH 6.0, at high and low concentrations 
as compared to MES buffer - in the presence of glycerol (Fig 4.2, lane 1-4). The influence of 
sodium chloride (lanes 5 and 6), Triton X-100 (lanes 7 and 8) and sucrose instead of glycerol 

















Figure 4.2. Photolabeling of 1 JlM 
sNBD2 with 50 JlM [y-32 p]TNP-8N3­
ATP under various conditions. 
Standard irradiation medium contained 
25 mM buffer, pH 6.0, 1 mM MgCh, 5 
mM EGTA and 20 % (v/v) glycerol. 
Lane 1: 40 mM KPi. Lane 2: 100 mM 
KPi. Lane 3: 25 mM MES. Lane 4: 
100 mM MES. Lane 5: 40 mM KPi 
and 500 mM NaC!. Lane 6: 25 mM 
MES and 500 mM NaCI. Lane 7: 20 
mM KPi and 0.1 % (v/v) Triton X-100. 
Lane 8: 25 mM MES and 0.1 % (v/v) 
Triton X-100. Lane 9: 100 mM KPi 
and 20 % (w/v) sucrose. Lane 10: 100 
mM MES and 20 % (w/v) sucrose. 
Labeling of sNBD2 with [y-32p]TNP-8N3-ATP (in the absence of Triton X-100) was optimal at 
either high KPi concentrations in the presence of glycerol, or at low MES concentrations in the 
presence of glycerol. However, the effects of buffer type and concentration as well as salt 
concentration are rather small. Triton X-100 showed the most pronounced effect with a 2 fold 
increase of photolabeling in the presence of 0.1 (vJv) triton X-100. 
Photolabeling of sNBD2 with [y_32prrNP-8N3-ATP in the presence of increasing 
concentrations of Triton X-100 (Fig 4.3) revealed that very low concentrations of Triton X-100 
( > 0.003 %) is adequate to facilitate maximal photolabeiing and that high concentrations of 
Triton X-100 ( > 0.1 % vJv ) is detrimental to photolabeling. Subsequently, 0.01 % (vJv) Triton 
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Figure 4.3. Photolabeling of 1 11M 
sNBD2 with 50 11M [y-32P1TNP-BN3-ATP 
in the presence of increasing 
concentrations of Triton X-100. 
Irradiation was done in 25 mM MES, 
pH 6.0 and 20 % (v/v) glycerol in 1mM 
MgCb. 
The divalent cation requirements for sNBD2 photolabeling with [y-32p]TNP-8N3-ATP was 
determined in the presence (open circles, solid line) and absence (filled circles, dashed line) 
of MgCI2 under standard conditions - 25mM MES, pH 6.0, 20 % (v/v) glycerol and 0.01 % 
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Figure 4.4. Concentration dependent 
photolabeling of 0.5 11M sNBD2 with [y­
32P1TNP-BN3-ATP in the presence of 1 
mM MgCI2 (filled circles, dashed line) 
and absence of MgCb - 2 mM EDTA 
(open circles, solid line). Irradiation 
was done in 25mM MES, pH 6.0, 20 % 
(v/v) glycerol and 0.01 % (v/v) Triton X­
100. The lower figure shows an 
autorad of the SDS-PAGE of this 
experiment. 
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CHAPTER 4: Characterisation of sNB02 by photolabeling with [y-32p]8N3-ATP and [y-32p]TNP-8N3-ATP. 
Unlike the intact yeast proteins Pdr5p and Yor1p, photolabeling of sNBD2 is not dependent 
on the presence of MgCI2 and sNBD2 binds [y_32pjTNP-8N3-ATP with an affinity (Kd) of 4 /lM 
in the presence of 1 mM MgCb or a Kd of 1.7/lM in EDTA. Binding appeared to be less tight 
in the presence of MgCI2. 
To detennine if the two ATP probes display similar divalent cation requirements, this 























Figure 4.5. Concentration dependent 
photolabeling of 0.5 /lM sNB02 with [y-
32p]8N3_ATP in the absence of MgCI2 
(filled circles, solid line) , in the 
presence of 10 mM MgCb (triangles, 
dashed line) and 30 mM MgCb 
(diamonds, dotted line) . Irradiation was 
--A done in 2SmM MES, pH 6.0, 20 % (v/v)-
~ .... . . ... . . . .. .... .. glyc rol and 0.01 % (v/v) Triton X-100. 
..~.~ . .. .. ... . .... .. . . . . 
The lower figure shows an autorad of 
the SOS-PAGE of this experiment. 
/ .,. 
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As for [y_32pjTNP-8N3-ATP, sNBD2 photolabeling with [y_32pj8N3-ATP was not dependent on 

the presence of Mg2+ - on the contrary, photolabeling is inhibited at high concentrations of 

MgCI2. The affinity of sNBD2 for [y_32pj8N3-ATP, as reflected in the Kd, is 57, 196 and 143 

/lM at 0, 10 and 30 mM MgCI2 respectively. It is not only the affinity for [y_32pj8N3-ATP that 

decreases at higher MgCI2 concentration, but also maximal labeling - reflecting a decrease in 

labeling efficiency at higher MgCI2concentrations. 

A more extensive concentration range of [y_32pjTNP-8N3-ATP and greater number of data 
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[y_32pjTNP-8N3-ATP (~M) 
Figure 4.6. 	 Concentration dependent 
photolabeling of 0.5 IlM sNBD2 with [y-
32p]TNP-8N:<-ATP in 2 mM EDTA . 
Irradiation was done in 25mM MES, pH 
6.0, 20 % (v/v) glycerol and 0.01 % 
(v/v) Triton X-100. 
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Figure 4.7. 	 Concentration dependent 
photolabeling of 0.5 IlM sNBD2 with [y-
32p]8N3-ATP in 2 mM EDTA. 
Irradiation was done in 25mM MES, pH 
6.0, 20 % (v/v) glycerol and 0.01 % 
(v/v) Triton X-100. 
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Figure 4.8. Inhibition of [y_32p]8NJ-ATP 
photolabeling of 0.5 j.!M sNBD2 with 
increasing concentrations of A TP. The 
concentration of [y-32p]8NJ-ATP was at 
the Kd for this probe - 36 J.lM. 
Irradiation was done in 25mM MES, pH 
6.0, 20 % (v/v) glycerol, 0.01 % (vlv) 
Triton X-100 and 2 mM EDTA 
[ATP] (mM) 
ATP completely blocked photolabeling with half maximal inhibition at 2 mM ATP. This 
translates to a Ki(ATP) of 1 mM. This value is similar to the Km value for the whole protein 
(reviewed by Senior and Gadsby, 1997). The results strongly suggest that the photolabeling 
is specific and the recombinant protein is correctly folded at the ATP binding site. 
The recombinantly expressed mouse C-terminal sNBD consequently binds both [y_32p]8N3_ 
ATP and (y-32PjTNP-8N3-ATP with an affinity of 37.2 ~M and 0.8 ~M respectively. The 
binding of both photoaffinity ATP probes is not dependent on the presence of Mg2+ and 
labeling is, on the contrary, perturbed by high concentrations of MgCI2. Maximal labeling 
takes place at acidic pH, 0.1 % (v/v) Triton X-100 and in the absence of MgCI2. Under these 
conditions, (y-32p ]8N3-ATP photolabeling of sNBD2 is completely inhibited by ATP, with a 











CHAPTER 5: CHARACTERISATION OF LNBD2 BY PHOTOLABELING WITH [y.32P]8N3­
ATP AND [y.32p]TNP-8N3-ATP. 
to Thr1224While working on the shorter mouse NBD2 (sNBD2 _Thr1044 ), a paper published by 
Sankaran demonstrated that Tyr1041 (Tyr1042 in the mouse sequence) of full length PiJp, 
isolated from hamster CHO cells, is the primary reaction target of BN3-ATP (Sankaran et aI., 
1997b). Since this amino acid is absent from the sequence of sNBD2, a longer polypeptide, 
LNBD2, from Lys1025 to Ser1276 was investigated. It was of interest to see if the longer 
recombinant NBD of the mouse PiJP interacted with the two ATP photoprobes in a similar 
fashion as was the shorter recombinant NBD. As for sNBD2, optimal labeling conditions for 
LNBD2 with [y_32p]BN3-ATP and [y_32p]TNP-8N3-ATP was assessed. The pH dependence of 
LNBD2 photolabeling with [y_32p]BN3-ATP and [y_32p]TNP-8N3-ATP was assayed under 
















5 6 7 8 9 10 
pH 
6 7 8 9 10 
Figure 5.1. pH dependent 
photolabeling of LNB02 with [y_32p]8N3­
ATP (triangles, dashed line) and [y­
32pjTNP-8N3-ATP (cirdes, solid line). 
LNB02 concentrations were 0.5 and 
0.1 JlM respectively. Irradiation was 
done in 25 mM buffer, pH 6.0, 1 mM 
MgCI2, 20 % (v/v) glycerol and 0.1 % 
(v/v) Triton X-1 00. The [y-32pjTNP-8N3­
ATP concentration was 11.1 JlM and 
the [y-32pj8N3-ATP concentration 25 
JlM. MES was used as buffer for pH 
6.0, HEPES for pH 7.0, EPPS for pH 
8.0 and CHES for pH 9.0 and 10.0. 
The figure below shows autorads of the 
SOS-PAGE of these experiments. The 
error bars show the standard deviation 
over 3 experiments. 
The pH dependent photolabeling of LNBD2 in 1 mM MgCI2 was also maximal at acidic pH for 
both probes, with pKa for [y-32p]BN3-ATP = 6.B and [y_32p]TNP-BN3-ATP = 7.B (the pKa values 
for [y_32p]TNP-BN3-ATP photolabeling is the average of two experiments and for [y_32p]BN3_ 
ATP the average of three experiments). 
Photolabeling LNBD2 with [y_32p]TNP-8N3-ATP with Triton X-100 - 0.01 % (v/v) and 0.1 % 










CHAPTER 5: Characterisation of LNB02 by photolabeling with [y-32Pj8N3-ATP and [y-32p]TNP-8N3-ATP. 
sucrose (10 % (wlv) and 20 % (wlv)), in increasing concentrations of NaCI (10, 100, 1000 
mM) and in the presence of 10 % (vlv) OMSO is shown in Fig 5.2. 
Figure 5.2. Effect of various conditions 
on LNB02 (0.5 llM) photolabeling with 
[yYp]TNP-8N3-ATP. Irradiation was 
done in 25 mM MES, pH 6.0, 10 mM 
EOTA, 20 % (v/v) glycerol and 0.1 % 
(v/v) Triton X-100, except where Triton 
X-100 concentrations were varied. . 
f'Z2ZZ2J % Triton 
[s::::s::J % Sucrose (v/v) 
~NaCI 
r::::=:::J 1 0 % OMSO 
Photolabeling of LNB02 appears comparable under all these conditions, except at very high 
salt concentrations (1000 mM NaCI), reflecting a more stable protein less influenced by the 
irradiation medium composition than sNB02. 
The divalent cation requirements for LNB02 photolabeling with [y_32p]TNP-8N:;-ATP was 
determined in the absence of MgCI2 (in 10 mM EOTA) and in the presence of 10 and 30 mM 
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Figure 5.3. Concentration dependent 
photolabeling of LNB02 (0.5 llM) with 
[y_32pjTNP-8N3-ATP in 10 mM EOTA 
(circles, solid line), in the presence of 
10 mM MgCh (squares, dashed line) 
and 30 mM MgCI2 (triangles, dotted 
line). Irradiation was done in 25 mM 
MES, pH 6.0, 20 % (v/v) glycerol and 
0.1 % (v/v) Triton X-100. The figure 
below shows an autorad of the SOS­



























CHAPTER 5: Characterisation of LNB02 by photolabeling with [y_32pj8N3-ATP and [y_32PjTNP-8N3-ATP. 
TNP-8N3-ATP (j.1M) 
omM MgCb 10 mM MgCb 30 mM MgCb 
I 0.3 1 3 10 3q 0.3 1 3 10 30 p.3 1 3 10 30 
As for sNBD2, photolabeling of LNBD2 with [y_32p]TNP-8N3-ATP is not dependent on the 
presence of divalent cations and is inhibited by high concentrations of MgCI2. The Kd of 
LNBD2 for [y_32p]TNP-8N3-ATP is 1.751J.M in EDTA, 4.88 IJ.M in 10 mM MgCI2 and 4.39 IJ.M in 
30 mM MgCb. Maximal labeling is also affected with 50% inhibition at approximately 30 mM 
MgCI2 . 
Photolabeling with [y_32p]8N3-ATP displayed similar divalent cation inhibition (Fig 5.4) . The 
Kd for [y_32p]8N3-ATP in EDTA is 17.4 iJ.M, in 1 mM MgCI2 59 IJ.M, in 10 mM MgCI2 68.7 IJ.M 
and in 30 mM MgCI2 100.9 IJ.M. The maximal photolabeling for [y_32p]8N3-ATP is , however, 
much more effected at high concentrations of MgCI2 than [y_32p]TNP-8N3-ATP, with 50% 
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Figure 5.4. Concentration dependent 
photolabeling of LNB02 (0.5 j.1M) with 
[y_32pj8N3-ATP in 10 mM EOTA 
(circles, solid line), in the presence of 1 
mM MgCb (triangles, dashed line), 10 
mM MgCb (squares, short dashed line) 
and 30 mM MgCb (diamonds, dotted 
line) Irradiation was done in 25 mM 
MES, pH 6.0, 20 % (v/v) glycerol and 
0.1 % (v/v) Triton X-100. The lower 
figure is an autorad of the SOS-PAGE 
of this experiment 
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CHAPTER 5: Characterisation of LNBD2 by photolabeling with [y-32p]8N3-ATP and [y-32p]TNP-8N3-ATP. 
Using a more extensive concentration range of [y-32p]TNP-8Ns-ATP and more data points, 
photolabeling of LNBD2 in 25 mM MES, pH 6.0,20 % (v/v) glycerol, 0.01 % Triton X-100 and 


















0 10 20 
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Figure 5.5. Concentration dependent 
photolabeling of 0.1 J.1M LNB02 with [y-
32p]TNP-8N3-ATP in 10 mM EOTA, 
Irradiation was done in 25 mM MES, 
pH 6.0, 20 % (v/v) glycerol and 0.1 % 
(v/v) Triton X-100. 




















Figure 5.6. Concentration dependent 
photolabeling of 0.5 J.1M LNB02 with [y-
32p]8N3-ATP in 10 mM EOTA. 
Irradiation was done in 25 mM MES, 
pH 6.0, 20 % (v/v) glycerol and 0.1 % 











32CHAPTER5: Characterisation of LNBD2 by photolabeling with [32p]8N3-ATP and [ p]TNP8N3-ATP. 
As the previous experiments on the pH dependence of photolabeling were conducted in the 
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Figure 5.7. pH dependent photolabeling 
of LNBD2 with [y_32p]BN3-ATP (top) and 
[y_32p]TNP-8N3-ATP (bottom) in 10 mM 
EDTA. The LNBD2 concentration was 
0.5 and 0.1 IlM respectively. The [y-
32p]TNP-8N3-ATP concentration was 
2.6 IlM and the [y-32p]BN3-ATP 
concentration 25 11M. MES was used 
for pH 6.0, HEPES for pH 7.0, EPPS 
for pH 8.0 and CHES for pH 9.0 and 
10.0. 
Photolabeling of LNBD2 with [y-32PJ8N3-ATP and [y-32PJTNP-8N3-ATP in EDTA, is similar to 










CHAPTER 5: Characterisation of LNBD2 by photolabeling with [y-32p]BN3-ATP and [y.32p]TNP-BN3-ATP. 
The effect of increasing concentrations of ATP on photolabeling of LNBD2 with both probes in 
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Figure 5.B. Inhibition of [y-32p]BN3-ATP 
(circles, solid lines) and [y-32p]TNP_ 
BN3-ATP (triangles, dashed line) 
photolabeling of LNBD2 with increasing 
concentrations of ATP. The LNBD2 
concentration was 0.5 and 0.1 f.lM 
respectively. The concentration of [y-
32p]TNP-BN3-ATP (2.6 f.lM) and [y-
32p]BN3-ATP (35.6 f.lM) was at the Kd 
of the probes. Irradiation was done in 
25 mM MES, pH 6.0, 20 % (vlv) 
glycerol, 0.1 % (v/v) Triton X-100 and 
10 mM EDTA. 
Increasing concentrations inhibited photolabeling. The Ki(ATP) for [y_32p]TNP-BN3-ATP and 
[y-32p]8N3-ATP was calculated to be 2.7 mM and 0.5 mM respectively. It is not clear why 
there should be a difference in Ki(ATP) for the two probes, but it is possible that photolabeling 
of one probe is on equivalent to an equilibrium situation. As for sNBD2, inhibition of 
photolabeling approaches completion at 30 mM ATP, indicating that for LNBD2, photolabeling 
is also specific and that the ATP binding site of this recombinant protein is intact. 
32TNP-ATP was also effective in blocking LNBD2 photolabeling with [y_ p]TNP-BN3-ATP and 
[y_32p]8N3-ATP (Fig 5.9). 
Figure 5.9. Inhibition of [y-32p]BN3-ATP 
100 























(circles, solid lines) and [y-32p]TNP_ 
8N3-ATP (triangles, dashed line) 
photolabeling of LNBD2 with increasing 
concentrations of TNP-ATP. The 
LNBD2 concentration was 0.5 and 0.1 
f.lM respectively. The concentration of 
[y-32p]TNP-8N;3-ATP and [y-32p]8N3­
ATP was at the Kd of the probes. 
Irradiation was done in 25 mM 
MES, pH 6.0, 20 % (v/v) glycerol, 












CHAPTER 5: Characterisation of LNBD2 by photolabeling with [y-32p]8N3-ATP and [y-32p]TNP-8N3-ATP. 
The Ki(TNP-ATP) for [y_32p]TNP-8N3-ATP and [y_32p]8N3-ATP was calculated to be 7.0 11M 
and 0.6 11M respectively. 
The high affinity of LNBD2 for [y_32p]8N3-ATP was unexpected as the affinity for ATP itself is 
in the mM range. ATP and 8Na-ATP differ in the adenine orientation about the glycoside bond 
- ATP being in the anti and 8N3-ATP in the syn conformation (Czarnecki, 1984, Suhadolnik et 
a/., 1988). The different orientation of the adenine ring could explain the difference in Kd for 
these two ligands. In order to test this hypothesis, the syn nucleotide, 8Br-ATP was tested as 
an inhibitor and the results are shown in Fig 5.10 (Tavale and Sobell, 1970). 
100 













Figure 5.10. Inhibition of [y_32p]8N3'" 
ATP photolabeling of 0.5 j.1M LNBD2 
with increasing concentrations of 8Br­
ATP. The concentration of [y_32p]8N3_ 
ATP was 36 j.1M. Irradiation was done 
in 25 mM MES. pH 6.0, 20 % (v/v) 
glycerol. 0.1 % (vlv) Triton X-100 and 
10mM EDTA. 




The Ki(Br-ATP) = 0.194 mM - 2.5 times tighter than the Ki(ATP) of 0.5 mM. Although Br-ATP 
binding is tighter than ATP. it is not in the concentration range of 35.6 11M. obtained for 8N3­
ATP ,suggesting that there may be a special interaction of the azido group with a side chain of 
the protein, in addition to it being in the syn confonnation. 
In summary, the long recombinant mouse C-tenninal nucleotide binding domain, LNBD2, 
interacts with the ATP photoactive probes. [y-32p]8N3-ATP and [y_32p]TNP-8N3-ATP. in a very 
similar fashion to the shorter NBD2. Photolabeling is pH dependent in the presence of Mg2+ 
with maximal labeling at pH 6.0. Photolabeling is inhibited by MgCbwith the TNP probe being 
less sensitive to the effects of the divalent cation. In the absence of MgCI2• [y-32p]8N3-ATP 
photolabeling is similar to that found in the presence of MgCI2, while [y_32p]TNP-8Na-ATP 
photolabeling is not much influenced by pH. Photolabeling is inhibited by increasing 
concentrations of ATP, TNP-ATP and Br-ATP. This provides evidence that the ATP binding 











CHAPTER 6: STABILITY OF THE 'Y·PHOSPHATE OF COVALENTLY ATTACHED 
NUCLEOTIDE 
One possible explanation for the pH dependence of photolabeling in MgCI2 is hydrolysis of the 
y-phosphate at alkaline pH. This possibility was tested by labeling sNBD2 with [y_32pJTNP­
8N3-A TP and the monitoring the stability of the 32p with time at 25°C. 
Samples of sNBD2 were photolabeled under standard conditions - 25 mM MES. pH 6.0. 20 
% (vlv) glycerol and 0.01 % (vlv) Triton X-100 - incubated at both pH 6.0 and pH 8.5 in the 
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MgCI2. MES was used for pH 6.0 and 
Time (min) EPPS for pH 8.0. 
No change in the amount of y-32p is observed over a period of one hour of incubation at both 
pH 6.0 and pH 8.5. A similar experiment carried out for LNBD2 also showed no hydrolysis 
(data not shown). 
Quantification of [y-32P1TNP-BN3-ATP photolabeling of sNBD2 and Pdr5p 
To determine the [y_a2p]TNP-8Na-ATP labeling efficiency of sNBD2 and Pdr5p, increasing 
concentration of protein (sNBD2: 0.25. 0.5, 1 and 2 IJ.M and Pdr5p: 0.2, 0.4, 0.8 and 1.37 IJ.M) 
photolabeled in the presence of saturating concentrations of [y-32p]TNP-8Na-ATP, were 
precipitated with 10 % (wlv) trichloroacetic acid, washed and the radioactivity assayed (Fig 
6.2). Controls were unirradiated samples treated in the same manner. 
Figure 6.1. Stability control of the y-
phosphate. sNBD2 (0.1 f.tM) was 
photolabeled at pH 6.0 with [y_32pJTNP_ 
8N3-Arp and incubated at pH 6.0 
(circles) and pH 8.5 (triangles) in the 
presence (filled symbols) and absence 
(open symbols) of 1 mM MgCb. 25°C. 
Irradiation was done in standard 
medium - 25 mM buffer, 20 % (v/v) 
glycerol and 0.01 % (v/v) Triton X-100 
with a final EDTA concentration of 1 0 



















Figure 6.2. Labeling efficiency of 
sNBD2 (cirdes, solid line) and purified 
Pdr5p (triangles, dashed line) at 
different amounts of protein - NBD2: 
0.25, 0.5, 1 and 2 I-lM and Pdr5p: 0.2, 
0.4, O.S and 1.37 I-lM) with [y_32p]TNP_ 
SN3-ATP. The (y-32PJTNP-SN3-ATP 
concentration was 50 I-lM for Pdr5p and 
30 I-lM for sNBD2. Labeling was done 
in 25 mM MES, pH 6.0, 20 % (v/v) 
0.0 ..: --...,----,-----..~-__._-___i glycerol and 0.01 % (v/v) Triton X-100 
0.0 0.5 1.0 1.5 2.0 2.5 with the Triton X-100 omitted from 
nmol Protein Pdr5p experiments. 
High labeling efficiencies of close to 0.8 nmol/nmol were obtained for both proteins at dilute 
concentrations of protein. Pdr5p appeared to be less efficiently photolabeled at higher 
concentrations compared to sNBD2. 
Reaction of N-ethylmaleimide with sNBD2 and LNBD2 
Several sulfhydryl modification agents have been shown to react with cysteine residues of the 
p-gps. In particular CyS1074 in the human and hamster sequence (CyS1072 in the mouse 
sequence) in the second nucleotide binding domain, located in the Walker A motif of the ATP 
binding site, seems highly reactive. Both N-ethylmaleimide (NEM) and 7 -<!hlor0-4-nitrobenzo­
2-oxa-1,3-diazole (NBD-CI) reacted with CyS1074 (Loo and Clarke, 1995b, Senior et al., 1998). 
NEM and 2-(4-maleitnidoanilino)naphthalene-6-sulfonic acid (MIANS) also compete for the 
same site on p-gp (Uu et al., 1996). It was demonstrated for both NBD-CI and MIANS that 
although ATP protects against reaction with these sulfhydryl modification agents, reaction 
prior to the addition of ATP does not inhibit the binding of ATP itself - indicating that the 
inhibition of ATPase activity by the reagents is not a result of competitive inhibition with ATP 
at the nucleotide binding site. 
The effect of NEM derivatization on [y-32p]TNP-8N:;ATP photolabeling of sNBD2 is shown in 
Fig 6.3. The experiments were done in· such way that the protein was preincubated for 
various times with NEM at pH 8.5. Then, at timed intervals, the pH was either kept at pH 8.5 








































Figure 6.3. The effect of NEM 
derivatization on [y-32PITNP-8N3-ATP 
photolabeling. sNBD2 (0.1 IlM) was 
preincubated with (filled symbols) or 
without (open symbols) 20 mM NEM, 
25 mM EPPS, pH 8.5 at 23 ac. At 
timed intervals aliquots were removed 
and the protein photolabeled with [y­
32PJTNP-8NJ-ATP (3 IlM) in 25 mM 
MES, pH 6.0, 20 % (v/v) glycerol and 
0.01 % (v/v) Triton X-100 (circles) or 25 
0 20 40 60 80 100 mM EPPS, pH 8.5, 20 % (vlv) glycerol 
Preincubation time with NEM (min) and 0.01 % (v/v) Triton X-100 
(triangles) in the presence of 1 mM 
MgCb. 
Both control and NEM derivatised sNBD2 show a similar extent of photolabeling over time. 
This indicates that NEM derivatization does not inhibit nucleotide binding. The fall off in 
photolabeling over the hour also indicates that the protein is unstable and shows that 
denatured sNBD does not photolabel. 
Similar results were obtained with LNBD2 using [y.32p]TNP-8N3-ATP or [y-32p]8N3-ATP as 
photoprobes (data not shown). The results are compatible with the previously mentioned 











CHAPTER 7: FLAVONOID BINDING TO THE ATP BINDING SITE OF SNBD2 AND LNBD2. 
Flavonoids are a family of inducible metabolites often synthesised in plants as a reaction to 
fungal attack or challenge with biotic or abiotic elicitors (Reviewed by Barron and Ibrahm, 
1996). Interaction of several flavonoids with the recombinantly expressed mouse NBDs has 
been detected using tryptophan fluorescence (Bois et a/., 1998, Conseil et a/. 1998, Perez­
Victoria et a/., 1999). In order to screen potential reversers binding to the ATP binding site of 
p-gp and identify positions on the flavonoid nucleus where elaboration may be possible, the 
effects of a variety of flavonoids on photolabeling of sNBD2 and LNBD2 with [y_32p]TNP-8N3­
ATP and [y_32p]8Ns-ATP, were tested. 
Flavonoids are divided into several classes and the ones investigated in this study are shown 
in Fig 7.1. 
Figure 7. 1. Structures of the different 
classes of flavonoids: flavonols (1), 
chalcones (2) and chrysins (3) 
Initially, four compounds were investigated for inhibition of [y_32p]TNP-8N3-ATP photolabeling 
of sNBD2 and LNBD2, namely 8(1,1-DMA)3-Me-kaemferide, 8(1,1-0MA)kaemferide, 
kaemferide and broussochalcone A (Fig 7.2). 
Figure 7.2. Structures of the flavones 
OCH3 8(1,1-0MA) 3-Me-kaemferide (1), 
8(1,1-0MA) kaemferide (2), kaemferide 

























Testing the effects of 1 and 10 IlM of these 4 compounds on photolabeling of sNBD2 in 
standard medium - 25 mM MES, pH 6.0, 20 % (v/v) glycerol and 0.01 % (v/v) Triton X-100, in 
1mM MgCI2 - with [y-32p]TNP-8N3-ATP, kaemferide and broussochalcone A showed some 
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Various compounds 
Figure 7.3. Effect of 1 and 10 11M of 
the ftavones 8(1 , 1-DMA) 3-Me­
kaemferide (1) 8(1, 1-DMA) kaemferide 
(2), kaemferide (3) and the chalcone 
broussochalcone A (4) on [y_32p]TNP_ 
8N3-ATP photolabeling of sNBD2 . 
Photolabeling was done in standard 
medium -25 mM MES, pH 6.0, 20 % 
(v/v) glycerol and 0.01 % (v/v) Triton X­
100 and 1 mM MgCb. The 
concentration of NBD2 and [y-32p]TNP_ 












CHAPTER 7: Flavonoid binding to the ATP binding site of sNBD2 and LNBD2. 
Firstly, the effects of increasing concentrations of kaemferide and broussochalcone A on 
















Figure 7.4. Effect of increasing 
concentrations of kaemferide (circles, 
solid line) and broussochalcone A 
(triangles, dashed line) on sNBD2 
photolabeling with [y_32p]TNP-8N3-ATP. 
Photolabeling was done in standard 
medium. The concentration of sNBD2 
and [y-32PJTNP-8N3-ATP was 0.1 IlM 
and 3 IlM respectively. 
0.01 	 0.1 1 10 100 
[Inhibitor] (~M) 
Under these conditions, photolabeling of sNBD2 by [y-32p]TNP-8N:;ATP is inhibited by 
increasing concentrations of both of these flavonoids with a Ki(kaemferide) = 1 ~M and 
Ki(broussochalcone A) = 0.4 ~M. 
This experiment was repeated at alkaline pH to determine if pH plays a role in flavonoid 
binding to sNBD (Fig 7.5). 
Figure 7.5. Effect of increasing 







and broussochalcone A 
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photolabeling with [y_32p]TNP-8N3-ATP. 
Photolabeling was done in standard 
medium. using EPPS buffer, pH 8.5. 
?f? ~ The concentration of sNBD2 and [y­

















CHAPTER 7: Flavonoid binding to the ATP binding site of sNBD2 and LNBD2. 
Photolabeling of sNBD2 by [y-S2p]TNP-8Ns-ATP at alkaline pH is also inhibited by increasing 
concentrations of both of these f1avonoids with similar Ki values to those calculated at pH 6.0­
Ki(kaemferide) =0.5 J.1M and Ki(broussochalcone A) =0.71 J.1M, assuming pH does not affect 
the affinity of the protein for TNP-8N3-ATP. 
Turning to the LNBD2, the effect of increasing concentrations of these two compounds in the 













Figure 7.6. Effect of increasing 
t concentrations of kaemferide (cirdes. I --- ........ 

solid line) and broussochalcone A 
(triangles, dashed line) on LNBD2 
photolabeling with [y-32p]TNP-8N3-ATP. 
Photolabeling was done in standard 
medium - 25 mM MES, pH 6.0, 20 % 
(v/v) glycerol and 0.01 % (v/v) Triton X­
100 - in 10 mM EDTA. The 
concentration of LNBD2 and [y-
32p]TNP-BN3'"ATP was 0.1 IlM and B 
t ~ 
0.1 1 10 100 1000 IlM respectively. 
[Inhibitor] (fJ.M) 
Inhibition of [y_32p]TNP-8N3-ATP photolabeling of LNBD2 is seen in the absence of MgCb with 
Ki(kaemferide) =5.6 J.1M and Ki(broussochalcone A) =4.7 fJ.M. 
Inhibition of [y-32p]8Ns-ATP photolabeling of LNBD2 with kaemferide and broussochalcone A 
was also investigated in the absence of MgCI2 (Fig 7.7). 
" "10"- ........... 
Figure 7.7. Effect of increasing 
100 • concentrations of kaemferide (cirdes, • 
-A.-.t...... • • solid line) and broussochalcone A 
.!1 80 ........ 
 (trian.9les, dashed line) on LNBD2c 
::::I 
photo/abeling with [y-32p]8N3'"ATP.8 
(I) 60 






Q) medium in 10 mM EDTA. The
400::: 
concentration of LNBD2 and [y_32p]':IeC> 
BN3-ATP was 0.5 IlM and 20 IlM20 
respectively. 
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CHAPTER 7: Flavonoid binding to the ATP binding site of sNBD2 and LNBD2. 
Both broussochalcone A and kaemferide prevent labeling of LNBD2 with [y-32p]8N3-ATP at 
increasing concentrations with a Ki(broussochalcone A) =9 ~M and Ki(kaemferide) =20.5 
l1M.· In summary, both kaemferide and broussochalcone A inhibit both TNP-8N3-ATP and 
8N3-ATP photolabeling, the binding to the shorter domain being approximately 10-fold tighter 
than to the longer NBD (0.5 - 1 ~ compared to 5 - 20 l1M ), assuming 1 mM Mg2+ does not 
have a large effect on the affinity (see Fig. 4.4 and 5.3). 
Another series of flavonoids (kaernferides and galangines) were screened for interaction at 
the ATP binding site of mouse p-gp at 5 and 50 ~ concentrations, using LNBD2 
photolabeling with [y-32p]TNP-8N~ATP in 25 mM MES, pH 6.0,20 % (v/v) glycerol and 0.01 
% (v/v) Triton X-100 and 10mM EDTA as standard conditions. No prominent inhibitory effect 
of 8(1,1,-DMA)3-Me-kaernferide and 8(1.1-DMA)kaernferide (see Fig 7.3) on LNBD2 
photolabeling at higher concentrations (5 and 50 l1M) could be seen (data not shown). 
Elaborations on the 8 position of ring A of the kaemferides are evidently not tolerated in the 
ATP binding site. 
Of three galangine derivatives (Fig 7.8), galangine, 6-prenyl-galangine and 8-prenyl­
galangine, tested at 5 and 50 l1M for their effect on LNBD2 photolabeling, only galangine itself 
showed significant inhibition (data not shown). For gal ngines, elaborations on the 6 or 8 
position of ring A appear not to be tolerated in the ATP binding site. 
1. 
HO 
Figure 7.8. Structures of galangine (1), 












CHAPTER 7: Flavonoid binding to the ATP binding site of sNBD2 and LNBD2. 
Using a more extensive concentration range of galangine 'and both [y-32p]TNP-8N3-ATP and 
[y_32p]8N3-ATP as photoprobes, the Ki(galangine) was calculated as 20 j.!M and 14 j.!M 
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Figure 7.9. The effect of increasing 
concentrations of galangine on LNBD2 
photolabeling with [y-32p]TNP-8N3-ATP 
(cirdes, solid line) and [y-32p]8N3-ATP 
(triangles, dashed line. Irradiation was 
done in standard medium in 10 mM 
EDTA. The concentration of LNBD2 
and [y-32p]TNP-8N3'"ATP was 0.1 IlM 
and 2.6 IlM respectively, while LNBD2 
concentrations was 0.5 IlM for 
photolabeling with 20 IlM [y-32p]8N3­
ATP. 
Another group of flavonols, called silybins, were also screened at 5 and 50 j.!M concentrations 
for their effect on LNBD2 photolabeiing with [y_32p]TNP-8N3-ATP. These compounds were 
silybin, dehydrosilybin, 6-prenyl-dehydrosilybin and 8-prenyl-dehydrosilybin (Fig 7.10). 
Figure 7.10. The structures of silybin 
(1), dehydrosilybin (2), 6-prenyl­


























OH o OCH3 
Dehydrosilybin inhibited photolabeling at high concentrations and a more extensive 
concentration range using both [y-32P1TNP-8N3-ATP and [y_32PJ8N3-ATP yielded a 
Ki(dehydrosilybin) =28 )J.M and 45 JJ.M respectively, showing that elaboration on the B ring is 
tolerated in the ATP binding site (Fig 7.11). As for galangine, 6 and 8-prenyl-dehydrosilybin 
showed no inhibition of photolabeling at a concentration of 50 )J.M, convincingly demonstrating 























> 60 .\. :;:::: 
m 
""iii .\ 
0::: 40 \ 
"* ~ 
20 • ~ 
1 10 100 1000 
[DHS] (f.tM) 
Figure 7.11. Effect of increasing 
concentrations of dehydrosilybin on 
photolabeling of LNBD2 with [y-
32p]TNP-8N3-ATP (circles, solid line) 
and [y-32p]8N3_ATP (triangles, dashed 
line). Irradiation was done in standard 
medium in 10 mM EDTA. The 
concentration of LNBD2 and [y-
32p]TNP-8Ns-ATP was 0.1 IlM and 2.6 
IlM respectively, while LNBD2 
concentrations was 0.5 /!M for 
photolabeling with 20 /!M [y..32p]8N3­
ATP. 
Surprisingly. silybin itself did not prevent photolabeling. pointing to the importance of the 
double bond between position 2 and 3 on ring C for recognition by the ATP binding site. 
An extensive group of chalcones (see Fig 7.1) was screened for inhibition of [y-32PlTNP-8N3­
ATP photolabeling in the 1 to 10 f.tM range: 4-F-chalcone, 4-1-chalcone, 4-(4-chalcone, 4-C4­
chalcone, 4-Coehalcone, 4-Ca-ehalcone, 2',4',4-triOH-3-prenyl-chalcone and 2',4',4-triOH­
chalcone. Except for broussochalcone A (see Fig 7.2), investigated initially, no other 
chalcone was inhibitory. What is unique about broussochalcone is the presence of a 3­
hydroxy group on ring B, absent from all the other chalcone derivatives, and presumably 
essential for recognition by the ATP binding site. 
A group of 12 chrysins was also investigated - chrysin (see Fig 7.1), 6(3,3-DMA)chrysin, 
7(3,3-DMA)chrysin,8(1,1-DMA)chry!\;in, 8(3,3-DMA)chrysin, 6,8(di-DMA)chrysin, 6-geranyl­
chrysin, 8-geranyl-chrysin, 6,8-di-geranyl-chrysin, 4'-F-chrysin and 4'-I-chrysin. None of these 
compounds prevented photolabeling of LNBD2 with [y-32p]TNP-8N3-ATP. Comparing the 
structure of galangine (see Fig 7.7), that does inhibit photolabeling, and chrysin that does not, 
it seems to be the absence of the 3-hydroxy group from chrysin that prevents binding to the 
ATP binding site. 
Of all 31 compounds tested for binding to the ATP binding site of mouse p-gP. 4 compounds 
successfully inhibited the binding of [y-32p]TNP-8N3-ATP to LNBD2 in the J.l.M concentration 











CHAPTER 8: ISOLATION AND PURIFICATION OF TNP-8N3-ATP PHOTOLABELED 
PEPTIDES OF SNBD2 AND LNBD2 
In order to identify the amino acidls derivatised upon photolabeling with TNP-8N3-ATP, the 
photolabeled protein must first be digested into sequence size peptides and the photolabeled 
peptides purified for sequencing. The TNP-8N3-ATP photolabeled peptides are identified, in 
this case, by absorption at 40a nm - characteristic of the TNP moiety. The first step towards 
a pure photolabeled peptide, is to remove the excess of free and noncovalently bound TNP­
aNs-ATP and photolysis products from the irradiated sample. This step also includes the 
preparation of the photolabeled sample for digestion, which involves the removal of glycerol 
(a protease inhibitor) and a change of buffer, optimal for the enzyme of choice. 
Previously, standard procedures for preparation of photolabeled protein for digestion in our 
laboratory involved removal of the noncovalently bound and free nucleotides by passage 
through an anion exchange column (resin: AG 1-X4) to which TNP-nucleotides bind 
irreversibly. Prior to digestion, the sample now containing only covalently attached TNP­
nucleotide, was passed through a Sephadex G-25M PD-10 column in order to remove the 
glycerol. We found that for sNBD2, the protein was retained by both the AG1-X4 column and 
PD10 column and could not be eluted. These procedures were replaced by dialysis of 
labeled protein to remove the glycerol and precipitate the protein. The precipitated protein 
was repeatedly washed and collected by centrifugation. The protein was then re-dissolved in 
a M urea, diluted to 4 M and digested with the relevant enzyme. Alternatively, photolabeled 
lNBD2 samples (expressed with a His-tag) were denatured in a M urea following irradiation 
and applied to a nickel chelate column. Free TNP-8Ns-ATP and glycerol were washed away 
with a M urea and the sample eluted with a M urea and imidazole, followed by dilution and 
digestion. The digest was analysed by reverse phase HPLC. 
sNBD2 and particularty lNBD2, are hydrophobic proteins that require special conditions in 
order to keep them soluble. Consequently, we reasoned that the peptides produced will also 
be hydrophobic and a C4 reverse phase column was chosen. In addition, the TNP-moiety 
tends to increase the hydrophobicity. Since several different enzymes and digestion 
conditions were investigated in order to optimize conditions for the processing and digestion 
of sNBD2 photolabeled with TNP-8N;r-ATP a rather short HPLC run time with a steep 
acetonitrile gradient was opted for. 
sNBD2 digestion with Thermolysin 
Thermolysin. an enzyme previously used in our laboratory to identify TNP-Iabeled amino 
acids (Mcintosh at a/., 1992), is a proteolytic enzyme that cleaves peptide bonds on the N­










Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
does not interact with the TNP moiety of TNP-8N3-ATP. The enzyme is stable at high 
temperatures and denaturing conditions and is active in 8 M urea, but the digestion 
temperature should be lowered to 25°C under these conditions (Wilkinson, 1986). This was 
confirmed by comparing the digestion of a sample of sarcoplasmic reticulum Ca2+-ATPase 
with 20 % (w/w) thermolysin, in the presence and absence of 6 M urea, at 28°C for 3 hand 
37°C for 30 min respectively - showing comparable protein digestion under both conditions 
(data not shown). All irradiations were done under standard conditions - 25 mM MES, pH 6.0, 
20 % (v/v) glycerol and 0.01 % (v/v) Triton X-100 and 1 mM MgCI2 - with the TNP-8N3-ATP 
concentration at 30 I-lM to compensate for higher protein concentrations (- 20 I-lM). The 
irradiation time was 5 min. In the following series of experiments a) the digestion time and b) 
the proteolytic enzyme concentration were varied. 
a) Digestion time: Fig 8.1 shows the HPLC profile of 0.5 mg sNBD2 digested with 4% (w/w) 
thermolysin for 30 min at 30°C. The peptide profile is seen in blue (210 nm) and the TNP 
profile is seen in green (408 nm). The bulk of the peptides elute between 30 and 65 min, 
while most of the TNP-peptides elute in a broad peak at 50 - 65 min. As will be seen below, 














Figure 8.1 C4 HPLC 
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Fig 8.2 shows the HPLC profile of 1 mg sNBD2 digested with 4% (w/w) thermolysin for 3 h at 
30°C. The longer digestion time had the effect of shifting the bulk of the peptide profile (210 
nm, blue) to the left. The TNP-peptide profile (408 nm, green) is spread from 35 min to 70 
min with the majority of the TNP-peptides clustered in two groups at 40 min and 65 min. 
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Figure 8.2 C4 HPLC 
elution profile of 
photolabeled sNBD2 
(1.0 mg) digested with 
4 % (w/w) thermolysin 
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Fig 8.3 shows the HPLC profile of 0.5 mg NBD2 digested with 4% (w/w) thermolysin for 16 h 
at 30 ac. The very long digestion time shifted the peptide profile (210 nm) even further to the 
left. The TNP-peptide profile (408 nm) is spread from 25 min to 70 min but again no single 
major peak is evident. The TNP-peptide yield after a 16 h digestion is comparable with the 
TNP-peptide yield after a 30 min digestion (as reflected by the area under the 408 nm trace in 
fig 6.1 and 6.3), providing evidence that the TNP-peptide and TNP-ribose linkages are stable. 
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Figure 8.3 C4 HPLC 
elution profile of 
photolabeled sNBD2 
(0.5 mg) digested 
with 4 % (w/w) 
thermolysin for 16 h 
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To determine the elution times of unphotolysed TNP-8N3-ATP and photolysis products, 











Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
and the supernatant after the first wash of the pellet (Fig 8.6), were analyzed on HPLC. A 
sample of TNP-8N3-ATP was also irradiated in standard medium and subjected to digestion 
conditions with 40% (w/w) thermolysin for 3 h at 37°C and analyzed on HPLC to identify 
possible mono- and di- phosphate TNP adducts (Fig 8.7). 
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Figure 8.4 C4 HPLC 
profile of unphotolysed 
TNP-8N3-ATP. 

































Figure 8.5 C4 HPLC 
profile of an aliquot of 
the dialysis bag contents 
after overnight dialysis ­
the majority of 
photolabeled sNBD2 
was precipitated at the 
bottom of the dialysis 
bag. 





























Figure 8.6 C4 HPLC 
profile of the 
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supernatant after the 
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unphotolysed TNP-8N3-ATP eluted at 30 - 35 min (Fig 8.4). Analysis of the soluble portion of 
the contents of the dialysis bag (Fig 8.5) and the supernatant following washing of the 
precipitated sNBD2, indicates that one particular photolysis product was being selectively 
retained by the denatured protein - a species eluting at 37 min. Analysis of the photolysis 
products themselves (Fig 8.7) indicates that this species is one of about five, and not the most 
plentiful. Therefore, in appraising the TNP-profile of photolabeled and digested sNBD2 (Fig 
8.1 to 8.3) peaks at 33 min (unphotolysed TNP-8N3-ATP ) and 37 min (photolysis product) 
should be treated with suspicion. However, the washing procedure seems fairly good as 











Chapter 8: Isolation and pUrification of TNP-8N3-ATP photolabeled peptides of sNBD2 and lNBD2 
b) Proteolytic enzyme concentration: sNBD2 appeared to be vvell digested after 16 h with 4% 
(w/w) thermolysin . Hovvever, wishing to avoid long digestion times, the thermolysin 
concentration was raised to 40 % (w/w). Fig 8.8 shows 0.25 mg of NBD2 digested with 40% 
(w/w) thermolysin at 30°C for 3.5 h. sNBD2 appears to be vvell digested, showing the peptide 
profile (210 nm) well shifted to the left, while the TNP profile (408 nm) is well separated from 
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So far, the TNP (408 nm) HPLC profiles of sNBD2 digested under different conditions varied 
between experiments. To test reproducibility, a second experiment was done under exactly 
the same conditions as above. As shown in Fig 8.9, the peptide profile (210 nm) shows 
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Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
Again as a test of reproducibility, 0.5 mg of sNBD2 was photolabeled and digested as above. 
As shown in Fig 8.10, sNBD2 digestion was successful, with the peptide profile (210 nm) 
shifted to the left and the majority of the TNP profile associated with a peptide peak at 40 - 45 
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In all seven experiments shown the TNP-peptide profile was extremely variable and no TNP 
peaks could be singled out as reproducibly dominating. We considered that perhaps the 
situation may be improved at pH 8.5 despite the fact that labeling is less at alkaline pH. Fig 
8.12 shows 0.5 mg of sNBD2, photolabeled at alkaline pH under standard conditions (EPPS, 
Figure 8.10 C4 HPLC 
profile of 0.5 mg sNBD2 
digested with 40% (w/w) 
thermolysin for 3.5 h at 30 
°C. Photolabeling was 
performed under standard 
conditions . 
Figure 8.11 The HPLC 
profile of 0.5 mg sNBD2 
digested with 40% (w/w) 
thermolysin for 3.5 h at 
30°C. Photolabeling 
was performed under 












Chapter 8: Isolation and purification ofTNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
pH 8.5) and digested with 40% (w/w) thermolysin at 30 °C for 3 h. The peptide yield 
compared well with experiments done at pH 6.0, but, not unexpectedly, the TNP profile (408 
nm) was significantly less than the experiments done at pH 6.0. There was no dominant TNP 
peak. 
Figure 8.12 C4 HPLC 
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In all of the above experiments efforts were made to purify and identify groups of TNP 
peptides or single TNP peaks by further HPLC and peptide sequence analysis. Individual 
TNP-peptides were difficult to purify as elution characteristics were very similar, possibly 
because of incomplete digestion, resulting in raggedy ends of essentially the same peptide. 
Sequence analysis consistently failed to yield PTH amino acids, probably because the 
concentration of TNP-adduct was too low. We have made an exploratory investigation into 
using MALDITOF mass spectroscopy to identify TNP-adducts and are hoping to utilize this 
method in identifying photolabeled peptides in the future. 
A spike of [y_32p]TNP-8N3-ATP was included in 7 of the above experiments in order to 
quantify sNBD2 photolabeling. The assays performed at pH 6.0 (total of 6) yielded a 
consistent ratio of 0.39 ± 0.07 nmol TNP-8N3-ATP per nmol of sNBD2 (assuming 100 % 
protein recovery). The one assay performed at pH 8.5 gave a ratio of 0.2 nmol TNP-8N3-ATP 
per nmol of sNBD2, consistent with less labeling observed at higher pH. 
sNBD2 digestion with trypsin 
Thermolysin cleaves at hydrophobic amino acids and in the case of a hydrophobic protein 
(like sNBD2 and LNBD2) , may digest the protein into small peptides of 2 or 3 amino acid 
lengths, or even single amino acids, which may make identification of the labeled amino acid 











Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
Trypsin cleaves at the C-terminal side of lysine and arginine residues, bonds of the type -Lys­
X- and -Arg-X- (Wilkinson, 1986). Previous experience with TNP-8N3-ATP photolabeled 
Ca2+-ATPase had shown that trypsin could not be used as it appeared to cleave the TNP 
moiety from the labeled peptide (Mcintosh et a/., 1992). However, this may be related to the 
fact that two arginine residues are in close proximity to the labeled lysine. The situation could 
be different for sNBD2. sNBD2 (1 mg) was photolabeled under standard conditions at pH 6.0 
and digested with 2% (w/w) trypsin at 37°C for 4 h in 4 M urea. Digestion appeared to be 
poor as most of the digestion products eluted late. This may be because trypsin is sensitive 
to high concentrations of urea. Trypsin also proved to interact with the TNP mOiety on the [y-
32p]TNP-8N3-ATP and the TNP profile (408 nm) was negligible in comparison with TNP 
profiles after thermolysin digestion (results not shown). 
sNBD2 digestion with va protease 
V8 protease was also investigated as an alternative to thermolysin. V8 protease is a 
proteolytic enzyme cleaving the C-terminal peptide bonds of glutamic acid residues 
(Wilkinson, 1986). The enzyme proved to be very sensitive to urea and exhibited significant 
auto-digestion at urea concentrations needed to solubilize precipitated sNBD2. sNBD2 
digestion was poor or negligible. 
sNBD2 digestion with clostripain 
Clostripain is a sulfhydryl protease, cleaving the C-terminal peptide bonds of arginine 
residues, at bonds of the type -Arg-X- (Wilkinson, 1986). The presence of a sulfhydryl­
reducing reagent is essential and the enzyme was activated for an hour before digestion in 
2.5 mM Dn and 1 mM calcium acetate, pH 7.7. Dn, like trypsin, interacted with the TNP 
moiety on the [y_32p]TNP-8N3-ATP and completely destroyed any TNP signal at 408 nm. 
When Dn was removed after activation, prior to digestion, by desalting with a Penefsky 
column (Penefsky, 1977), the enzyme appeared to become inactivated and sNBD2 digestion 
was poor in comparison with the experiment where Dn was included in the digestion 
medium. 
LNBD2 digestion with thermolysin 
TNP-8N3-ATP photolabeling of LNBD2 followed by thermolysin digestion was also 
investigated. Digestion was routinely done with 20 % (w/w) thermolysin in 4 M urea at 30 °C 
for 2 h. In particular, preparative photolabeling was performed under similar conditions as 
was used for SDS-PAGE experiments where complete inhibition of photolabeling was 











Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
For the first experiment, 0.5 mg of LNBD2 (0.8 !lM) was photolabeled in 25 mM MES, pH 6.0, 
20 % (v/v) glycerol, 0.01 % (v/v) Triton X-100 and 1mM MgCb, with 8 !lM TNP-8N:0TP, the 
sample denatured in 8 M urea and applied to a nickel chelate column. The column was 
washed with buffer (including 8 M urea) to remove free TNP-8N3-ATP and eluted. The 
sample was diluted to a final concentration of 4 M urea and 0.5 M imidazole, digested with 20 
% (w/w) thermolysin at 30°C for 2 h, and the digest analyzed by HPLC (Fig 8.13). 
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LNBD2 appears to be well digested under these conditions with the bulk of the peptides 
eluting in under 30 min. The majority of the TNP peptides eluted between 55 and 70 min. 
The TNP peak eluting between 35 and 40 minutes, previously identified as a tight binding 
photolysis product (Fig 8.5 and Fig 8.6) suggested that the washing step in this experiment 
was inadequate to remove all of the free TNP-species from the denatured protein. There 
appeared to be some interesting large TNP peaks eluting between 60 - 70 min. To 
determine whether these later eluting TNP peaks could be obtained reproducibly, the 
experiment was repeated under the same conditions - except that more rigorous washing of 
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Chapter 8: Isolation and purification of TNP-8N3-ATP photolabeled peptides of sNBD2 and LNBD2 
Additional washing of the protein adsorbed to the nickel column markedly decreased the 
amount of TNP signal seen before 55 min, while the TNP cluster just after 60 min remained, 
suggesting that the latter are TNP peptides. 
To confirm reproducibility again, a repeat of the previous experiment was performed (Fig 
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Figure 8. 15. C4 HPLC 
profile of 0.5 mg 
LNBD2 photolabeled 
with 8 11M TNP-8N3-
ATP and digested with 
20 % (w/w) thermolysin 




A bulk experiment, using 2.6 mg of protein, was performed (using the above conditions) in an 
effort to isolate and purify larger amounts concentrations of TNP peptides for sequencing (Fig 
8.16). This necessitated the irradiation of 112 ml of medium over a period of 3 h. This large 
volume was forced through the Nickel chelate column under mild pressure and washed, 
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Figure 8.16. C4 HPLC 
profile of 2.6 mg LNBD2 
photolabeled with 8 11M 
TNP-8N3-ATP and 
digested with 20 % (w/w) 
thermolysin at 30°C for 2 
hours. Photolabeling was 












Chapter 8: Isolation and .....""' ..r .... of TNP-8N3-ATP photolabeled peJ;IUOE*i of sNBD2 and LNBD2 
Regrettably. the TNP peptide profile differed from the experiments performed with 0.5 mg of 
protein, and eluted as a large cluster from 30 to 64 min with no apparent prominent It 
appears that the only reason for this is that the high concentration of protein altered 
the course of olQestlon 
As for sNBD2, in all of the above were made to purify and identify 
promising by HPLC and sequence In the 
TNP-peak eluting at 62 min seen in Figs 8.8 8.9, was subjected to 
HPLC, the peak collected and sent for Sequence analysis again 
consistently failed to PTH amino acids, either because the concentration of the TNP­
adduct was too low, the amino terminal blocked, or the TNP was too short. 
Limited amounts of protein available for bulk preparative experiments and time constraints 











CHAPTER 9: SYNTHESIS AND CHARACTERISATION OF ANP-AMP AND ANP-TNP-AMP 
AS PHOTOAFFINITY PROBES FOR MOUSE LNBD2 
Synthesis and Characterisation of ANP-AMP 
The photoaffinity probe 4-azido-2-nitrophenyl phosphate (ANPP) has been used previously to 
probe the phosphate binding sites of the F1-ATPase, Ca2+-ATPase and the Na+/K'-ATPase 
(Garin et aI., 1989., Lacapere and Garin, 1994., Tran and Farley, 1996). A disadvantage of 
ANPP is that irradiation tends to split off the phosphate and If the probe is 32p labeled, it 
would be lost (Garin et aI., 1989). However, it appears that on covalent attachment to the 
protein the phosphate remains attached. (Garin et aI., 1989, Michel et al., 1992). We 
considered that attaching ANP to AMP could yield a photoprobe where the azido group is 
almost exactly in the position of the end of the gamma phosphate of ATP, and make it a 
potentially powerful probe of the gamma phosphate binding region of ATP sites of enzymes. 
In general, there are few probes of this region, although adenosine triphosphopyrodoxal and 
5'-{p-(fJuorosulfonyl)benzoyl)-8-azidoadenosine have been used in the past (Dombrowski et 
aI., 1992., Yamamoto et aI., 1988., Yamamoto et aI., 1989). In addition to introducing a single 
azido group there is the possibility of combining ANP with 8-azido ATP to make a bifunctional 
crosslinker. The addition of the TNP group could make the binding much tighter, especially in 
the case of p-gp. 
ANP-AMP synthesis was followed by TLC and purification was carried out as described in the 
Methods section. ANP-AMP formation from AMP was apparent on TLC as the only other time 
dependent major species being formed after initiation of the reaction. ANP-AMP migrated just 
below AMP and roughly 80 % conversion of AMP to AMP-ANP was apparent after the 
reaction was continued overnight. After purification, analysis of the purified product yielded a 
species migrating similarly to that seen for the major species formed during synthesis. 
Irradiation of this product in 10 mM KPi, pH 7.0 for 2 min showed the formation of several 
species upon TLC analysis - an indication that this species is photoactive. A scan of ANP 
(Fig 9.1) shows two peaks, the main peak at 250 nm with a smaller second peak at 388 nm. 
II V II 
Figure 9.1. Absorption..., 
spectra of ANP in 10 mM .... 












CHAPTER 9: Synthesis and Characterisation of ANP-AMP and ANP-TNP-AMP as photoaffinity probes 
for mouse LNBD2 
After the chemical addition of AMP to yield ANP-AMP, a shift in the maximal absorbance of 
the latter peak can be observed from 388 nm to 350 nm (Fig 9.2) - this scan can be 
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Figure 9.2. Absorption spectra of 
ANP-AMP in 10 mM KPi, pH 5.5 
'i'A'I'El.DCTH tr.l 
To confirm that the azido group was photoactive, a sample of purified ANP-AMP in 10 mM 
KPi, pH 5.5 was irradiated up to 120 s with no toluene filters (Fig 9.3). A decrease in the main 
absorbance of the peak is seen as well as a peak maximum shift from 250 nm to 263 nm. 
The second smaller peak shows an increase in absorbance and a significant red shift from 
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Figure 9.3. Absorption spectra of 
ANP-AMP irradiated for 0, 15, 30, 
45,60 and 120 s in 10 mM KPi, pH 
5.5. 
"Avn.EHGlM Cr.) 
The irradiated sample was analysed on analytical HPLC on a C18 reverse phase column 
using standard solvents (Fig 9.4). Activation of the azido group led to the formation of several 
products and under these conditions, three major products were formed: peak 2.8'-3.6', peak 
12.9'-14.2' and peak 16'-16.8' . Peak 16.8'-17.8' was identified as unphotolysed ANP-AMP 











CHAPTER 9: Synthesis and Characterisation of ANP-AMP and ANP-TNP-AMP as photoaffinity probes 
for mouse LNBD2 
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Figure 9.4. HPLC profile of 
ANP-AMP irradiated for 120 
seconds in 10 mM KPi, pH 
5.5, analysed on a C18 
reverse phase column. 
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To detennine whether ANP-AMP is interacting with the ATP binding site of mouse LNBD2, 
the effect of increasing concentrations of ANP-AMP on the photolabeling of LNBD2 with [y-
32p]8N3-ATP was assessed (Fig 9.5). Increasing concentrations of ANP-AMP inhibited the 
binding of [y-32p]8N3-ATP to LNBD2 with Ki(ANP-AMP) = 550 I-lM. 
Figure 9.5. Effect of increasing 
concentrations of ANP-AMP on LNBD2 
(0.5 11M) photolabeling with [y-32p]8N3­
ATP. The samples were irradiated under 
standard conditions - 25 mM MES, pH 
6.0, 20 % (v/v) glycerol, 0.01 %(v/v) Triton 
X-100 in 10 mM EDTA 
It can be concluded that ANP-AMP is photoactive and binds to the ATP binding site of LNBD2 
with similar affinity as ATP. 











~\lr..th~,,,i,, and Characterisation of ANP-AMP and ANP-TNP-AMP as nnr\Tn~lm 
4-Azido-2-nitrophenyl-2' ,3' -0-(2,4,6-trinitrophenyl) adenosine monophosphate (AN P-TN P­
AMP) synthesis was carried out by TNBS with ANP-AMP as in the 
methods section. The reaction prcc91ooeK1 smoothly with a yield of about 30 %. The product 
was identified as ANP-TNP-AMP from its scan, its light sensitivity and it the major 
product with a typical Meisenheimer complex. A scan of purified ANP-TNP-AMP shows a 
major peak at 252 nm with a smaller doublet at 408 nm and nm The doublet of 
408 nm and 468 nm is of the TNP moiety . 
9.6. Absorption of 
ANP-TNP-AMP in 10 mM KPi, pH 
The photosensitivity of the azido group was verified by irradiating a pure sample of ANP-TNP­
AMP with toluene in 10 mM KPi, pH 5.5 up to 12 min Similar to ANP-AMP, 
ANP-TNP-AMP also displayed a decrease in maximal absorbance at the 252 nm major peak 

























Figure 9.7. Absorption 
spectra of ANP-TNP-ANP 
irradiated with toluene 
filters in 10 mM KPi, pH 











CHAPTER 9: Synthesis and Characterisation of ANP-AMP and ANP-TNP-AMP as photoaffinity probes 
for mouse LNBD2 
When analysed on analytical HPLC on a C18 reverse phase column using standard solvents, 
one major photolysis product was observed, 20.6'-21.4', with two smaller peaks, 22.3'-23.3' 




















Figure 9.B. HPLC profile of 
ANP-TNP-AMP irradiated for 
12 min with toluene filters in 
10 mM KPi, pH5.5, analysed 
on a C18 reverse phase 
column. 
When ANP-TNP-AMP was irradiated using a glass cuvette (cut off at 350 nm), 50 mM MOPS, 
pH 7.5 for up to 20 min, it resulted in a markedly different scan indicating different products 
(Fig 9.9). This is because the reaction of nitrenes is fairly indiscriminate and various 
irradiation products can be formed depending on reaction conditions such as type of buffer, 
medium composition, pH and possibly wavelength of irradiation. The HPLC profile obviously 
differed from the previous experiment (data not shown). 
If A YD...EHC rH tr.) 
The binding of ANP-TNP-AMP to LNBD2 was determined as for ANP-AMP (Fig 9.10) . ANP­
TNP-AMP inhibited the binding of [y_32p]8N3-ATP to LNBD2 with an affinity of 7.44 /-lM. This 










Figure 9.9. Absorption spectra of 
ANP-TNP-AMP irradiated in a 
glass cuvette for 0, 5, 10 and 20 











Svr,th~'~i~ and Characterisation of ANP-AMP and ANP-TNP-AMP as photoaffinity probes 

















9. 10. The effect of 
concentrations of ANP-TNP-AMP on 
LNBD2 photolabeling with [r-32p]8N3­
ATP. The were irradiated 
under standard conditions in 10 mM 
EDTA 
0.1 10 100 1000 
[TNP-ANP-AMP](J.lM) 
Binding of a photoactive probe to the binding site does not necessarily lead to the successful 
photoinsertion into an amino acid. To determine if ANP-TNP-AMP is not only binding to, but 
also capable of photolabeling an amino acid in the ATP binding site of LNBD2, prelabeling of 
LNBD2 with ANP-TNP-AMP was carried out before photolabeling with [y_32p]8N3-ATP. 
Photolabeling with saturating concentrations of ANP-TNP-AMP followed by a large dilution 
should leave the majority of the ATP binding sites occupied with covalently attached ANP­
TNP-AMP, blocldng interaction and photolabeling with [y_32PJ8N3-ATP. Or. in the case of no 
favourable reactions with the binding a large dilution should leave the majority of the 
binding sites available for interaction with [y_32p]8N3-ATP. 
Samples of LNBD2 were irradiated under standard conditions in EDT A in the presence of 
22.5 !J.M ANP-TNP-AMP (3X Kd). The sample was diluted i0-fold in standard medium and a 
second irradiation carried out in the presence of concentrations of [y-
Concurrently. a control was carried out to determine the amount of unreacted ANP-TNP-AMP 
with the binding site after the dilution. In the control, no irradiation of ANP-TNP­
AMP was done before dilution of the As seen in Fig 9.11, preirradiation of LNBD2 
with ANP-TNP-AMP had no effect on with [y_32p]8N3-ATP and 
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Figure 9. 11. The effect of increasing 
concentrations of [y-32p]8N3-ATP on 
0.5 f.lM LNBD2 prelabeled with 
saturating concentrations of ANP-TNP­
AMP (circles) under standard 
conditions in 10 mM EDTA; as 
compared to a control (triangles). 
o 20 40 60 80 100 120 
[8N3-ATP] (~M) 
In conclusion, both ANP-AMP and ANP-TNP-AMP are photoactive and bind to the ATP site of 
LNBD2. Formation of a covalent bond between activated ANP-TNP-AMP and an amino acid 
in the ATP binding site of LNBD2, appears to be unsuccessful as prelabeling with ANP-TNP­
AMP does not preclude [y-J2p]8NJ-ATP photolabeling of LNBD2. Consequently, work on 











CHAPTER 10: DISCUSSION 
This study set out to explore the use of TNP-8N3-A TP as a photoprobe of the A TP sites of p­
gps in order to shed light on site architecture and function . We found that the yeast pumps 
Pdr5p and Yor1p are well photolabeled at acidic pH with a fairly modest affinity (Kd = 16 - 40 
I-lM, and efficiency of labeling approximately 80 % for Pdr5p). Photolabeling is dependent on 
Mg2+ and is inhibited up to 90 % by ATP. Recombinant expression of mouse NBD2 allowed 
investigation of the photolabeling characteristics of the isolated domain. Interestingly, we find 
that the soluble domain is labeled extremely well even in the absence of Mg2+ (Kd =2 I-lM, 
and efficiency of labeling approximately 80 %) and the specificity is excellent as judged from 
the complete inhibition of photolabeling by various nucleotides. It suggests that the isolated 
domain is largely folded correctly and yet there may be important differences in site 
architecture especially in relation to the Mg2+ site. An exciting possibility is that the 
differences reflect the lack of the trans membrane domain in the isolated NBD2. It could 
mean that the two fairiy large extra membranous loops of the transmembrane domain are 
required for proper constitution of the ATP site. This study also demonstrates that certain 
flavonoids bind reasonably tightly to the ATP site and identifies ring C of the flavonoid nucleus 
as the only direction in which elaborations on the structure are tolerated. This is important for 
the future design of more powerful flavonoid reversers of mu/tidrug resistance. Perhaps as 
important is the finding that hydrophobic f1avonoids that previously have been shown to bind 
to the isolated NBDs and to reverse drug pumping do not bind at the ATP site and therefore 
must be binding at another site (Conseil et aI., 1998, Perez-Victoria et al. , 1999). 
The yeast pumps 
Photolabeling of the yeast p-gps, Pdr5p and Yor1p, by TNP-8N3-ATP was characterised by 
fairiy tight binding affinities (Kd =16 - 40 ~, respectively) , a strong pH dependence (pKa = 
7.3 for Pdr5p) and a strong Mg2+ dependence. The photolabeling of both proteins was 
inhibited up to 90 % (in 20 % (v/v) glycerol) by millimolar concentrations of ATP (Ki = 0.4 and 
0.3 mM, respectively) suggesting labeling at one or both ATP sites. The ten-fold increase in 
affinity for the TNP-nucleotide over ATP is compatible with the tight binding of TNP-ATP to 
CHO p-gp (Senior et al., 1995) and the common finding that the TNP moiety increases 
binding affinity in many proteins (Seebregts and Mcintosh, 1989, Baubichon-Cortay et al., 
1994). 
The TNP grouping is fairiy large and either there must be a convenient pocket adjacent to the 
ATP site for it to fit into or it significantly distorts the binding of the nucleotide. It should also 
be recalled that the bulky azido group causes the adenine moiety to adopt a syn rather than 
an anti confonnation around the glycosidic bond, and hence the adenine position of TNP-8N3­
ATP may not be in the natural position in the binding site. The efficiencies of photolabeling of 
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judging from a comparison of PMA1 and Yor1p, at acidic pH, Yor1p was slightly better 
labelled than the proton pump and in a significantly lower concentration range. The labeling 
efficiency of purified Pdr5p at acidic pH was determined to be approximately 80 %. 
The strong Mg2+ dependence suggests that either the nucleotide does not bind in the absence 
of Mg2+ (i.e. affinity for ATP is negligible) or Mg2+ is required for proper constitution of the site 
and positioning of the azido in proximity to a nucleophile. The correct answer may be a 
contribution from both quarters. The yeast pumps are rather nonspecific in their nucleotide 
requirements, with GTP, UTP and ATP being hydrolyzed at near1y equal rates in similar 
concentration ranges, suggesting that the base-protein interaction is not an important 
determinant of binding affinity and catalysis (Decottignies et al., 1994, 1995, 1998). However, 
this lack of interaction is now probably offset by the favourable TNP-protein interaction which 
increases the affinity at least 10-fold. Also, as will be expanded on below, recombinant 
mouse NBD2 is well photolabeled and is strongly inhibited by ATP in the absence of Mg2+, 
suggesting that nucleotide binding is not impaired in the absence of Mg2+. This is borne out in 
recent work from Senior's laboratory where ATP was shown to bind to mouse Mdr3 p-gp in 
the absence of Mg2+. The Kd(ATP) was similar in the presence and absence of Mg2+ (Lemer­
Mannarosh et aI., 1999). Overall, it seems that Mg2+ may enhance the affinity to some extent 
but a more significant effect may be restructuring of the binding site and realigning the azido 
group in proximity to a nucleophile. 
The strong pH dependence, with enhanced labeling at acidic pH was a surprise. The 
situation is exactly the opposite to that found for photolabeling of Lys492 of sarcoplasmic 
reticulum Ca2+ATPase by TNP-8N3-ATP (MCintosh et aI., 1992). In the latter case the 
labeling exhibits a pKa = 7.5 with stronger labeling at alkaline pH, and at pH 6.0 the small 
amount of labeling occurs outside of the ATP site and does not inactivate ATPase activity. 
The pH dependence may be explained by the greater nucleophilic nature of the neutral -NH2 
group compared with -NH3+. In the case of yeast, exactly the same pH dependence is found 
for PMA1 as for the p-gps, suggesting that the acidic optimum may be related to protonation 
of the nucleotide. However, there are no ionisable groups on TNP-8N3-ATP in this range in 
the presence of Mg2+. The hydroxyls of the phosphates have pKa's at 4.72 (Pecoraro et al., 
1984) and the 2' oxygen of the ribose is protonated with a pKa = 5.1, converting the spiro 
linkage of the Meissenheimer complex into a 3' trinitrophenyl grouping and 2' hydroxyl 
(Hiratsuka, 1982). An alternative explanation is that the yeast plasma membrane has a 
surface charge that is altered in this range and protonation pennits easier access to the ATP 
site. However, as will be elaborated on below, soluble NBD2 exhibits a very similar pH 
dependence of photolabeling as the yeast pumps, suggesting that the H+ concentration effect 
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At the outset of the study of the two yeast Jrgps, Pdr5p had been well characterized in tenns 
of high nonspecific triphospho nucleotide hydrolysis and pleiotropic drug pumping 
(Decottignies et al., 1994). This was not the case for Yor1p where no nucleotide hydrolysis 
could be detected. Our photolabeling results suggested that Yor1 p did indeed possess intact 
ATP sites, compatible with its drug pumping activity. This prompted a re-investigation of the 
hydrolysis activity of Yor1 p by the Goffeau laboratory and low activity (100 nmollmin/mg of 
protein) was eventually detected in the purified protein (Decottignies et al., 1998). What is 
puzzling considering the 10-15 fold difference in hydrolysis activity is that the drug pumping 
activity of Yor1 p in yeast cells, appears to be as good as Pdr5p. This might indicate that 
Yor1 p is a much better coupled pump than Pdr5p, or else purification of the fonner has 
removed an effector protein or lipid. 
Recombinant mouse NBD2 
The modular structure of the ABC transporters suggests that the NBD's of Jrgps may be able 
to be reconstituted as separate semi-functional entities from the transmembrane domains. 
Accordingly, the laboratory of Dr ADi Pietro embarked on a programme to express the NBDs 
of mouse JrgP recombinantly in E.co/i and to study the properties of the isolated soluble 
domains. This would have several advantages induding an abundance of protein allowing 
standard physio-chemical studies to be perfonned, being able to detennine unequivocally if 
reverser binding sites were located on these domains, and differences in ATP binding and 
function between the soluble domains and the whole protein may provide clues into the 
coupling mechanism. 
Analysis of the amino acid sequence of the NBDs in terms of homology and secondary 
structure predictions suggested to Di Pietro's group that two lengths of NBD2 should be 
produced, namely sNBD2: Thr1044_Thr1224 and LNBD2: Lys1025_Ser1276 - both including the 
Walker A and Walker B ATP binding motifs, but the shorter excluding adjacent, nonconserved 
segments. Both proteins proved to be extremely difficult to maintain as soluble proteins but 
especially the longer one. Therefore, most of the earlier work was carried out on the shorter, 
more soluble protein. This turned out to be unfortunate as during our study Senior's group 
identified Tyr1041 of hamster CHO JrgP as a target of 8-azido ATP, and this residue is just 
outside of sNBD2 (Sankaran et al., 1997b). Also, when the tertiary structure of bacterial HisP 
protein was elucidated (Hung et aI., 1998), it appeared that missing segments on both the N­
tenninal and C-tenninal ends of sNBD2 fonned central strands in the two f3-sheets that flank 
the ATP site (see Fig 10.3). This necessitated repeating most of the work with the longer 
protein. At this stage of the programme, it was also deemed wise to compare the labeling 
characteristics of TNP-8N3-ATP and 8N3-ATP largely because of Senior'S work. 
Photolabeling of both proteins was characterised by tight nucleotide binding (Kd(TNP-8N3­
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mol/mol) at acidic pH (pKa =6.8 and 7.8 for sNBD2 and LNBD2 respectively) in the absence 
of Mg2+. The labeling of both proteins with both probes at acidic pH was completely inhibited 
by ATP. These characteristics strongly suggest that the isolated domains have a properly 
constituted ATP site and yet important differences between it and the whole protein ­
assuming the yeast pumps are suitable models - are apparent. 
Unexpectedly, short and long NBD2s behaved very similarly. In order to appreciate why this 
is surprising, one needs to discuss it in the context of the structure of the ATP binding subunit 
of the bacterial HisP. 
The crystal structure of the nucleotide binding subunit of the ABC transporter, histidine 
permease (HisP), became available in late 1998 (Hung et al., 1998). The membrane-bound 
complex of the prokaryotic histidine permease is composed of two hydrophobic subunits, 
HisQ and HisM, and two identical, soluble ATP-binding subunits, HisP. Transport of histidine 
is energized by ATP hydrolysis. The soluble histidine binding protein, HisJ, in the periplasm 
binds to HisQ and HisM, inducing ATP hydrolysis by HisP and transport of histidine into the 
bacterium. Proteins of the ABC family demonstrate extraordinary redundancy, for example 
the bacterial antibiotic-resistance protein, LmrA, is completely functionally interchangeable 
with human p-gp MDR1. Therefore HisP could be a good model for mouse NBD2. An 
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Chapter 10: Discussion 
The alignments were done with ONAMAN (ver 4.13, Lynnon BioSoft, USA), initially 
automatically but with some manual adjustments. This was guided by a similar alignment 
done by A. Oi Pietro using Network Protein Sequence @nalysis (NPS@) in Lyon, France 
(personal communication). Several amino acids are highly conserved and most of the amino 
acid changes are conservative. Even outside of the Walker A and B motifs and the 
conserved linker peptide there are several completely conserved amino acids and only 3 or 4 
small gaps. Many of the secondary structural elements of HisP can be found in mouse 
NB02. An energy minimised structure of LNB02 (coordinates from Oi Pietro, Lyon, France 
and structure reproduced here with kind permission), using HisP as a template is shown in 
Fig 10.2a, alongside the HisP structure, Fig 10.2b. The conserved a-helices 1 (shown in 
yellow) have been orientated in similar positions for ease of comparison. It can be seen that 
most of the secondary elements are almost the same in both structures, however one can see 
differences in their overall positions resulting in a change from the L-shape of HisP to a V­
shape of the energy minimised LNB02 (compare distances between bottom loops). 
Postulated 3­
structure of LNBD2 
provided by Di Pietro, 
All p-strands are in blue 
and conserved a-helix one in vellow. 
Backbone 3-dimensional 
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The shorter NBD2 (sNBD2) had substantial sections missing from the HisP structure. This is 
shown in Fig 10.3, where the HisP structure (Fig1.14, p 24) is compared with a similar 




Figure 10.3. The 3-dimensional structure of HisP with the missing parts of mouse 
sNBD2 painted out (adapted from Hung et al., 1998). Bridging a-helices 1 and 2 are 
labeled. 
On the N-terminal end, p-strand 1 is missing. Note that the N-terminal end of sNBD2 consists 
of the residues GS whereas in the native structure of the mouse p-gp we have residues NYP 
(or RYG in HisP), where the tyrosine residue is that labeled by 8N3-ATP in CHO p-gp 
(Sankaran et al., 1997b). On the C-terminal side, the cut is made just before p-strand 10, 
which removes 3 p-strands and 3 a-helices. The loss of the central two p-strands of both 
sheets could be expected to severely compromise the native structure. However, our 
photolabeling results indicate otherwise. 
Both sNBD2 and LNBD2 showed identical or very similar pH dependencies for photolabeling 
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than for LNBD2 (Kd(TNP-8N3-ATP) =O.B and 2.6 JlM, Ki(ATP) =1 and 2.7 mM, respectively) . 
The Kd value for ATP binding to whole mouse p-gp (MDR3) is approximately 10 mM (Lemer­
Marmarosh et al., 1999), indicating that the binding to sNBD2 is significantly tighter. It is 
interesting that TNP-ATP binds with similar affinity to the whole mouse protein as TNP-BN3­
ATP to LNBD2 (Kd = 2.7 J.LM and 2.6 JlM ,respectively). However, again one needs to bear in 
mind that the conformation of the TNP nucleotides differs around the glycosidic bond. 
Another difference between sNBD2 and LNBD2 was the Triton X-100 sensitivity of the 
photolabeling of sNBD2. Low concentrations of Triton X-100 « 0.01 %) enhance labeling of 
sNBD2 2-fold whereas LNBD2 was insensitive. This indicates that monomeric Triton X-100 
(critical micelle concentration approximately 0.2 %) binds to the shorter protein and possibly 
increases the efficiency of labeling by stabilising the ATP site. This may come about by two 
detergent molecules fitting in the structure where the two central ~-strands are missing, 
stabilising the flanking sheets. ~-strands 11 and 12 may also be replaced by detergent. The 
extra labeling is not due to an affinity change by detergent, because a high concentration of 
50 JlM TNP-8N3-ATP was used in the experiments and initial photolabeling data in the 
absence of Triton X-100 displayed a similar TNP-BN3-ATP concentration dependence as with 
the detergent (latter data not shawn). These results leave one no option but to conclude that 
the nucleotide binding site of sNBD2 is largely correctly constituted. 
There seem to be two possibilities. The 3-dimensional structure of HisP indicates that a­
helices 1 and 2 are "bridges" connecting the two ~-sheets, with a-helix 1 assuming a central 
position between the two ~-sheets and with a-helix 2 more peripheral. Both of these helices 
are present in sNBD2 (see Fig 10.3). The one end of a-helix 1 and the loop connecting it with 
~-strand 4 interacts with a-helix 2 and ~-strands Band 9 (Fig 10.4). 
Figure 10.4. 3-dimensional 
structure of HisP, showing 
the loop connecting a-helix 
1 with ~-strand 4 in blue, a­
helix 2 in red and ~-strands 
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The interactions between the two a-helices and the rest of the protein may be sufficient to 
stabilise the correct abuttment of the C-terminal half of sNBD2 with the N-terminal half even in 
the absence of ~-strand 2 and ~-strands 10-12, such that the ATP site remains intact. The 
Mg2+ site may be disrupted by virtue of the fact that the membrane section of the whole 
protein is missing in the recombinant sNBD2. This will be enlarged upon later, especially with 
regard to LNBD2. 
A second possibility is that the ATP site is constituted entirely from the N-terminal half and the 
C-terminal half is superfluous and indeed need not be properly folded. The lack of interaction 
of bound ATP with the C-terminal half of HisP is clearly seen in Fig 1.13 (p 23), where a­
helices 3-9 are contained in the top half of the picture completely separate from the 
nucleotide. It is this top portion that is postulated to interact with the membrane section 
(Petronilli and Ames, 1991). In this second possibility it is not difficult to understand how the 
Mg2+ site is disrupted as this appears to be formed by residues from the end of ~-strand 9. 
Positioning of the nucleotide in sNBD2 and LNBD2 
All the amino acids of HisP interacting with ATP as elucidated by Hung et aI., are shown in 
Fig 10.5. The adenine moiety is mostly complexed with water molecules, but does sit on a 
single amino acid, Tyr16 (green). The ribose 2'-oxygen is complexed with water, while the 3'­
oxygen interacts with His19 (yellow) . The phosphate tail of ATP interaes with the P-loop main 
chain amides, stretching from Ser41 _Thr47 (Ser4\ blue; Gll2, orange; Ser43 , purple; Gly44, 
green; Lys45, yellow; Ser46, purple; and Thr47, blue) . The putative amino acids important for 
Mg2+ complexation and ATP hydrolysis are also shown - Gln1°O (green), ASp178 (orange), 
Glu179 (purple) and His211 (yellow). 
Figure 10.5. 3-dimensional structure of 
HisP with all the amino acids interacting 
with MgATP, highlighted. The putative 
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The position of Tyr16 in HisP (Tyr1042 in LNBD2), shown by Senior's group to be the main 
target for 8N3-ATP derivatisation in hamster p-gp, is in close proximity to the adenosine 
moiety (Fig 10.6, green). Flipping the adenine moiety into the expected syn conformation of 
8N~TP places the azido group in close proximity to the hydroxyl of the tyroSine. Mimura et 
al. photolabeled HisP with 8N3-ATP and identified His
19 (blue) and Ser41 (yellow) as 
Ser41derivatized amino acids (Mimura et al., 1990). forms part of the Walker A consensus 
sequence in HisP while His19, as indicated above, interacts with 3'-oxygen of the ribose and is 
located close to Tyr16 (Fig 10.6). 
Figure 10.6. 3-dimensional structure of 
HisP with the amino acids photolabeled 
Ser41by 8N3""ATP, highli~hted - , yellow: 
His19, blue; and Tyr 6, green. 
Tyr16 and His19 are not highly conserved in p-gps - the tyroSine is absent from both NBDs of 
Pdr5p and NBD1 of Yor1 p, while the histidine is absent from the mouse, Pdr5p and Yor1 p 
NBDs (Fig 10.7). 
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Figure 10.7. Amino acid sequence alignment of NBD1 and NBD2 of mouse p-gp 
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Photolabeling of Ser4l is unexpected. since there is a large distance between the adenosine 
moiety and this amino acid. It is possible that. since the affinity for ATP is so low for these 
proteins. the binding of the nucleotide is dominated by the phosphate tail. which allows the 
adenosine ring to move around fairly freely. Photolabeling of His19 is not unreasonable. if 
again some movement of the adenine is p,ermitted. 
The TNP moiety of TNP-8N3-ATP is attached to the hydroxyls of the ribose via a spiro linkage 
which orientates the TNP ring at" right angles to the plane of the furanyl ring. This creates a 
rigid Miessenheimer complex that is fluorescent. In the proposed crystal structure of NBD2. 
the ribose hydroxyls of ATP are orientated outwards from the structure pointing in the 
direction of a groove formed between the ends of the two ~-sheets . This is well illustrated in 
Fig 10.8 where lIe18 (purple) and Asn2l6 (green) arising from ~-sheet 1 and 2 respectively are 
highlighted. The ribose appears to be tilted towards ~-sheet 1 rather than 2 and interactions 
with the former may dominate. This is borne out by the tighter binding of TNP-8N3-ATP to 
sNBD2. which has the end of ~-sheet 2 missing and hence Asn2l6. One side of the groove 
may also arise from the P-loop (shown in turquoise), obviating the need for ~-sheet 2. 
Figure 10.8. The putative 3­
dimensional structure of 
LNBD2, highlighting the 
amino acids that possibl~ 
flanks the TNP moie~; lie1 
in purple and Asn 16 in 
green. The P-Ioop is shown 
in turquoise. 
The amino acid(s) derivatized in mouse sNBD2 and LNBD2 by TNP-8N:rATP could not be 
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the recombinant proteins were very hydrophobic which made them difficult or impossible to 
manipulate using standard digestion and purification procedures formerty followed in our 
laboratory. Initially, the recombinant proteins were expressed as fusion proteins, without a 
His tail, that required precipitation of the protein after photolabeling to remove photolysis 
products. Precipitated protein needed to be re-<1issolved in 8 M urea and the solubulized 
protein tended to come out of solution when the urea concentration was lowered below 4-6 M. 
The recombinant proteins containing His tails allowed affinity chromatography purification 
using a nickel chelate resin, but had to be denatured in 8 M urea prior to addition to the nickel 
column, otherwise the majority of the labeled protein bound irreversibly. Few proteolytic 
enzymes are active at high urea concentrations and thermolysin was the only enzyme of 
several that were tested, that showed significant activity in 4 M urea. Unfortunately, 
thermolysin is not very specific and mainly cleaves peptide bonds on the N-terminal side of 
hydrophobic residues. Nonspecific cleavage obviously tends to produce variable length 
peptide fragments, which is a serious disadvantage. Since none of the semi-preparative or 
preparative experiments done on the sNBD2, which did not contain a His tag, were 
reproducible, it was also considered that the concentration of protein during digestion could 
influence the outcome of digestion. Precipitation of sNBD2 by dialysis and repeated washing 
of the precipitate to remove the photolysis products, could lead to inconsistent yields of 
protein for each experiment, leading to different digestion products. Elution of LNBD2 from a 
nickel column appeared to be more quantitative as a series of experiments done with 0.5 mg 
protein/ml (protein concentration during photolabeling) yielded reproducible digestion 
products. To complicate matters further, the Ca2 +, that is mandatory for thermolysin activity, 
catalyses the hydrolysis of the phosphates of the attached TNP-8N3-ATP derivative, causing 
the triphosphate to be converted into the di- or monophosphate - each of these having 
different elution characteristics. There is evidence of tight binding photolysis products, but 
these are mostly eliminated by repeated washing steps. All of the above could contribute to 
the complicated TNP profile seen after HPLC analysis of the digest. 
In cases where some larger peaks were successfully carried through to a purified species, no 
amino acids were detected by standard sequencing (Edman degradation followed by HPLC 
analysis of PTH amino acid derivatives). This could be due to the small amount of TNP­
peptide, a single amino acid or a very short peptide, or because the particular amino acids in 
the peptide do not have a high PTH yield (serines, threonines, Iysines and arginines were 
sometimes problematical amino acids at the sequence facilities at UCT). In order to 
overcome these difficulties, MALDITOF analysis of purified peptides was attempted since 
much lower concentrations of peptide can potentially be detected and the peptide length is of 
less consequence. Analysis of TNP-ATP, TNP-8N3-ATP, TNP-AMP and TNP-adenosine 
showed that each of these could be detected by MALDITOF, but several peaks were 
produced from the first three nucleotides whereas a single prominent peak was found for the 
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complicates the mass spectrum. It appears that a worthwhile protocol may be developed in 
the future in which the phosphates could be cleaved from the TNP-peptide using alkaline 
phosphatase, perhaps immediately before analysis of the digest by HPLC. This would also 
solve the problem of variable phosphate species (tri, di or mono-phosphates). 
While the amino acids(s) photolabeled in PdrSp, sNBD2 and LNBD2 could not be identified, 
some speculation is warranted. Considering the yeast pumps first, we find that Yor1 p 
possesses the tyrosine in NBD2 labeled with 8N3-ATP in hamster p-gp by Senior's group, but 
not in NBD1. I n the al ignments shown before (Fig 10.7), PdrSp does not appear to have a 
tyrosine in this position. However, there is a tyrosine three amino acids residues to the left in 
NBD2. A re-analysis in which this tyrosine is aligned with the labeled one in mouse NBD1, is 
shown as follows: 
* 
Mouse NBD1: G N L E F K N VHF N Y P 
PdrSp NBD2: SEA I F H N R N L C Y E 
This repositioning seems quite feasible since three amino acids align perfectly and three align 
conservatively, but it does mean that the loop following YE and preceding l3-strand 2 would be 
larger. It is interesting that if this is the case both yeast pumps may only be photolabeled at 
the NBD2 and not NBD1, which may prove useful in future functional studies. 
In HisP, His19 and Ser41 appear to be preferentially targeted by 8N3-ATP, rather than Tyr
16 
(Mimura et aI. , 1990). As mentioned before, the equivalent histidine is missing in the yeast 
pumps, being replaced by glycine and lysine in Yor1p and glutamine and valine in PdrSp. 
The hydrophobic residues (glycine and valine) are unlikely to be labeled because they are 
poor nucleophiles. The other two residues are possibilities but a Iysyl-nitrene linkage is 
known to be unstable (Mcintosh et aJ. , 1992) and we have found that the linkage in the case 
of p-gp is stable over several days at 4 °C. The other labeled residue in HisP, namely Ser41 , 
is present in PdrSp and NBD2, and Yor1 p has a threonine in this position in NBD2. However, 
while the adenosine in 8N3-ATP may be mobile in the binding pocket as discussed above, this 
is unlikely for TNP-8N3-ATP because of the inflexible spiro linkage as well as the positive 
contribution the TNP moiety makes to the binding energy. Overall, the tyrosine may be the 
most likely candidate as the photolabeled target. 
In the case of the mouse sNBD2, the equivalent residue to HisP Tyr16 and His19 are missing 
and are therefore not in contention. As can be seen from the putative structure of sNBD2 
presented previously (Fig 10.3), the thrombin cleavage site introduced a glycine in this 
position. This is the last residue on the N-terminal end (GSTRP.. ) and is likely to be 
unstructured and mobile. HisP His 19 is replaced by an arginine residue in mouse NBD2 and 
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HisP Ser
41 
is present in the mouse sequence, but for reasons given above it is an unlikely 
target for TNP-8N3-ATP, but may be for 8N3-ATP. 
Interestingly, the structure of RbsA, the ATP binding subunit of a bacterial ribose transporter, 
contains another tyrosine residue interacting with the adenine moiety of ATP (information 
supplied by A. Di Pietro from the work of C.S. Stauffacher) . The equivalent residue in the 
mouse sequence is Tyr1085 and is positioned between a-helix 1 and ~-strand 4, as shown in 
Fig 10.9 (shown in blue, the other tyrosine of LNBD2 is shown in green). It can be seen that 
this tyrosine is also well positioned to react with the azido group and could be a strong 
contender for nitrene interaction, at least for sNBD2. This tyrosine is missing from the yeast 
pumps. 
Figure 10.9. The putative 3-dimensional structure of LNBD2 with TyrlU4~ (green) 
and Tyr1085 (blue) are highlighted. 
pH effects 
Photolabeling of mouse sNBD2 and LNBD2, as also seen for the yeast pumps, are maximal 
at acidic pH. As discussed before, this trend is unexpected because all ionised amino acids 
are better nudeophiles at alkaline pH (e.g. -OH ~ OW, His+ ~ His, NH3+ ~ NH2). And, as 
also elaborated on before, the dependence cannot be linked to protonation of the TNP-8N3­
ATP nudeotide in the presence of Mg2+. This suggests that the pH dependence may be 
related to ionisable groups at the ATP site itself. Since the pH dependence is similar (in the 
presence of Mg2+) for all the proteins used in this study, a conserved amino acid would be a 
likely candidate. Sequence alignments of mouse, Yor1 p and Pdr5p NBD1 and NBD2 show 
two conserved lysine residues in and next to the Walker A motif and two conserved aspartic 
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conserved lysine in the Walker A motif interacts with two oxygens on the [3-phosphoryl group. 

The second is positioned just after [3-strand 2 and could playa crucial role in positioning of a.­

helix 1 which forms the bed of the ATP site (Fig 10.10 ). 

Protonation of either lysine could influence the interaction of the activated azido group with its 

Figure 10.10. The two conserved 
Iysines (Lys 1060, blue; and Lys 1074 , 
green) may playa role in the pH 
dependent photolabeling of mouse 
NBD2, Yor1 p and Pdr5p. a-Helix 
one is shown in yellow. 
targeted residue. A pKa shift from pH 8.95 to pH 6.8 - 7.5, for an active site residue, is not 
unusual. The conserved aspartates seem less likely because they are further away from 
ATP, and perhaps are not correctly configured in sNBD2, and a pKa shift of 3 units from 3.86, 
to 6.8 - 7.5 is rather large. A conserved histidine is situated in close proximity to the 
phosphate tail of the ATP in the putative structure of LNBD2 (Fig 10.11). 
Figure 10.11. The conserved 
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Protonation of this side chain could also promote binding of the negatively charged phosphate 
groups. However, sNBD2 does not contain His 1230, making a role for this histidine in the pH 
dependence less likely. We favour the possibility that the two conserve lysine residues are 
responsible for the pH dependent photolabeling of the p-gps and isolated NBDs. 
NEM derivatisation 
NEM derivatization of both sNBD2 and LNBD2 prior to photolabeling did not prevent 
photolabeling with either [y_32p]8N3-ATP or [y_32p]TNP-8N3-ATP, supporting previous findings 
that sulfhydryl modifying agents like NEM, NBD-CI and MIANS do not compete with ATP for 
the same binding site on the NBD (Loo et al., 1995, Liu et aI., 1996, Senior et al., 1999). In 
the putative structure of LNBD2 (and HisP, not shown), a possible binding pockeUgroove is 
located to the right of, and in close proximity to, the ATP binding site (Fig 10.12, shown with 
an arrow). Binding here of - SH reactive reagents need not interfere with ATP binding. 
However, it appears that the reverse is not true as ATP binding blocks NEM derivatisation (A1­
Shawi et al., 1994). A fact which can only be explained by ATP inducing a conformational 
change which covers the -SH group. In the case of sNBD2, which lacks the terminal 2 ~­
strands and a-helices, there may not be a binding pocket as such and the reaction may take 
place similar to a free sulphydryl. 
Figure 10.12. The putative 3­
dimensional structure of LNBD2 
showing the postulated NEM 
binding pocket (arrow) and the 
amino acids that interacts with 
NEM, Cys'072. 
An interesting outcome of the NEM labeling experiments, a procedure which involved lengthy 
incubation at pH 8.5 at 23°C, was that the longer the incubation of control protein the less the 
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with increasing time of incubation, do not label efficiently and provides compelling evidence 
that the recombinant NBDs are, prior to incubation, properly folded. 
Mg2+ effects 
Full length yeast proteins Pdr5p and Yor1p - as well as human MDR1 p-gp (Hrycyna et al., 
1999) - are effidently photolabeled by TNP-8N3-ATP and/or 8N3-ATP only in the presence of 
Mg2+. In contrast, photolabeling of the recombinant mouse proteins do not require Mg2+, and 
in fact Mg2+, at relative high concentrations, is inhibitory. The failure to label the whole pumps 
2in the absence of Mg + is not due to poor nucleotide binding. ATP binding to mouse MDR3 is 
not Mg2+ dependent and Mg2+ actually lowers the affinity for TNP-ATP and TNP-ADP (Lemer­
Marmarosh et al., 1999). This latter negative effect of Mg2+ on the binding of TNP-nucleotides 
is similar to the lowering of affinity seen with the photolabeling of sNBD2 and LNBD2 with 
both TNP-8NT ATP and 8N3-ATP. 
The fact that the recombinant proteins do not require Mg2+ for photolabeling i dicates that the 
Mg2+ site is at least partially disrupted. This is not entirely unexpected for sNBD2, since the 
amino acids postulated to interact with bound Mg2+ in the HisP structure, either directly 
(Asp118) or indirectly through water molecules (Glu 119 and Gin 1(0), are located in the ~-strands 
adjacent to the miSSing ~-strand 10. However, another possibility is discussed below in 
relation to LNBD2. 
In the case of LNBD2, all the amino adds of HisP are contained in this recombinant protein. 
Therefore, one could expect that the entire domain is folded correctly and this is substantiated 
by the complete inhibition of photolabeling by several nucleotides. However, the different 
Mg2+ effects from the whole protein suggest that something is disrupted at the Mg2+ site, a 
finding compatible with the inability of the recombinant protein to hydrolyse ATP (Baubichon­
Cortay et al., 1994). The reason for these differences may lie in the fact that the soluble 
recombinant NBDs are not linked to the membrane section. Coupling of drug transport to 
ATP hydrolysis must require linking of conformational changes in the NBDs, brought about by 
the binding/hydrolysis of ATP, to the translocation of the drug through or along the membrane 
helices in the TMD. This is well supported by findings that wild type HisP, in reconstituted 
proteoliposomes as HisQMP2, displayed undetectable ATPase activity in the absence of 
histidine, indicating obsolete coupling of transport to hydrolysis, while mutations in the 
membrane interacting part of HisP (top part of protein in Fig 1.13), uncouples ATP hydrolysis 
from regulatory control by HisJ (Petronilli et al., 1991 and Hung et al., 1998). The modular 
structure of the bacterial ABC transporters suggest that the NBDs, such as HisP and RbsA, 
binds by means of simple association with the three fairly large cytoplasmic loops of the 
membrane section (between TM8 and 9, TM10 and 11 and following TM12 to the start of 
NBD2). Mutations in the long arm (C-terminal half) of HisP mentioned above, facilitate the 
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• 
emphasising again that in the native protein, HisJ binding complexed with histidine is an 
absolute requirement for ATP hydrolysis and of histidine pumping. It is clear that these 
interactions playa pivotal role in energy transduction. It is not inconceivable that the proper 
constitution of the Mg2+ site is dependent on this interaction. This is an extremely exciting 
possibility as it would explain the abnormal Mg2+ effects of the recombinant protein and 
indicate a close tie between the Mg2+ site and interaction with the membrane section which 
harbour the drug binding site(s). 
Flavonoid binding to the ATP binding site of sNBD2 and LNBD2 
Flavonoids constitute a large and diverse pool of plant metabolites that are being intensely 
investigated because of their suitability as a scaffold to drug diversity and because some have 
been shown to interact with ATP sites. In this study, a group of 31 flavonoids, consisting of 
various flavonols (1), chalcones (2) and chrysins (3) (Fig 10.13), was screened for inhibition of 
photolabeling of the recombinant mouse NBDs with TNP-8N3-ATP and 8N3-ATP. 
Figure 10.13. Structures of the 
different classes of flavonoids studied 
here: flavonols (1), chalcones (2) and 
chrysins (3) 
Many elaborations on these basic structures were explored and found not to be tolerated, and 
out of these, four flavonoids prevented photolabeling in the micromolar range and may show 
some promise as reversers of multidrug resistance. This pattern with the same four, was 
repeated with both sNBD2 and LNBD2 and with both probes. at pH 6.0 and pH 8.5. in the 
presence and absence of Mg2+. The four were kaempheride (Ki(av) = 2.4 11M). 
broussochalcone A (Ki(av) =211M), galangine (Ki(av) =17 11M) and dehydrosilybin (Ki(av) =37 















Figure 10.14. The chemical 
structures of kaempheride (1), 
broussochalcone A (2), galangine 









Interestingly. in the case of the two flavonoids that were studied more intensively, namely 
kaempheride and broussochalcone A, the binding to sNBD2 was approximately 10-fold tighter 
than to the LNBD2 which mimics what was found for TNP-8N3-ATP and ATP binding to 
sNBD2 compared with LNBD2. In terms of the architecture of the ATP site and future drug 
development, knowledge of the flavonoids that did not bind to the ATP site may be as 
important as knowing those that did. 
A discussion of these results may be facilitated by reference to Fig 10.15. Virtually all 
compounds tested here had hydroxyl groups at positions 5 and 7 of ring A. Compounds with 
(flavonols, e.g. galangine) or without (chrysins) the 3 hydroxyl on ring C, and some lacking 
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Figure 10.15. A general 
scaffold structure of 
compounds tested in this 
study. 
None of the twelve chrysins had any effect on photolabeling indicating that they do not bind to 
the ATP site and highlighted the importance of the 3-OH for interaction with the ATP site. 
Chrysin itself binds to NB02 of Leishmania tropica with Kd =17.5 flM (Perez-Victoria et al., 
1999). Interestingly, many of the chrysin derivatives used in our study bind in the nanomolar 
range to mouse NB02 (A. Oi Pietro, personal communication). Therefore, importantly, there 
must be another flavonoid binding site, besides that of ATP, on the NBO. 
In the case of the eight chalcones, which have an open ring C and lack the 3-0H, only 
broussochalcone A inhibited photolabeling. The lack of inhibition by the others again pOints to 
the importance of the 3-OH. The reason why broussochalcone A is the exception may be 
because it has a hydroxyl on ring B. Ring B may swivel such that the hydroxyl occupies the 
same position as the 3-OH of ring C in the A TP site. This may be possible because of the 
opening of ring C and increased flexibility around the carbonyl. 
Galangine, with hydroxyl groups at positions 3,5, and 7 inhibited photolabeling. Elaborations 
at position 6 and 8 were not tolerated. An elaboration at the 4' position (OCHa, kaempheride ) 
was acceptable. A finding which prompted exploration of a group of compounds called 
dehydrosilybins which link to the 4' and 5' position of ring B. The dehydrosilybins have large 
extensions to the 4' and 5' positions including a cyclised ether and methoxy phenol. 
Excitingly, dehydrosilybin inhibited photolabeling, showing that these large extensions to the 
B ring were accommodated at the A TP site. Hydrophobic elaborations on the 6 and 8 
positions of ring A. as for the galangines, were not tolerated. It is noteworthy that reducing 
the double bond between position 2 and 3 of ring C, producing silybin, destroys the ability to 
bind to the ATP site. A similar detrimental effect of such reduction has previously been found 
in the binding of nanngenin versus apigenin (Conseil et al., 1998). However, the latter binding 
may be at a site other than the ATP site as apigenin lack the WH. The existence of a 
flavonoid binding site distinct from the ATP binding site on the NBOs of p-gps had been 
proposed and is supported by the evidence presented here. 
The structure that emerges from these studies is fair1y straightforward and illuminating. The 
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approximately 100 fold tighter than ATP. Hydroxyl groups at the 3,5 and 7 positions of ring A 
and C seem favourable. That at the 3 position is essential. No hydrophobic elaborations are 
tolerated on either of these rings. The double bond between C2 and 3 is also essential and 
this may relate to the electronegativity of the 3-OH, perhaps it is even required to be ionised. 
Ring B is the only direction in which extensions are possible, and they may be very large, 
(dehydrosilybins), pointing to the existence of a binding pocket/groove in this direction. 
Considering the ATP binding site of HisP again the adenine mainly interacts with water 
molecules and a tyrOSine, the ribose with a histidine and a water molecule, and the 
phosphates with five main chain amines (Ser41-Lys45) and water molecules. Positioning of 
the f1avonoids is obviously guesswork, but there are two grooves emanating from the ATP 
site, . one that we postulate to accommodate the TNP moiety and the other the maleimide 
mOiety, either of which may accommodate the silybins extensions. In either case, the rest of 
the flavonoid nucleus is positioned approximately where the adenosine moiety lies. We 
considered that the all important 3-0H may then interact with one of the amides of the P-loop. 
Other hydroxyls may do the same and may provide the added binding energy. 
A second flavonoid binding site 
Of great significance is the finding that many hydrophobic f1avonoids, in particular many 
prenylated chrysins, which have been shown to bind tightly to the isolated NB02 (A. Oi Pietro, 
personal communication), do not bind to the ATP site. This means that there is a second 
flavonoid binding site on the NBD. Several of these more hydrophobic f1avonoids reverse 
multidrug resistance in Leishmania parasites (Perez-Victoria et a/., 1999). A steroid binding 
site has been found to over1ap or be adjacent to the ATP site (Conseil et aI., 1998). It seems 
an exciting possibility that such hydrophobic pocket neighbouring the ATP site may be utilised 
to design more efficacious nucleotide based inhibitors of human p-gp. 
Characterization of ANP·AMP and ANp·TNP-AMP as photoaffinity probes for mouse 
LNBD2 
The photoaffinity probe 4-azido-2-nitrophenyl phosphate (ANPP) has been used previously to 
probe the phosphate binding sites of the F1-ATPase, Ca2+-ATPase and the Na+n<-ATPase 
(Garin et a/., 1989., Lacapere and Garin, 1994., Tran and Far1ey, 1996). Attaching ANP to 
AMP could yield a photoprobe for the binding site of the phosphate tail of ATP, since the 
azido group is almost exactly in the position of the end of the gamma phosphate. Addition of 
the TNP group could also make the binding much tighter, especially in the case of p-gps. 
Two new azido-ATP analogues - 4-azido-2-nitrophenyl adenosine monophosphate (ANP­
AMP) and 4-azido-2-nitrophenyl-2' ,3' -O-(2,4,6-trinitrophenyl) adenosine monophosphate 
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prevented photolabeling of LNBD2 with [y_32p]8N3-ATP, yielding a Ki(ANP-AMP) =0.55 mM, 
very similar to that seen for ATP. Similarty, [y_32p]8N3-ATP photolabeling of LNBD2 was 
prevented by increasing concentration of ANP-TNP-AMP, yielding a Ki(ANP-TNP-AMP) = 
7.44 I-LM, again comparable with the Kd(TNP-ATP). 
Prelabeling of LNBD2 with ANP-TNP-AMP did, however, not prevent photolabeling ~th [y-
32p]8N3-ATP, indicating that although these two new probes do bind to the ATP binding site of 
LNBD2, the photolabeUng reaction as such is not successful. As mentioned in the literature 
overview, binding of a photoprobe to the active site does not necessarily result in a favourable 
photolabeling reaction. The azido group on the phenyl ring could be facing away from the 
protein prohibiting a favourable reaction with a nucleophilic amino acid. These probes may 
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